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Abstract
Over 35 million people are living with human immunodeficiency virus (HIV-1). The mechanisms causing
integrated provirus to become latent, the diversity of spliced viral transcripts and the cellular response to
infection are not fully characterized and hinder the eradication of HIV-1. We applied high-throughput
sequencing to investigate the effects of host chromatin on proviral latency and variation of expression and
splicing in both the host and virus during infection.
To evaluate the link between host chromatin and proviral latency, we compared genomic and epigenetic
features to HIV-1 integration site data for latent and active provirus from five cell culture models. Latency was
associated with chromosomal position within individual models. However, no shared mechanisms of latency
were observed between cell culture models. These differences suggest that cell culture models may not
completely reflect latency in patients.
We carried out two studies to explore mRNA populations during HIV infection. Single-molecule
amplification and sequencing revealed that the clinical isolate HIV89.6 produces at least 109 different spliced
mRNAs. Viral message populations differed between cell types, between human donors and longitudinally
during infection. We then sequenced mRNA from control and HIV89.6-infected primary human T cells. Over
17 percent of cellular genes showed altered activity associated with infection. These gene expression patterns
differed from HIV infection in cell lines but paralleled infections in primary cells. Infection with HIV89.6
increased intron retention in cellular genes and abundance of RNA from human endogenous retroviruses. We
also quantified the frequency and location of chimeric HIV-host RNAs. These two studies together provided a
detailed accounting of both HIV89.6 and host expression and alternative splicing.
A more cost-effective method of detecting viral load would aid patients with poor access to healthcare. We
developed improved methods for assaying HIV-1 RNA using loop-mediated isothermal amplification based
on primers targeting regions of the HIV-1 genome conserved across subtypes. Combined with lab-on-a-chip
technology, these techniques allow quantitative measurements of viral load in a point-of-care device targeted
to resource-limited settings.
This work disclosed novel HIV-host interactions and developed techniques and knowledge that will aid in the
study and management of HIV-1 infection.
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ABSTRACT
LATENCY, EXPRESSION AND SPLICING DURING INFECTION WITH HIV
Scott Sherrill-Mix
Frederic D. Bushman, Ph.D.
Over 35 million people are living with human immunodeficiency virus (HIV-1). The
mechanisms causing integrated provirus to become latent, the diversity of spliced viral
transcripts and the cellular response to infection are not fully characterized and hinder the
eradication of HIV-1. We applied high-throughput sequencing to investigate the effects of
host chromatin on proviral latency and variation of expression and splicing in both the host
and virus during infection.
To evaluate the link between host chromatin and proviral latency, we compared genomic and
epigenetic features to HIV-1 integration site data for latent and active provirus from five cell
culture models. Latency was associated with chromosomal position within individual models.
However, no shared mechanisms of latency were observed between cell culture models. These
differences suggest that cell culture models may not completely reflect latency in patients.
We carried out two studies to explore mRNA populations during HIV infection. Single-
molecule amplification and sequencing revealed that the clinical isolate HIV89.6 produces at
least 109 different spliced mRNAs. Viral message populations differed between cell types,
between human donors and longitudinally during infection. We then sequenced mRNA
from control and HIV89.6-infected primary human T cells. Over 17 percent of cellular genes
showed altered activity associated with infection. These gene expression patterns differed
from HIV infection in cell lines but paralleled infections in primary cells. Infection with
HIV89.6 increased intron retention in cellular genes and abundance of RNA from human
endogenous retroviruses. We also quantified the frequency and location of chimeric HIV-host
RNAs. These two studies together provided a detailed accounting of both HIV89.6 and host
v
expression and alternative splicing.
A more cost-effective method of detecting viral load would aid patients with poor access to
healthcare. We developed improved methods for assaying HIV-1 RNA using loop-mediated
isothermal amplification based on primers targeting regions of the HIV-1 genome conserved
across subtypes. Combined with lab-on-a-chip technology, these techniques allow quantitative
measurements of viral load in a point-of-care device targeted to resource-limited settings.
This work disclosed novel HIV-host interactions and developed techniques and knowledge
that will aid in the study and management of HIV-1 infection.
vi
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CHAPTER 1: Introduction
1.1 The HIV epidemic
In 1981, physicians began to notice a mysterious increase, often clustered in men who
had sex with men or intravenous drug users, in the occurrences of Kaposi’s sarcoma and
pneumocystis pneumonia1–6.
Kaposi’s sarcoma was, until 1981, a rare cancer in the US found largely in elderly men with
Jewish or Mediterranean ancestry7. Kaposi’s sarcoma had also been seen in immunocom-
promised individuals8–10 and there were suggestions that it was a virus-associated cancer11
although the causative human herpesvirus would not be discovered for another decade12,13.
Pneumocystis pneumonia was known to be caused by infection of the alveoli with the yeast-
like fungus Pneumocystis jirovecii 14,15. Pneumocystis pneumonia was almost exclusively
seen in patients with suppressed immune systems or immune disorders and rarely, if ever, in
immunocompetent individuals15.
The mechanism for this spike of opportunistic infections was clarified when researchers found
severe T cells depletion and decreases in cellular immunity in these patients4–6,16,17. This
disease was eventually labeled acquired immunodeficiency syndrome (AIDS). However, the
underlying cause remained unclear.
Potential transmissions by transfusion18–20, injection drug use4,17,21, maternal transmission22
and both homosexual16,23 and heterosexual17,24 contact pointed towards an infectious agent.
In 1983, a virus later named human immunodeficiency virus type 1 (HIV-1) was isolated
from patient samples25–28 and soon detected in most immunodeficient patients28–31.
Reports of AIDS and associated opportunistic infections in sub-Saharan Africa soon revealed
widespread endemic infection32–35 and a great diversity of viruses36–41. Retrospective studies
suggested that the virus had been present, at least sporadically, in Europe and the USA
for decades42,43 and circulating for even longer in Africa33,44–48. Archived patient samples
1
containing HIV-1 genome fragments from as early as 1959 were found in what is now
Kinshasa, in the Democratic Republic of Congo46. These samples showed extensive genome
diversification already present in the 1960s, suggesting that HIV-1 had been circulating in
humans for some time47,48. Phylogenetic analyses adding in contemporary HIV-1 type M
sequences estimated a most recent common ancestor in the early 1900s48–53.
A virus similar to HIV causing AIDS in monkeys was soon discovered in macaques54,55 and
many other primates56. HIV-1 appeared most similar to a virus found in chimpanzees55,57
and surveys of wild chimpanzees in Africa revealed a closely related simian immunodeficiency
virus infecting chimpanzees in central Africa58–60.
Thus, the ancestor of HIV-1 was likely transmitted from a chimpanzee to a human, likely
during harvest of chimpanzees for food61–66, in the forests of southeastern Cameroon.
The virus was probably transported down the Sangha River67 to the city of Kinshasha,
where HIV-1 began its global spread38,48,53,68. A combination of social upheaval, increased
mobility, urbanization and mass vaccination campaigns with unsterilized needles appear to
have provided fuel for the growing epidemic53,69–71. A virus appears to have been carried
from Africa to Haiti in the 1960s, perhaps by workers returning home from an exchange
program35,68, and then into the US in the 1970s72 before being detected in the US in 1981.
In the past 34 years, HIV-1 has spread to over 78 million people and caused over 35 million
deaths73.
In the early days of the epidemic, there were no tests to detect the virus, and no treatments.
The presence of the virus was often revealed by the onset of AIDS. Opportunistic infections74
and death usually followed soon after. The median survival time after diagnosis with AIDS
was about 1 year75,76.
Isolation of the virus allowed the detection of HIV infection through assays of antibody
response to viral proteins. Testing revealed that patients had a median survival time of
around a decade from initial infection77–80.
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In 1987, the successful trial of the reverse transcriptase inhibitor azidothymidine provided
the first hope for treatment81–83 but it soon became apparent that the fast mutation rate of
HIV84–90 and strong selection by drug therapy could quickly create drug-resistant forms of
virus in patients receiving single drug therapy91–100. Even with therapy, median survival
time from AIDS diagnosis rose to only about 2 years76,82,101,102.
Additional antiretrovirals, again targeting reverse transcriptase, were developed103. Sequen-
tial or alternating administration of different antiretroviral drugs did not greatly improve
prognosis104–108. Simultaneous treatment with two reverse transcriptase inhibitor offered
modest benefits but viral escape was still common109–113.
Development of drugs targeting other stages of the HIV replication cycle allowed synergistic
combinations of antiretroviral drugs114–119. The difficulty for HIV to evolve multiple drug
resistant mutations120,121 meant that therapy using simultaneous combinations of drugs
finally began to offer patients more hope of long term survival122–126. With early triple
therapy, median survival time rose to 20 years79,127 and, with further development, now
approaches the life expectancy of control populations128–131.
However although antiretrovirals effectively suppress HIV, there is currently no practicable
cure132,133. If a patient, even a patient who had the virus suppressed to undetectable
levels for years, stops treatment, then virus abundance quickly rebounds to pretreatment
levels134–136.
Upon infection, latent HIV are quickly137,138 established in resting CD4+ T cells and
macrophages. These latent provirus are long-lived and resistant to therapy and immune
response139,140. Resting CD4+ cells have half-lives of up to 40 months141,142 meaning
significant proportions of HIV will remain latent for decades yet can be stimulated at any
time by activity in their host cell to reactivate and restart viral replication134–136,140,141,143,144.
Latently infected cells are one of the most significant barriers to curing HIV145. If the latent
proviruses could be induced into activity and their host cells eliminated then the virus might
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Figure 1.1: The HIV replication cycle
be eradicated from its host146–149. Cell models of latency are used to study this problem in
the lab150–152. In Chapter 2, we compare latent and active provirus among these cell models
to see if latency relates to the chromosomal position of integration and whether models
share the same drivers of latency.
1.2 The HIV virus
HIV is an enveloped, single-strand positive-sense retrovirus (Figure 1.1). To replicate, the
virion gains access into a host cell through cellular receptors153–160. The viral RNA genome
is reverse transcribed to create a DNA intermediate that is integrated into a host cell
chromosome161–164. Host polymerase then transcribes viral messenger RNAs which are
translated in the cytoplasm. Full length RNA is packaged into budding particles along with
expressed viral proteins and the virion buds from the cell.
The HIV genome encodes genes for at least two polyproteins and seven proteins:
Gag (group specific antigens) is a myristoylated membrane protein which is anchored on
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the virion surface and cleaved by viral protease after virion budding to produce matrix,
capsid, nucleocapsid and p6 protein along with two small spacer peptides SP1 and
SP2.
MA p17 (matrix) is a trimeric protein that supports the inside of the viral lipid bilayer
to stabilize the virion165. It also aids in transport of the genome to the nucleus
through a nuclear localization signal166 and in nuclear import in non-dividing
cells167.
CA p24 (capsid) proteins assemble to form a protective shell around the RNA genome
of the virus. The viral capsid is composed of around 1500 copies of CA arranged
into hexameric rings interspersed with 12 pentameric rings to form a fullerene
cone168–171. CA binds cellular CPSF6172, cyclophilin A173,174 and RanBP2175,
perhaps to gain access to the nucleus175,176 and to avoid premature uncoating
and exposure of the viral genome to innate immune factors177.
NC p7 (nucleocapsid) recognizes the ψ packaging element of the viral genome178
through two zinc-finger motifs and is packaged together with the RNA into
virions179.
p6 (protein 6 kDa) is a small protein which appears to primarily recruit cellular
proteins to allow virion budding from the cell membrane180–182 and aid in the
packaging of Vpr in to particles183.
Pol (polymerase) is cleaved by viral protease to produce reverse transcriptase, integrase
and HIV protease. The Pol protein is generated when a ribosome translating gag
meets a stem-loop in the HIV mRNA184, stutters and moves back a base, causing a
-1 nucleotide frameshift when it continues translation185. Translational frameshifting
happens in about 120 of translations
186.
RT p51 (reverse transcriptase)187 generates DNA from an RNA template161,162.
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Retrovirus package two copies of RNA in each virion188–190. If two different virus
infect the same cell then interstrand transfer during the reverse transcription step
allows recombination between strains191–193. A lack of proofreading in the RT
step leads to the high mutation rate of around 2 × 10−5 mutations per base per
replication84–90.
IN p31 (integrase) is a dimeric enzyme which integrates the retroviral DNA into host
chromatin164,194–197. Integrase removes two nucleotides from from the 3′ ends of
the viral DNA and inserts the pair of viral ends into host DNA198.
PR (protease) is a dimeric aspartyl protease199 that cleaves viral polyproteins Gag
and Pol200,201.
Env gp160 (envelope) is a trimeric transmembrane protein that mediates entry through
fusion of viral and cellular membrane by binding its receptor CD4153–157 and coreceptors
CXCR4158, CCR3 or CCR5159,160. gp160 is cleaved into its active form, consisting of
two subunits gp41 and gp120202, by cellular furin protease203. The envelope protein is
highly glycosylated to form a mutable ‘glycan shield’ against host adaptive immune
response204. There are about 14 Env proteins per virion205. Env sequence is highly
variable within and between patients206,207 due to positive selection from host immune
recognition208–210.
Tat (trans-activator of transcription) protein is a transactivator of expression from the
HIV-1 long terminal repeat211–213. The virus does not replicate efficiently without this
transactivation214. Tat may also regulate cellular expression such as downregulation
of major histocompatibility complex type I expression215. Tat may suppress miRNA
silencing pathway216–218 but this remains controversial219.
Rev (regulator of expression of virion proteins) is a transactivator protein that shuttles
between the nucleus and cytoplasm220 and causes the export of partially spliced and
unspliced viral transcripts221–225 from the nucleus through the recognition of a rev
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response element226,227.
Nef (negative factor) is a myristoylated membrane-associated protein228 that is involved
in multiple functions. Nef causes endocytosis of the viral entry receptors CD4229–233
and CCR5234 and major histocompatibility complex molecules235–238. Nef also in-
duces T cell activation through interactions with signaling kinases and the T cell
receptor239–243. In contrast, Nef in most other primate lentiviruses inhibits activation
and inflammation244 perhaps indicating that the gain of vpu in HIV-1 and its simian
relatives allowed the loss of the immune inhibitory traits of nef and thus contributes
to the increased pathogenicity of these viruses245,246.
Vpr (viral protein R) is a 15 kDa protein247,248 with diverse functions. Vpr arrests the cell
in the G2 phase of the cell cycle249–253 and aids in transport of the viral genome to the
nucleus166. Vpr protein may disrupt nuclear membrane integrity253. Vpr also appears
to transactivate viral expression254,255 and induce apoptosis256,257 but these may be
linked to conditions caused by cell cycle arrest. Vpr is incorporated into virions258,259.
Vif (virion infectivity factor) counteracts the cellular restriction factor APOBEC3G260 by
excluding APOBEC3G from incorporation into the virion261 and causing APOBEC3G
to be ubiquitinated and degraded262–264. APOBEC3G is otherwise packaged into
virions265 and deaminates the HIV genome during reverse transcription causing G-to-A
hypermutation265–268.
Vpu (viral protein U)269,270 is a small integral membrane protein which has two known
functions; degradation of CD4 and downregulation of BST-2 from the cell membrane.
Vpu causes cellular CD4 to be ubiquitinated and degraded271,272 which prevents
interactions between progeny virus and host cell CD4 receptor232,233,273,274 and super-
infection by other viruses230 while also releasing Env proteins from CD4 interactions in
the endoplasmic reticulum275,276. Vpu also counteracts the cellular restriction factor
BST-2, which would otherwise interfere with viral budding277,278. Vpu does not appear
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to be found in the virion279.
A strong selective pressure for genome compactness280–282 pushes HIV and other lentiviruses
to subvert host cell alternative splicing pathways to allow tighter packing of their genetic
information. Through weak splice sites283 and overlapping reading frames (Figure 1.2), the
virus manages to produce regulated quantities of these nine proteins and polyproteins from
its single transcription start site and less than 10 kilobase genome284.
In HIV, splicing occurs between at least four splice donors and eight splice acceptors284.
Two splice donors, D1 and D4, are relatively strong while the remaining donors and all
acceptors are fairly weak285. The weak acceptors seem balanced with Rev’s nuclear export
activity283. Several exonic splicing silencers286,287 and exon splicing enhancers288,289 and a
single intronic splicing silencer290 in the viral genome interact with many human splicing
factors, including hnRNPs A1287,290 H, F, 2H9, and A2291 and SR proteins SRp40288,292,
SRp75292, ASF/SF2288 and SC35291, to alter viral splicing284,293.
In Chapter 3, we investigate viral splicing and reveal unappreciated splice sites, novel proteins
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and dynamic changes in viral splicing between human subjects, over time and between cell
types.
Inclusion and exclusion of a particular stretch of RNA into an mRNA is determined
by a balance of RNA secondary structure291,294,295, chromatin structure296, nucleosome
positioning297, histone marks298, previous splicings299, order of intron removal300,301 and
enhancers302 and suppressors303 that bind specific motifs304. Together these factors create
a controllable splicing code305–307.
Alternative splicing may also play an unappreciated role in HIV-host interactions. Viral
proteins interact with components of the cellular splicing complex308–310. These interactions
have been reported to change splicing in viral309,311,312 and cellular transcripts313,314 and
raise the possibility that the virus has evolved to alter host splicing. Although infection
has been shown to cause genome-wide changes in the expression of cellular genes315–319,
no genome-wide study of cellular alternative splicing during HIV infection has ever been
reported.
Several viral proteins affect mRNA abundances. Rev causes export of unspliced viral mRNA
that would otherwise be trapped in the nucleus320 to be exported321,322 and may also interact
with splicing factors to alter viral splicing308. The HIV protein Tat is best known for its trans-
activation of viral transcription211,323 and triggering apoptosis in uninfected cells324,325 but
Tat also appears to independently affect alternative splicing of viral transcripts309,311,312,326.
Viral protein Vpr is known to cause cell cycle arrest252 with corresponding changes in ex-
pression. Vpr also appears to alter alternative splicing of some cellular transcripts313,314 and
interact with the SMN complex310, which assembles spliceosomal snRNP327. Although all
three of these proteins modify viral splicing, whether they also cause widespread alterations
in cellular splicing is unknown.
HIV infection also appears to induce the expression of certain human endogenous retroviruses
(HERVs)328–333 and retrotransposons334. These HERV and retrotransposon mRNA and
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their translated proteins offer potential markers of infection and vaccine targets335–340 but
no genome-wide screen of the effects of HIV infection on the transcription of these elements
has been reported.
In Chapter 4, we investigate splicing and expression during HIV infection and report
global changes in intron retention and in the expression of endogenous retrovirus and
retrotransposons.
1.3 HIV detection
Immunoassays are the current standard of care for the detection of HIV infection. These
tests are based on the enzyme-linked immunosorbent assay (ELISA), using an enzyme linked
to an antibody to produce a detectable signal only in the presence of antigen341–343.
The isolation of HIV25–28 allowed the production of large quantities of virions that could
be used as antigen. These virions were bound to a substrate, sera from patients added and
any patients antibodies sensitive to HIV allowed to bind. Any unbound antibodies were
washed away. Then a peroxidase enzyme-labeled antibody targeted to human antibody was
added, allowed to bind and the unbound antibodies again washed away. Any HIV-targeted
patient antibodies would bind the antigen and be bound in turn by the peroxidase-labeled
antibody so that the peroxidase would change the color of media30,31,344. These tests had a
large false positive rate and the standard procedure was to perform multiple ELISA tests
follow by a Western blot test before informating patients345,346 but false positives were still
prevalent347. More conservative criteria and cleaner lab procedures reduced false positives348.
Four generations of development349 have resulted in more sensitive and specific detection of
patient antibodies along with earlier detection using antibodies directly able to detect the
HIV capsid protein350,351.
Rapid immunoassays with less specificity but able to provide results in 30 minutes have
been developed to allow point-of-care testing. Immediate results reduce patient stress and
reduces the number of patients lost to follow up prior to delivery of results352–354. Rapid
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tests detecting HIV in oral fluids have been developed and obviate the need for a blood
draw355–357 and allow self testing at home358,359.
Immunoassays provide robust and affordable point-of-care detection of HIV but no viable
point-of-care assays for viral load exist360. Existing laboratory-based tests are relatively
expensive and require specialized equipment making access difficult in resource-limited
settings361,362. Without viral load measures, CD4+ T cell counts or clinical presentation
are used to infer the emergence of viral drug resistance. These criteria are not specific nor
sensitive enough without viral load measures so many patients are unnecessarily switched to
second line therapy363,364 or switched too late leading to accumulations of drug resistant
mutations365. Medecins Sans Frontieres describe point-of-care viral load tests as “desperately
needed”360. In Chapter 5, we design loop-mediated isothermal amplification methods that
can be used with microfluidics to create a point-of-care assay viral load in resource-limited
settings.
1.4 Contributions
Much of this work was performed as part of a large collaboration. It would not tell a
complete story in isolation. Therefore, I have preserved the chapters in published form and
detailed my contribution to each project at the start of the chapter.
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2.1 Abstract
Background: HIV infection can be treated effectively with antiretroviral agents, but the
persistence of a latent reservoir of integrated proviruses prevents eradication of HIV from
infected individuals. The chromosomal environment of integrated proviruses has been
proposed to influence HIV latency, but the determinants of transcriptional repression have
not been fully clarified, and it is unclear whether the same molecular mechanisms drive
latency in different cell culture models.
Results: Here we compare data from five different in vitro models of latency based on
primary human T cells or a T cell line. Cells were infected in vitro and separated into
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fractions containing proviruses that were either expressed or silent/inducible, and integration
site populations sequenced from each. We compared the locations of 6,252 expressed
proviruses to those of 6,184 silent/inducible proviruses with respect to 140 forms of genomic
annotation, many analyzed over chromosomal intervals of multiple lengths. A regularized
logistic regression model linking proviral expression status to genomic features revealed no
predictors of latency that performed better than chance, though several genomic features
were significantly associated with proviral expression in individual models. Proviruses in the
same chromosomal region did tend to share the same expressed or silent/inducible status if
they were from the same cell culture model, but not if they were from different models.
Conclusions: The silent/inducible phenotype appears to be associated with chromosomal
position, but the molecular basis is not fully clarified and may differ among in vitro models
of latency.
2.2 Background
Highly active antiretroviral therapy (HAART) can suppress HIV-1 replication in infected pa-
tients, but the ability of HIV to persist as an inducible reservoir of latent proviruses134,140,143
obstructs eradication of the virus and functional cure145. These latent proviruses are long
lived141,142 and relatively invisible to the immune system139,140. The potential for even a
single virus to restart infection despite successful antiviral therapy means that it may be
necessary to eliminate all latent proviruses to eradicate HIV from an infected person.
After integration, a positive feedback loop of Tat transactivation appears to partition
proviral gene activity into either of two stable states367–369—abundant Tat driving high
proviral expression or little Tat leading to quiescent latency. Similar to the positional effect
variegation observed in fruit fly chromosomal rearrangements370,371, studies on cell clones
with single integrations show that differing integration sites can have large differences in
proviral expression372–374. These data suggest that integration site location, along with the
cellular environment374–377, influences the balance between latency and proviral expression.
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Associations between latency and genomic features have also been reported in collections of
integration sites from cell culture models although the consistency of these effects across
model systems and their relationships to latency in patients remains uncertain. Lewinski
et al. 150 reported that proviruses integrated in gene deserts, alphoid repeats and highly
expressed genes are more likely to have low expression. Shan et al. 151 reported an association
between latency and integration in the same transcriptional orientation as host genes. Pace
et al. 152 found that silent and expressed provirus integration sites differed in the abundance
and expression levels of nearby genes, GC content, CpG islands and alphoid repeats. In
model systems with defined integration sites, Lenasi et al. 378 reported decreased and Han
et al. 379 reported increased viral transcription when the provirus is downstream of a highly
expressed host gene.
Cell-based models of latency are important for many aspects of HIV research, including
screening small molecules that can reverse latency and potentially allow eradication380,381.
Location-driven differences in expression are preserved even after demethylation and histone
deacetylase treatment372, which suggests that integration location has the potential to
confound “shock and kill” anti-latency treatments382,383. A greater understanding of the
effects of integration site location on latency could thus affect antiretroviral development.
To search for features of integration site associated with latency, we generated a set of
inducible and expressed integration sites using a primary central memory CD4+ T cell model
of latency384,385, collected four previously reported integration site datasets and modeled
the effects of genomic features near the integration site on the expression status of these
proviruses. Although some genomic features associated with latency in individual models,
no feature was consistently associated with proviral expression across all five cell culture
models. However, closely neighboring proviruses within the same cellular model shared the
same latency status much more often than expected by chance suggesting that chromosomal
position of integration affects latency but that the mechanism remains unclear or differs
between cell culture models. Thus these data help inform the design of experiments in HIV
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eradication research.
2.3 Methods
2.3.1 Integration sites
Naive CD4+ T cells were purified by negative selection from peripheral blood mononuclear
cells. The cells were activated with anti-CD3 and anti-CD28 (+TGF-beta, anti-IL-12, and
anti-IL-4) to generate “non-polarized” cells (the in vitro equivalent of central memory T
cells). Five days after isolation, cells were infected with an NL4-3-based virus with GFP in
place of Nef and the LAI envelope (X4) provided in trans at a concentration of 500 ng of
p24 as measured by ELISA per million cells. Based on previous experience with this model,
this amount of p24 should produce an MOI of approximately 0.15. Cells were cultured
in the presence of IL-2. Two days post-infection, cells were sorted for GFP+; this active
population expresses GFP even when treated with flavopiridol, although for this study they
were not treated. The inducible population was the set of GFP negative cells from the initial
sort that, 9 days post-infection, were activated with anti-CD3 and anti-CD28 and sorted for
GFP production.
Genomic DNA from the inducible and expressed populations was digested with MseI, ligated
to an adapter, and amplified by ligation-mediated PCR essentially as in Wu et al. 386 and
Mitchell et al. 387 except that the nested PCR primers included sequence for the Ion Torrent
P1 adapter and adapter A sequence with a 5 base barcode sequence specific to the inducible
or expressed conditions. Amplicons were sequenced using an Ion Torrent Personal Genome
Machine (PGM) according to manufacturer’s instructions using an Ion 316 chip and the Ion
PGM 200 Sequencing kit (Life Technologies). The sequence reads were sorted into samples
by barcode. All reads were required to match the expected 5′ sequence with a Levenshtein
edit distance less than 3 from the expected barcode, 5′ primer and HIV long terminal repeat
(LTR). The 5′ primer and HIV sequence, along with the 3′ primer if present, were trimmed
from the read. Sequences with less than 24 bases remaining or containing any eight base
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window with an average quality less than 15 were discarded. Duplicate reads and reads
forming an exact substring of a longer read were removed.
2.3.2 Analysis
All statistical analysis was performed in R 2.15.2388. The analyses are described in a
reproducible report (Appendix A.2). The annotated integration site data necessary to
perform the analyses and the compilable code to generate this reproducible report are
provided as supplemental information366. The new Central Memory CD4+ data set was
analyzed as in Berry et al. 389 . The integration patterns appeared similar to previously
reported HIV integration site datasets390.
2.3.3 Previously published data
We collected integration sites from three previously reported studies (Table 2.1), for a total
of four expressed versus silent/inducible pairs of samples. These studies used primary CD4+
T cells or Jurkat cells infected with HIV or HIV-derived constructs as cell culture models of
latency. Flow cytometry allowed cells expressing viral encoded proteins to be sorted from
non-expressing cells. In two of the studies, these non-expressing populations were stimulated
to ensure that the provirus could be aroused from latency. Specific differences in protocol
between the study sets are summarized below.
Jurkat Lewinski et al. 150 infected Jurkat cells with a VSV-G pseudotyped, GFP-expressing
pEV731 HIV construct (LTR-Tat-IRES-GFP)372 at an MOI of 0.1. The cells were
sorted into GFP+ and GFP- two to four days after infection. GFP+ cells were sorted
again two weeks after infection and cells that were again GFP+ were collected for
integration site sequencing. GFP- cells were sorted for GFP negativity twice more
then stimulated with TNFα . Cells that were GFP+ after stimulation were collected
for integration site sequencing. DNA was digested with MseI or a combination of NheI,
SpeI and XbaI, ligated to adapters for nested PCR, amplified and sequenced by Sanger
capillary electrophoresis.
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Bcl-2 transduced CD4+ Shan et al. 151 transduced CD4+ T cells with Bcl-2, costimulated
with bound anti-CD3 and soluble anti-CD28 antibodies, interleukin-2 and T cell growth
factor and then infected with X4-pseudotyped GFP-expressing NL4-3-δ6-drEGFP
construct391 at an MOI of less than 0.1. DNA was extracted, digested with PstI and
circularized392. HIV-human junctions were amplified by reverse PCR and sequenced
using Sanger capillary electrophoresis.
Active CD4+ & Resting CD4+ Pace et al. 152 spinoculated CD4+ T cells with HIV NL4-
3 at an MOI of 0.1. After 96 hours, the cells were stained for intracellular Gag CD25,
CD69 and HLA-DR and sorted into four subpopulations based on activation state
and Gag expression; activated Gag-, activated Gag+, resting Gag- and resting Gag+.
The ability of the viruses to reactivate was not tested although previous studies have
shown that the majority are likely inducible393. Genomic DNA was extracted and
digested with restriction enzymes MseI and Tsp509 and ligated to adapters. Proviral
LTR-host genome junctions were sequenced by 454 pyrosequencing after nested PCR.
All datasets were processed using the hiReadsProcessor R package394. Adaptor trimmed
reads were aligned to UCSC freeze hg19 using BLAT395. Genomic alignments were scored
and required to start within the first three bases of a read with 98% identity. Alignments for
a given read with a BLAT score less than the maximum score for that read were discarded.
Reads giving rise to multiple best scoring genomic alignments were excluded, while reads
with a single best hit were dereplicated and converged if within 5bp of each other. The
Bcl-2 transduced CD4+ sample was sequenced from U3 in the 5′ HIV LTR while the other
samples were sequenced from U5 in the 3′ LTR. To account for the 5 base duplication of
host DNA caused by HIV integration, the chromosomal coordinates of the Bcl-2 transduced
CD4+ sample were adjusted by ±4 bases.
To allow for alignment difficulties in the analysis of genomic repeats, reads with multiple
best scoring alignments, along with the single best hit reads used above, were included in
the repeat analyses. If any best scoring alignment for a read fell within a repeat, then that
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Title Cell
type
Virus Time of
harvest
after
infection
Sequenc-
ing
Gener-
ation of
expressed
vs. silent/
inducible
Citation Silent/
induc-
ible
unique
sites
Ex-
pressed
unique
sites
Jurkat Jurkat
cells
HIV vector
pEV731
(LTR-Tat-
IRES-GFP)
2 weeks Sanger TNFα , GFP
expression
Lewinski
et al. 150
463
inducible
643
Bcl-2
trans-
duced
CD4+
Primary
CD4+
T cells
(Bcl-2
trans-
duced)
HIV NL4-3-
δ6-drEGFP
(inactivated
gag, vif, vpr,
vpu, nef and
env replaced
by GFP)
3 days +
3-4 weeks
+ 3 days
Sanger anti-CD3,
anti-CD28
antibodies,
GFP
expression
Shan
et al. 151
446
inducible
273
Active
CD4+
Primary
active
CD4+ T
cells
HIV NL4-3 3 days 454 high vs. low
Gag
Pace
et al. 152
1604
silent
1274
Resting
CD4+
Primary
resting
CD4+ T
cells
HIV NL4-3 3 days 454 high vs. low
Gag
Pace
et al. 152
1942
silent
784
Central
Mem-
ory
CD4+
Primary
central
memory
CD4+ T
cells
HIV NL4-3
∆Nef GFP
2 days/9
days
Ion-
Torrent
anti-CD3,
anti-CD28
antibodies,
GFP
expression
This
paper
1729
inducible
3278
Table 2.1: HIV-1 integration datasets from in vitro models of latency where the proviruses
were determined to be silent/inducible or expressed
read was considered to map to that repeat.
2.3.4 Genomic features
A total of 140 whole genome features for CD4+ T-cells were gathered from data sources
indicated in Table 2.2. For features encoded as peaks or hotspots, the log of the distance of
each integration site to the nearest border was used for modeling. Integration sites from
HIV 89.6 infection in primary CD4+ T cells396 were used to count nearby integrations and
determine a ±20bp position weight matrix for integration targets. Illumina RNA-Seq from
active CD4+ cells (Chapter 4) was used to estimate raw cellular expression and fragments
per kilobase of transcript per million mapped reads for genes as calculated by Cuﬄinks397.
For sequence-based data like RNA-Seq and ChIP-Seq, the number of reads aligned within
a ± 50, 500, 5,000 50,000 and 500,000 bp windows of each integration site were counted
and log transformed. In addition, chromatin state classifications derived from a hidden
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Markov model based on histone marks and a few binding factors398 were included as binary
variables. All data from previous genomic freezes were converted to hg19 using liftover399.
2.4 Results
The combination of integration site data newly reported here (set named “Central Memory
CD4+”) with previously published data (sets named “Jurkat”, “Bcl-2 transduced CD4+”,
“Active CD4+”, and “Resting CD4+”) provides a collection of 12,436 integration sites (Table
2.1) where the expression status of the provirus—silent/inducible or expressed—is known.
In three of the datasets, Jurkat, Central Memory CD4+ and Bcl-2 transduced CD4+, the
proviruses were sorted based on inducibility. In the Resting CD4+ and Active CD4+ datasets,
cells were sorted only based on proviral expression. Previous studies have shown that most
silent proviruses in this model system are inducible393.
2.4.1 Global model
If a genomic feature and latency are monotonically related then we should be able to detect
this relationship using Spearman rank correlation. In addition if a feature has a consistent
effect across models we should see a consistent pattern in the direction of correlation. A
simple first look for correlation between genomic features (Table 2.2) and latency status
yielded inconsistent results among the five samples with no variables having a significant
Spearman rank correlation across all, or even four out of five, of the samples (Figure 2.1).
This suggests that there is not a consistent simple monotonic relationship between the
genomic variable and latency, or that any such correlations are modest and not detectable
across all studies given the available statistical power. We return to some of the stronger
trends below.
To investigate whether a combination of variables may affect latency, we fit a lasso-regularized
logistic regression, as implemented in the R package glmnet408, to predict latency using
the genomic variables. The relationship between silent/inducible status and each genomic
variable was allowed to vary between models by including the interaction of genomic features
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Group Type Source Number Types
T cell expression RNA-Seq Chapter 4 1 RNA
Jurkat expression RNA-Seq Encode400 1 wgEncodeHudsonalphaRnaSeq
Integration sites Locations Berry
et al. 396
1 sites
DNase sensitivity DNA-Seq/peaks Encode400 1 wgEncodeOpenChromDnase
Methylation DNA-Seq
401
1 Methyl
CpG Locations UCSC402 1 cpgIslandExt
Sequence-based Continuous — 4 % GC, HIV PWM score, distance to
centrosome, chromosomal position
Repeats Locations UCSC402 16 DNA, LINE, Low complexity, LTR,
Other, RC, RNA, rRNA, Satellite,
scRNA, Simple repeat, SINE, snRNA,
srpRNA, tRNA, alphoid
Histone features ChIP-Seq/Peaks Wang
et al. 403
18 H2AK5ac, H2AK9ac, H2BK120ac,
H2BK12ac, H2BK20ac, H2BK5ac,
H3K14ac, H3K18ac, H3K23ac,
H3K27ac, H3K36ac, H3K4ac, H3K9ac,
H4K12ac, H4K16ac, H4K5ac, H4K8ac,
H4K91ac
Histone features ChIP-Seq/Peaks Barski
et al. 404
23 CTCF, H2AZ, H2BK5me1,
H3K27me1, H3K27me2, H3K27me3,
H3K36me1, H3K36me3, H3K4me1,
H3K4me2, H3K4me3, H3K79me1,
H3K79me2, H3K79me3, H3K9me1,
H3K9me2, H3K9me3, H3R2me1,
H3R2me2, H4K20me1, H4K20me3,
H4R3me2, PolII
Chromatin state Binary Ernst and
Kellis 398
51 state1,state2,...,state51
HATs and HDACs ChIP-Seq Wang
et al. 405
11 Resting-HDAC1, Resting-HDAC2,
Resting-HDAC3, Resting-HDAC6,
Resting-p300, Resting-CBP,
Resting-MOF, Resting-PCAF,
Resting-Tip60, Active-HDAC6,
Active-Tip60
Nucleosome ChIP-Seq Schones
et al. 406
2 Resting-Nucleosomes, Active
Nucleosomes
UCSC genes Locations Hsu et al. 407 4 in gene, in gene (same strand), gene
count, distance to nearest gene, in
exon, in intron
Table 2.2: Genomic data available for comparison to HIV integration sites
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Figure 2.1: Spearman rank correlation between proviral expression status and genomic
features. Only genomic features with at least one correlation with latency with a false
discovery rate q-value < 0.01 (marked by asterisks) are shown.
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Figure 2.2: Misclassification error from cross validation for lasso regressions of silent/inducible
status on genomic features as a function of λ, the regularization coefficient for the lasso
regression, for all cell culture models combined and each individual cell culture model.
The number of variables included and size of coefficients in the model increases to the left.
Whiskers show the standard error of mean misclassification error. Dashed vertical lines
indicate the minimum misclassification error and the simplest model within one standard
error. Dotted horizontal line indicates the misclassification error expected from random
guessing.
with dummy variables indicating cellular model. The λ smoothing parameter of the lasso
regression was optimized by finding the λ with lowest classification error in 480-fold cross
validation and finding the simplest model with misclassification error within one standard
error.
The proportion of silent/inducible sites varied between the samples. To avoid the model
overfitting on this source of variation, an indicator variable for each sample was included in
the base model. The base model with no genomic variables was selected as the best model by
cross validation (Figure 2.2A). This suggest that there is not a consistent linear relationship
between an additive combination of genomic variables and latency across all models.
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When each dataset was fit individually with leave-one-out cross validation, improvements in
cross-validated misclassification error were only observed in the Active CD4+ (5.8% decrease
in misclassification error, standard error: 2.1) and Jurkat (6.7% decrease in misclassification
error, standard error: 3.5) samples (Figure 2.2B-F). There was no overlap in variables
selected for the Active CD4+ and Jurkat samples.
Finding little global association between latency and genomic features, we investigated
whether predictors of latency reported previously by single studies were consistently associ-
ated with latency across studies.
2.4.2 Cellular transcription
Model systems with defined integration sites show upstream transcription can interfere with
viral transcription409 and that cellular transcription in the same orientation may interfere
with viral transcription378 or increase viral transcription379 and in opposite orientations
may decrease transcription379. In integration site studies, integration outside genes appears
to increase latency150 but high transcription of nearby host cell genes may cause increased
latency150,151. In addition, Tat or other viral proteins may affect cellular transcription319,410.
To look at transcription and latency, we ran a logistic regression of silent/inducible status
on a quartic function of RNA expression, as determined by RNA-Seq reads within 5,000
bases in Jurkat cells for the Jurkat sample or CD4+ T cells for the remaining samples,
interacted with indicator variables encoding cell culture model. There appears to be little
agreement between samples (Figure 2.3). The Resting CD4+ and Active CD4+ datasets
show an enrichment in silent proviruses in regions with low gene expression. The other three
studies show the opposite or no relationship for low expression regions. The two samples
showing increased silence in areas of low expression (Resting CD4+ and Active CD4+) are
from a study that did not check whether inactive viruses could be activated. One possible
explanation is that regions with low gene transcription may harbor proviruses that are not
easily activated, though some other discrepancy between in vitro systems could also explain
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Figure 2.3: Predictions from a logis-
tic regression of silent/inducible status
on cellular RNA expression. High y-
axis values are predicted to be silent/in-
ducible. Dashed line shows where equal
odds of silent/inducible and expressed
are predicted. Solid lines show predic-
tions from the regression for each sam-
ple and shaded regions indicate one stan-
dard error from the modeled predictions.
the difference. Both the Jurkat and Active CD4+ samples appear to increase in latency with
increasing expression while the remaining three studies did not show a strong trend.
2.4.3 Orientation bias
Shan et al. 151 reported that inducible proviruses were oriented in the same strand as the
host cell genes into which they had integrated more often than chance. This orientation bias
was still reproduced after our reprocessing of the Bcl-2 transduced CD4+ sample from Shan
et al. 151 . However, the proportion of provirus oriented in the same strand as host genes did
not differ significantly from 50% in the other samples (Figure 2.4). Perhaps orientation bias
and transcriptional interference are especially sensitive to parameters of the model system.
2.4.4 Gene deserts
Lewinski et al. 150 reported increased latency in gene deserts. In the collected data, integration
outside known genes was associated with latency (Fisher’s exact test, p < 10−6). This
seemed to largely be driven by the Active CD4+ and Resting CD4+ samples with significant
association found individually in only those two samples (both p < 10−8) and no significant
association observed in the other three samples (Figure 2.5A). Looking only at integration
sites outside genes, silent sites in the Resting CD4+ sample had a mean distance to the
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Figure 2.4: The proportion of provirus
integrated in the opposite strand com-
pared to cellular genes in silent/inducible
(blue) and expressed (red) samples. Er-
ror bars show the 95% Clopper-Pearson
binomial confidence interval.
nearest gene 2.5 times greater than that of expressed sites (95% CI: 2.2–6.2×, p < 10−6,
Welch two sample t-test on log transformed distance) (Figure 2.5B). The Active CD4+
sample had a small difference that did not survive Bonferroni correction.
Lewinski et al. 150 also reported decreased latency near CpG islands and reasoned this was
tied to the increased latency in gene deserts. In the Resting CD4+ sample, silent sites were
on average further from CpG islands than expressed sites (Bonferroni corrected Welch’s two
sample T test, p = 0.006), but there was no significant relationship between silent/inducible
status and log distance to CpG island after Bonferroni correction if the integration site’s
location inside or outside of a gene was accounted for first (analysis of deviance).
2.4.5 Alphoid repeats
Alphoid repeats are repetitive DNA sequences found largely in the heterochromatin of
centromeres411. Integration near heterochromatic alphoid repeats has been reported to
associate with latency150,152,373. Looking only at uniquely mapping sites, there was no
statistically significant association between latency and location inside an alphoid repeat in
pooled or individual samples (Fisher’s exact test).
Since alphoid repeats are both problematic to assemble in genomes and difficult to map
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Figure 2.5: (A) The proportion of provirus integrated outside genes in silent/inducible
(blue) and expressed (red) samples. Error bars show the 95% Clopper-Pearson binomial
confidence interval. (B) The nearest distance to any gene for integration sites (points)
outside genes in the five samples. Points are spread in proportion to kernel density estimates.
Horizontal lines indicate sample means where there was a significant difference in means
between silent/inducible and expressed provirus (black) or no significant difference (grey).
onto, we reasoned that some alphoid hits might be lost or miscounted in the filtering
procedures of the standard workup. To counteract this, we treated each sequence read as an
independent observation of a proviral integration and included sequence reads with more
than one best scoring alignment. For multiply aligned reads, we considered the read to have
been inside an alphoid repeat if any of its best scoring alignments fell within a repeat. We
found 74 reads with potential alphoid mappings. Integration inside alphoid repeats was
significantly associated with the expression status of a provirus in the Resting CD4+, Jurkat
and Central Memory CD4+ datasets (Bonferroni corrected Fisher’s exact test, all p < 0.05)
and approached significance in the Active CD4+ dataset (p = 0.053) (Figure 2.6). The Bcl-2
transduced CD4+ data did not contain any integration sites in alphoid repeats, probably due
to 1) the relatively low number of integration sites in the dataset and 2) to the requirement
for cleavage at two Pst1 restriction sites, which are not found in the consensus sequence of
alphoid repeats412. Of the 1340 repeat types in the RepeatMasker database412, only alphoid
repeats achieved a significant association with proviral expression in more than two datasets.
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Figure 2.6: The proportion of integra-
tion sites with matches in alphoid re-
peats in silent/inducible (blue) and ex-
pressed (red) cells in five samples. Er-
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2.4.6 Acetylation
Histone marks or chromatin remodeling, especially involving the key “Nuc-1” histone near
the transcription start site in the viral LTR, appear to affect viral expression374,413,414.
Based on this effect, histone deacetylase inhibitors have been developed as potential HIV
treatments and show some promise in disrupting latency383. In these genome-wide datasets,
we do not have information on the state of individual LTR nucleosomes. However, repressive
chromatin does seem to spread to nearby locations if not blocked by insulators370,371 and
the state of neighboring chromatin could affect proviral transcription independently of
provirus-associated histones.
We found that the number of ChIP-seq reads near an integration site from several histone
acetylation marks (Figure 2.1) were associated with efficient expression in the Active
CD4+, Resting CD4+ and Central Memory CD4+ samples. H4K12ac had the strongest
association (Bonferroni corrected Fisher’s method combination of Spearman’s ρ, p < 10−25)
with silence/latency (Figure 2.7A).
Although the appearance of several significantly associated acetylation marks might suggest
acetylation exerts a considerable effect on the expression of a provirus, there are strong
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correlations among these marks, so their effects may not be independent. To account for
the correlations between these variables, we performed a principal component analysis
(PCA) to convert the correlated acetylation marks into a series of uncorrelated principal
components that capture much of the variance within a few components. Here, the first
principal component explained 59% of the variance and the first ten components 84%.
Several of these principal components again displayed significant associations with latency
in the Active CD4+, Resting CD4+ and Central Memory CD4+ samples but no significant
correlations in the Bcl-2 transduced CD4+ or Jurkat samples (Figure 2.7B). A logistic
regression of expression status on the first ten principal components and sample did not
reduce misclassification error from a base model including only sample in 480-fold cross
validation (base model misclassification error: 36.4%, PCA model: 36.5%). This suggests
that acetylation of neighboring chromatin does not exert strong effects on latency in all
samples.
2.4.7 Clustering
We reasoned that if there was a strong relationship between latency and chromosomal
position, then integration sites that are near one another on the same chromosome should
share the same expression status more often than expected by chance. To test this, we
compared how often pairs of proviruses shared the same expression status in relation to
the distance between the two sites (Figure 2.8). Pairs of sites with little distance between
integration locations did share the same expression status more often than expected by
chance (e.g. neighbors closer than 100bp, Fisher exact test p = 0.0002). Breaking out the
data to separate between sample and within sample pairings showed that this matching was
limited to neighbors within the same experimental model (Figure 2.8), emphasizing that
chromosomal environment does appear to influence latency, but the factors involved differ
among experimental models of latency.
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Figure 2.7: (A) The number of ChIP-seq reads for H4K12ac, the histone mark with the
lowest Fisher’s method p-value for correlation with latency, within 50,000 bases across the
five samples. Integration sites (points) are spread in proportion to kernel density estimates.
Horizontal lines indicate sample means where there was a significant difference (black) in
means between silent/inducible and expressed provirus or no significant difference (grey).
(B) The correlation (points) and its 95% confidence interval (vertical lines) between principal
components of acetylation and silent/inducible status for each of the five samples. Red
indicates correlations with a Bonferroni-corrected p-value < 0.05.
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Figure 2.8: The ratio of the number of
pairs of proviruses with matching expres-
sion status to the number of matches
expected by random pairings given the
frequency of silent/inducible proviruses.
All possible pairs of proviruses inte-
grated within a given distance of each
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with both proviruses from within the
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Pearson binomial confidence interval for
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The dashed horizontal line shows the
ratio of 1 expected if there is no associ-
ation between the expression status of
neighboring proviruses.
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2.5 Conclusions
Here we compared the latency status of HIV-1 proviruses in five model systems with the
genomic features surrounding their integration sites. Surprisingly, no relationships between
genomic features near the integration location and latency achieved significance in all models.
Proviruses from the same cellular model integrated in nearby positions did share the same
latency status much more often than predicted by chance, indicating the existence of local
features influencing latency, but these were not consistent among models. This suggests that
whatever features are affecting latency are highly local and model-specific, and that we may
not have access to all relevant chromosomal features e.g. 415–418.
In addition to differences in experimental conditions, methodological issues have the potential
to obscure patterns. Examples include multiply infected cells, inactivated viruses and
inaccurate assessment of HIV gene activity—each of these are discussed below.
A latent provirus integrated into the same cell as an expressed provirus will be erroneously
sorted as expressed, potentially confounding analysis. A low multiplicity of infection (MOI)
will help to avoid this problem, but there is still the potential for a significant proportion of
the cells studied to contain multiple integrations. This problem arises because although cells
with multiple integrations form a small proportion of total cells, most of the total are cells
lacking an integrated provirus and thus are excluded by experimental design. For example,
assuming integrations are Poisson distributed with an MOI of 0.1 (1 integration per 10 cells),
90.5% of cells will not contain a provirus, 9% of cells will contain one proviral integration
and 0.5% of cells will contain multiple integrations. The cells without an integration are
not amplified by HIV-targeted PCR leaving only 9.5% of the total cells. Of these cells
actually under study, 4.9% will contain multiple integrations. Thus the signal from expressed
proviruses may be muted by the presence of latent proviruses in the expressed population.
The replication cycle of HIV is error prone, and a significant proportion of virions contain
mutated genomes87. In studies that do not check for inducibility, mutant proviruses
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integrated in regions of the genome otherwise favorable to proviral expression can be sorted
into the latent pool due to mutational inactivation. This problem of inactivated provirus
is worse when latent provirus are rare and exacerbated further when looking at latency in
the cells of HIV patients due to selective enrichment of inactivated proviruses incapable
of spreading infection140. Here, the effects of mutation are minimized in the datasets that
required inducible viral expression (Jurkat, Bcl-2 transduced CD4+, Central Memory CD4+)
but may be a confounder in the two datasets that were sorted based on lack of viral expression
only (Active CD4+, Resting CD4+).
Inaccurate staining or leaky markers may also result in misclassification of proviruses. False
positives and false negatives will result in incorrectly sorted latent and expressed integrations.
For example, if 5% of cells not containing Gag are labeled as Gag+ and there are an equal
amount of latent and expressed integration sites, then 4.8% of integrations labeled expressed
will actually be latent. If a category is rare, false staining has even greater potential to cause
error. For example, if only 5% of sites are latent and a Gag stain has a false negative rate
of 5%, then we would expect 48.7% of sites classified as latent to actually be mislabeled
expressed integrations.
Attempts to induce latent proviruses in patients have so far focused on using histone
deacetylase inhibitors, raising interest in associations with histone acetylation in these data.
An important caveat in results from these genome-wide data is that histone modification
near the integrated provirus may not be representative of modification within the provirus
at the key “Nuc-1” nucleosome of the transcription start site414, though local correlations in
chromatin states are well established from studies of position effect variegation370,371. We
found that some histone acetylation marks were significantly associated with viral expression
in some but not all samples (Figures 2.1, 2.7). This lack of association may be due to a
lack of power in these studies, but the confidence intervals suggest that any correlations
between acetylations and latency are unlikely to be strong. These weak correlations raise
the possibility that there are populations of latent proviruses that are not associated with
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acetylation and may not be inducible by histone deacetylase inhibitors.
This study highlights that the choice of model system can have a large effect on measurements
of latency. Further studies are needed to determine which in vitro models best reflect latency
in vivo. Different cell models may report genuinely different mechanisms of latency. While we
did see some relationship between histone acetylation and latency, paralleling a recent clinical
trial of SAHA383, associations with histone acetylation did not explain a large fraction of
the difference between latent and expresssed proviruses in any of the five models. One
possible explanation is that there may be multiple mechanisms that maintain proviruses in a
latent state. To be successful, shock-and-kill treatments must induce and destroy all latent
proviruses to eliminate HIV from an infected individual, raising the question of whether
multiple simultaneous inducing treatments will be necessary.
2.6 Availability of supporting data
Sequence reads from the Central Memory CD4+ sample reported here, the Resting CD4+
and Active CD4+ data reported by Pace et al. 152 , the Bcl-2 transduced CD4+ data reported
by Shan et al. 151 and reprocessed data originally reported by Lewinski et al. 150 are available
at the Sequence Read Archive under accession number SRP028573.
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3.1 Abstract
Alternative RNA splicing greatly expands the repertoire of proteins encoded by genomes.
Next-generation sequencing (NGS) is attractive for studying alternative splicing because
of the efficiency and low cost per base, but short reads typical of NGS only report mRNA
fragments containing one or few splice junctions. Here, we used single-molecule amplification
and long-read sequencing to study the HIV-1 provirus, which is only 9700 bp in length, but
encodes nine major proteins via alternative splicing. Our data showed that the clinical isolate
HIV89.6 produces at least 109 different spliced RNAs, including a previously unappreciated
∼1 kb class of messages, two of which encode new proteins. HIV-1 message populations
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differed between cell types, longitudinally during infection, and among T cells from different
human donors. These findings open a new window on a little studied aspect of HIV-1
replication, suggest therapeutic opportunities and provide advanced tools for the study of
alternative splicing.
3.2 Introduction
Alternative splicing greatly expands the information content of genomes by producing
multiple mRNAs from individual transcription units. Approximately 95% of human genes
with multiple exons encode RNA transcripts that are alternatively spliced, and mutations
that affect alternative splicing are associated with diseases ranging from cystic fibrosis to
chronic lymphoproliferative leukemia420–424. Work to decipher an RNA ‘splicing code’ has
revealed that multiple interactions between trans-acting factors and RNA elements determine
splicing patterns, though regulation is little understood for most genes305.
The integrated HIV-1 provirus is ∼9700 bp in length and has a single transcription start
site, but according to the published literature yields at least 47 different mRNAs encoding
9 proteins or polyproteins, making HIV an attractive model for studies of alternative
splicing425. HIV mRNAs fall into three classes: the unspliced RNA genome, which encodes
Gag/Gag-Pol; partially spliced transcripts, ∼4 kb in length, encoding Vif, Vpr, a one-exon
version of Tat, and Env/Vpu; and completely spliced mRNAs of roughly 2 kb encoding
Tat, Rev and Nef (Figure 3.1A). Additional rare ‘cryptic’ splice donors (5′ splice sites) and
acceptors (3′ splice sites) contribute even more mRNAs426–431. A complex array of positive
and negative cis-acting elements surrounding each splice site regulates the relative abundance
of the HIV-1 mRNAs, and disrupting the balance of message ratios impairs viral replication
in several models284,432–438. Studies have suggested strain-specific splicing patterns may
exist425,439,440. However, detailed studies of complete message populations have not been
reported for clinical isolates of HIV-1.
Several groups have demonstrated tissue- and differentiation-specific splicing of cellular
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Figure 3.1: Mapping the splice donors and acceptors of HIV89.6. PacBio sequence reads
of HIV89.6 cDNA from infected HOS-CD4-CCR5 (HOS) and CD4
+ T cells were aligned to
the HIV89.6 genome shown in (A). Exons of the conserved HIV-1 transcripts are colored
according to the encoded gene. Conserved (black) and published cryptic (brown) splice
donors (‘D’) and acceptors (‘A’) are shown. Gaps in HIV-1 sequence alignments with at least
one end located at a published or verified splice donor or acceptor were defined as introns.
For each base of the HIV89.6 genome, the number of sequence reads in which that base
occurred at the 5′-end (B) or 3′-end (C) of an intron is plotted for each cell type. Putative
splice donors and acceptors were defined as loci that were found in at least 10 reads at the
5′- and 3′-ends of introns in sequence alignments from T-cell infections. Regions containing
splice sites are enlarged for clarity. Asterisks indicate putative splice sites that are adjacent
to dinucleotides other than the consensus GT and AG.
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genes421,441,442. Importantly for HIV, these include changes during T-cell activation443,444,
raising the question of how cell-specific splicing affects HIV replication. While most studies
of HIV-1 splicing have been conducted in cell lines using lab-adapted viral strains, limited
works in PBMCs from infected patients, monocytes and macrophages have suggested that
differences may indeed exist in relevant cell types427,439,445,446. Moreover, human splicing
patterns differ between individuals, but such polymorphisms have not been investigated in
the context of HIV infection447,448.
Here, we use deep sequencing to comprehensively characterize the transcriptome of an early
passage clinical isolate, HIV89.6
449, in primary CD4+ T cells from seven human donors and
in the human osteosarcoma (HOS) cell line. Many deep sequencing techniques provide
short reads, which rarely query more than a single exon-exon junction. To distinguish
the full structure of HIV-1 mRNAs, which can contain several splice junctions, we used
Pacific Biosciences (PacBio) sequencing technology, which yields read lengths up to 10 kb450.
We used RainDance Technologies single-molecule PCR enrichment to preserve ratios of
RNAs during preparation of sequencing templates. We identified previously published and
novel HIV-1 transcripts and determined that HIV89.6 encodes a minimum of 109 different
splice forms. These included a new size class of transcripts, some of which contain novel
open reading frames (ORFs) that encode new proteins. We also found significant variation
between cell types, over time during infection of HOS cells and among individuals. These
data reveal unanticipated complexity and dynamics in HIV-1 message populations, begin
to clarify a little studied dimension of HIV-1 replication and suggest possible targets for
therapeutic interventions.
3.3 Materials and methods
3.3.1 Cell culture and viral infections
HIV89.6 was generated by transfection and subsequent expansion in SupT1 cells. Primary
T cells were isolated by the University of Pennsylvania Center for AIDS Research Im-
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munology core and confirmed to be homozygous for the wild-type CCR5 allele as shown
in Supplementary Table S1 and described in Supplementary Methods. HOS-CD4-CCR5
cells451,452 were obtained through the AIDS Research and Reference Reagent Program,
Division of AIDS, NIAID, NIH from Dr Nathaniel Landau. Single round infections in T
cells and HOS-CD4-CCR5 cells were performed using standard methods (see Supplementary
Methods).
3.3.2 RNA and reverse transcription
Total cellular RNA was purified using the Illustra RNA kit (GE Life Sciences, Fairfield, CT,
USA) from 5 × 106 cells per infection. Viral cDNA was made using a reverse transcription
primer complementary to a sequence in U3 (RTprime, Supplementary Table S2). We used
Superscript III reverse transcriptase (Invitrogen) in the presence of RNaseOUT (Invitrogen)
to conduct first-strand cDNA synthesis from equal amounts of total cellular RNA from each
HOS-CD4-CCR5 time point (15.2 µg) and from each T-cell infection (3 µg) according to the
manufacturer’s instructions for gene-specific priming of long cDNAs, and then treated with
RNaseH (Invitrogen). We checked for full reverse transcription of the longest (unspliced)
viral cDNAs by PCR using primers that bind in the first major intron of HIV89.6 (keo003,
keo004, Supplementary Table S2, data not shown).
3.3.3 Bulk RT-PCR and cloning
Transcripts were amplified from cellular RNA using the Onestep RT-PCR kit (Qiagen)
with primer pairs keo056/keo057 and keo058/keo059 (Supplementary Table S2) with the
following amplification: 5 cycles of 30 s at 94◦C, 12 s at 56◦C, 40 s at 72◦C; then 30 cycles
of 30 s at 94◦C, 14 s at 56◦C, 40 s at 72◦C; and finally 10 min at 72◦C. For verification of
dynamic changes, primers F1.2 and R1.2 were used with 35 cycles of 30 s at 94◦C, 30 s at
56◦C and 45 s at 72◦C followed by 10 min at 72◦C. Products were resolved on agarose gels
(Nusieve 3:1, Lonza for verification of dynamic changes, Invitrogen for cloning) stained with
ethidium-bromide (Sigma) for visualization, or SYBR Safe DNA gel stain (Invitrogen) for
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cloning (keo056/keo057 amplified material). DNA was purified using Qiaquick gel extraction
kit (Qiagen) and cloned using the TOPO TA cloning kit (Invitrogen). Plasmid DNA was
prepared using Qiaprep Spin Miniprep kit (Qiagen). Inserts were identified and verified
using Sanger sequencing. The cDNAs for tatˆ8c, tat (1 and 2 exon), ref, rev and nef, and the
transcript with exon structure 1-5-8c were cloned into the expression vector pIRES2-AcGFP1
(Clonetech) as described in Supplementary Methods.
3.3.4 Assays of protein activity and HIV replication
Activity and HIV replication assays were performed as described in Supplementary Methods.
Tat activity expressed from each cDNA was measured in TZM-bl cells204 (gift of Dr Robert
W. Doms). Rev activity was assayed in HEK-293T cells co-transfected with pCMVGagPol-
RRE-R, a reporter plasmid from which Gag and Pol are expressed in a Rev-dependent
manner (gift of David Rekosh)453. Intracellular and released supernatant p24 was measured
from cells transfected with expression constructs and infected with HIV89.6.
3.3.5 Western blotting
HEK-293T cells were transfected with expression constructs and treated with MG132 (EMD
Chemicals) to inhibit the proteasome or DMSO (Supplementary Methods). Proteins were
detected by immunoblotting using a mouse antibody that recognizes the carboxy terminus
of HIV-1 Nef diluted 1:1000 in 5% milk (gift of Dr James Hoxie)454. Horseradish peroxidase
(HRP)-conjugated secondary rabbit-anti-mouse antibody (p0260, DAKO) was used for
detection with SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific).
Beta-tubulin was used as a loading control, detected by the HRP-conjugated antibody
(ab21058, Abcam).
3.3.6 Single-molecule amplification
Amplification was performed by RainDance Technologies using a protocol similar to that
previously reported (detailed description in Supplementary Methods)455. Amplification
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was carried out in droplets to suppress competition between amplicons. PCR droplets
were generated on the RDT 1000 (RainDance Technologies) using the manufacturer’s
recommended protocol. The custom primer libraries for this study contained 18 (HOS-CD4-
CCR5 cells) or 20 (primary T cells) PCR primer pairs designed to amplify different HIV
RNA isoforms (Supplementary Table S2).
3.3.7 Single-molecule sequencing
DNA amplification products from the RainDance PCR droplets were converted to SMRTbell
templates using the PacBio RS DNA Template Preparation Kit. Sequencing was performed by
Pacific Biosciences using the PacBio SMRT sequencing technology as described450. Sequence
information was acquired during real time as the immobilized DNA polymerase translocated
along the template molecule. Prior to sequence acquisition, hairpin adapters were ligated to
each DNA template end so that DNA polymerase could traverse DNA molecules multiple
times during rolling circle replication (SMRTbell template sequencing456), allowing error
control by calculating the consensus (‘circular consensus sequence’ or CCS). For raw reads,
the average length was 2860 nt, and 10% were > 5000 nt. After condensing into consensus
reads, the mean read length was 249.5 nt, due to the use of a shorter Pacific Biosciences
sequencing protocol to accommodate the small size of many amplicons. Consensus reads of
1% were > 1100 nt. Sequencing data were collected in 45-min movies.
3.3.8 Data analysis
Raw reads were processed to produce CCSs. Raw reads were also retained to help in primer
identification and to avoid biasing against long reads. Reads were aligned against the human
genome using Blat395. Misprimed reads matching the RT primer, reads with a CCS length
shorter than 40 nt or raw length shorter than 100 nt and reads matching the human genome
were discarded. Filtered reads were aligned against the HIV89.6 reference genome. Potential
novel donors and acceptors were found by filtering putative splice junctions in the Blat
hits for a perfect sequence match 20 bases up- and downstream of the junction, ignoring
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homopolymer errors, and requiring that one end of the junction be a known splice site. Local
maximums within a 5-nt span with > 9 such junctions were called as novel splice sites.
Filter-passed reads were aligned against all expected fragments based on primers and known
and novel junctions. Primers were identified in CCS reads by an edit distance ≤ 1 from
the primer in the start or end of the read, in raw reads by an edit distance ≤ 5 from a
concatenation of the primer, hairpin adapter and the reverse complement of the primer, and
in both types of reads by a Blat hit spanning an entire expected fragment.
Gaps in Blat hits were ignored if ≤ 10 bases long or in regions of likely poor read quality
≤ 20 bases long where an inferred insertion of unmatched bases in the read occurred at the
same location as skipped bases in the reference. Any Blat hits with a gap > 10 nt remaining
in the query read were discarded. If HIV sequence was repeated in a given read (likely due
to PacBio circular sequencing), the alignments were collapsed into the union of the coverage.
Gaps in the HIV sequence found in uninterrupted query sequence were called as tentative
introns. Splice junctions were assigned to conserved or previously identified (published
or in this work) splice sites and reads appearing to contain donors or acceptors further
than 5 nt away from these sites were discarded. Reads with Blat hits outside the expected
primer range were discarded from that primer grouping. The assigned primer pair, observed
junctions and exonic sequence were used to assign each read to a given spliceform (specific
transcript structure) or set of possible spliceforms. Partial sequences that did not extend
through both primers were assigned to specific transcripts if the read contained enough
information to rule out all other spliceforms or if all other possible spliceforms contained
rare (< 1% usage) donors or acceptors (Supplementary Table S3). Otherwise, the read was
called indeterminate.
To calculate the ratios of transcripts within the partially spliced class, we counted the
number of reads for each assigned spliceform amplified by primer pair 1.3 and divided by the
total number of assigned partially spliced reads amplified with these primers (Supplementary
Figure S1 and Supplementary Table S2). Assigned sequences amplified with primer pairs
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1.4 and 4.1 (full-length cDNAs, T cells only) were used to calculate ratios of transcripts
within each of the two completely splice classes (∼2 and ∼1 kb). To compare ratios of ∼2 kb
transcripts calculated within reads from primer pairs 1.4 and 4.1, we normalized ratios from
pair 4.1 to the nef 2 transcript (containing exons 1, 5 and 7). Due to size biases inherent
in the approach, we did not compare across size classes, and unspliced transcripts were
not included in ratio analysis. For all ratio analysis, transcripts including cryptic or novel
junctions were counted only if they appeared in at least five reads, otherwise they were
excluded from the analysis and from the count of total assigned reads.
To estimate the minimum total number of transcripts present, partial sequence reads were
included. Each exon-exon junction occurring in at least five reads and not previously assigned
to a particular transcript (Figure 3.2) was counted as evidence of an additional transcript
(47 additional junctions were detected, see Supplementary Table S4). If two such junctions
could conceivably occur in a single mRNA, we counted only one unless we could verify from
sequence reads that they were amplified from separate cDNAs, resulting in 31 additional
transcripts. The minimum transcript number calculated by a greedy algorithm treating
introns as events in a scheduling problem agreed with the above calculation.
Several groups have demonstrated tissue- and differentiation-specific splicing of cellular
genes421,441,442. Importantly for HIV, these include changes during T-cell activation443,444,
raising the question of how cell-specific splicing affects HIV replication. While most studies
of HIV-1 splicing have been conducted in cell lines using lab-adapted viral strains, limited
works in PBMCs from infected patients, monocytes and macrophages have suggested that
differences may indeed exist in relevant cell types427,439,445,446. Moreover, human splicing
patterns differ between individuals, but such polymorphisms have not been investigated in
the context of HIV infection447,448.
For studies of transcript dynamics, reads from primer pairs 1.2, 1.3 and 1.4 containing
junctions between D1 or any donor and each of five mutually exclusive acceptors, A3, A4c,
A4a, A4b, A5 and A5a, were collected and their ratios calculated.
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Figure 3.2: HIV89.6 transcripts in T cells for which the full message structure was determined
are shown arranged by size class. Thick bars correspond to exons and thin lines to excised
introns. For the well-conserved transcripts, encoded proteins are indicated. The relative
abundance of each transcript within its size class is indicated by color. Asterisks denote
transcripts that have not been reported previously to our knowledge. Of the 47 conserved
HIV-1 transcripts, three were detected in fewer than five reads (indicated with ) and
two messages were not detected and are not shown (one encoding Vpr and one encoding
Env/Vpu). Depicted non-conserved transcripts (using novel or cryptic splice sites) were
each detected in at least five independent sequence reads across samples from at least two
different human T-cell donors.
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3.3.9 Statistical analysis
Statistical modeling was performed using generalized linear modeling as described in Ap-
pendix A.1. All analyses were performed in R 2.14.0 (R Development Core)388.
3.3.10 Data access
Sequence data is available in the SRA database with the following accession numbers:
SRP014319.
3.4 Results
3.4.1 Sequencing HIV-1 transcripts produced in primary T cells and HOS cells
In order to characterize HIV-1 transcript populations, we prepared viral cDNA from primary
CD4+ T cells of seven different healthy human donors infected in vitro with HIV89.6, an early
passage dual-tropic clade-B clinical isolate (Supplementary Figure S1, human donor data
in Supplementary Table S1)449. We also studied HIV messages produced in infected HOS
cells engineered to express CD4 and CCR5 (HOS-CD4-CCR5) because these cells support
efficient HIV replication and engineered variants are widely used in HIV research. HOS
cells were harvested at 18, 24 and 48 hours post infection (hpi) to investigate longitudinal
changes during infection, and for comparison to 48 h infected T cells.
To preserve the relative proportions of template molecules while amplifying the cDNA, we
used RainDance Technologies’ single-molecule micro-droplet based PCR455. Droplet libraries
containing multiple overlapping primer pairs were designed to query all message forms and
allow later calculation of relative abundance (Supplementary Table S2 and Supplementary
Figure S1). Each primer was unique so that sequences could be assigned to a specific
primer pair, which helped reconstruct the origin of sequence reads and deduce message
structures. Amplified DNA products were sequenced using Single Molecule Real-Time
(SMRT) technology from Pacific Biosciences450,456. We obtained 847 492 filtered reads of
amplified HIV-1 transcripts in primary CD4+ T cells and 89 350 in HOS cells. The longest
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sequenced continuous stretch of HIV-1 cDNA was 2629 bp.
3.4.2 Splice donors and acceptors
We aligned PacBio reads containing HIV sequences to the HIV89.6 genome and identified
candidate introns as recurring gaps in our sequences. Using this approach, we observed
splicing at each of the widely conserved major splice donors and acceptors and several
published cryptic sites (Figure 3.1A, hereafter referred to by their identifications shown in
this figure, ‘D’ for donors, ‘A’ for acceptors).
In addition, we identified 13 putative novel splice sites: 2 donors and 11 acceptors (Figure
3.1 and Supplementary Table S3). In order to be selected as a bona fide splice site and
remove artifacts possibly created by recombination during sample preparation, we required
that the new acceptor or donor was observed spliced to previously reported splice donors or
acceptors in > 10 sequence reads in CD4+ T cells. The most frequently used novel splice site
was an acceptor that we have termed A8c because it lies near A8, A8a and A8b (discussed
in detail below). Additional novel sites are further discussed in Supplementary Report S1.
Most of the new splice sites adhered to consensus sequences for the standard spliceosome
(Supplementary Table S3). However, there appeared to be one splice donor upstream of
D1 with a cytidine in place of the usual uracil 2 nt downstream of the splice site. Similar
‘GC donors’ appear in 1% of known splice junctions in humans457. Of the novel splice
acceptors, three were preceded by dinucleotides other than the consensus AG. Alternative
dinucleotides are used infrequently as splice acceptors458–461; however, it is possible that our
deep sequencing method allowed us to observe rare events.
3.4.3 Structures of spliced HIV89.6 RNAs
To quantify the populations of HIV-1 transcripts, we aligned all reads to the collection of
47 well-established spliced HIV-1 transcripts and detected 45 of them (Figure 3.2). We
additionally aligned reads to the HIV89.6 genome allowing all possible combinations of splice
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junctions—canonical, cryptic or novel—determined from the sequencing data (Figure 3.1),
yielding an additional 32 complete transcripts, 19 of which were novel. The data also provide
evidence for more novel splice junctions but in incomplete sequences, implying the existence
of additional new transcripts (Supplementary Table S4 and Supplementary Report S1). The
full data set taken together provides evidence for least 109 different HIV89.6 transcripts in
primary T cells.
Amplification primers that isolated the two main classes of spliced messages allowed us to
determine the ratios of mRNAs in each (Figure 3.2 and Supplementary Table S5). Within
the partially spliced class of transcripts, env/vpu, tat (1-exon), vpr and vif messages existed
in an average ratio of 96:4:< 1:< 1 in CD4+ T cells. The ratio of nef :rev :tat :vpr within
the ∼2 kb transcript class was 64:33:3:< 1. Consistent with previous reports, the most
abundant transcript in each class contained the splice junction from D1 to A5 (D1ˆA5)—
an env/vpu transcript contributing 64% of the partially spliced class, and a completely
spliced nef transcript contributing 47% of ∼2 kb messages (Figure 3.2)425,462. The relatively
low abundance of transcripts encoding Tat suggests that Tat sufficiently stimulates HIV
transcription elongation at low concentrations, or that the tat transcripts must be efficiently
translated. Due to biases inherent in the reverse transcription step, we could only compare
transcripts within each size class, and we note that our methods have not been validated
for empirical quantification. However, the ratios were roughly confirmed using overlapping
sequence reads obtained with alternate primer pairs and by end point RT-PCR analysis of
HIV-1 RNAs (data not shown).
Exons 2 and 3 are non-coding exons whose inclusion in transcripts other than vif and vpr
has no known function. We found that they were included in other messages infrequently,
each in ∼7–8% of transcripts in the ∼2 kb completely spliced class of transcripts and 5%
of partially spliced transcripts accumulating in T cells. This is consistent with previous
measurements in the partially spliced class but much lower than has been estimated for
completely spliced transcripts in HeLa cells, suggesting cell-type-specific splicing patterns
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may influence inclusion of these exons425.
3.4.4 A novel ∼1 kb class of completely spliced transcripts
Primers placed near the 5′- and 3′-ends of the HIV89.6 genome amplified a second class of
completely spliced transcripts ∼1 kb in length. In place of A7, these transcripts use a set of
little studied splice acceptors located ∼800 bp downstream within the 3′-TR. Two groups
have previously observed splicing from D1 to acceptors A8, A8a and A8b in this region,
yielding messages of this size class in patient samples; however, none of these could be
translated to a protein of significant length427,431. We determined the complete structure of
29 members of the 1-kb class (Figure 3.2 and Supplementary Table S5). The most abundant
messages observed in this class use the novel acceptor A8c to define their terminal exon. For
HIV89.6, acceptor A8c was used nearly as frequently as A7, which gives us the 2-kb class
of transcripts (Supplementary Table S3), and this was supported by end point RT-PCR
analysis (data not shown).
Acceptor A8c is not well conserved in HIV-1/SIVcpz (14%), although it is conserved in clade
G viruses (> 95%) and most HIV-2/SIVsmm genomes (86%)463. This is due to the poor
conservation of an adenosine at the wobble base position of the 123rd codon (proline) of the
Nef reading frame, which creates the AG dinucleotide generally required at splice acceptors.
Since any base at this position would code for proline, there does not seem to be strong
selection for a splice acceptor here. However, A8c is displaced from nearby well-conserved
(> 90%) cryptic acceptors A8a and A8b by multiples of 3 bp (12 and 21 bp, respectively),
so splicing to any of these three acceptors would create similar ORFs. All HIVs and SIVs
maintain at least one of these three acceptors, suggesting possible function463. We confirmed
that the 1 kb transcripts using A8a, A8b and A8c were present in infected HOS and T cells
by end point RT-PCR using additional primer pairs and by Sanger sequencing of cloned
transcripts (Figure 3.3A and B; data not shown).
The 1-kb transcript containing exons 1, 4 and 8c (1-4-8c, where exon 8c begins at A8c
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Figure 3.3: HIV89.6 transcripts were amplified by RT-PCR using RNA from infected
HOS-CD4-CCR5 cells with primers keo056 and keo057. Major bands detected after gel
electrophoresis were cloned from the 48 hpi sample and message structures determined by
Sanger sequencing. Thick bars represent exons and dashed lines excised introns. Genes are
shown above (not to scale) with start codons indicated by circles. Messages 1, 2, 4 and 5 were
cloned into expression plasmids for activity assays. (B) Confirmation of presence of the ∼1
kb message RNAs in HOS-CD4-CCR5 and primary CD4+ T cells (human donor 1, harvested
24 and 48 hpi). An independent primer pair (keo058 and keo059) was used to amplify
transcripts by RT-PCR. (C) Tat activity was measured in Tzm-bl cells as Tat-dependent
luciferase production after transient transfection with expression plasmids. (D) Western blot
showing expression of protein of the predicted size for Ref (12.5 kb) in cells transfected with
the Ref expression construct and treated with proteasome inhibitor MG132, detected by an
antibody recognizing the carboxy-terminus of Nef. Expression plasmid encoding Nef was
included to control for possible expression of partial Nef peptides or breakdown products
from the Nef ORF.
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and extends to the poly-adenylation site) encodes the first exon of Tat followed by 25
novel amino acids (termed Tatˆ8c). Tatˆ8c showed activity when overexpressed in cells
containing a Tat reporter construct (Figure 3.3C, nucleotide and amino acid sequences in
Supplementary Table S6). Transcripts with exon structures 1-4a/b/c-8c encode a novel
fusion of the amino-terminal 26 amino acids of Rev and the carboxy-terminal 80 amino acids
of Nef, hereafter referred to as Ref. We did not detect Rev activity on overexpression of
the ref transcript, and Ref did not appear to interfere with the normal function of Rev or
with HIV replication (Supplementary Figure S2). Ref was detectable by western blot using
antibodies targeting the C terminus of Nef after inhibition of the proteasome, suggesting
that the fusion is expressed but not stable (Figure 3.3D). Thus, Ref has the potential to
encode a new epitope potentially relevant in immune detection of HIV. The transcripts with
exon structures 1-5-8c and 1-8c encode at most a short peptide, and so are candidates for
acting as regulatory RNAs.
3.4.5 Temporal dynamics of transcript populations
To assess longitudinal variation, we investigated HIV89.6 transcript populations during the
course of a single round of infection in HOS-CD4-CCR5 cells. A sensitive method for
comparison among conditions involves quantifying utilization of six mutually exclusive splice
acceptors A3, A4c, A4a, A4b, A5 and a novel acceptor just downstream of A5 termed
A5a. Splicing at these acceptors determines the relative levels of messages encoding Tat
and Env/Vpu in the partially spliced class and messages encoding Tat, Rev and Nef in the
completely spliced class.
We observed longitudinal changes in the levels of these messages in HOS cells over 12–48 h
that were statistically significant (p < 10−10; generalized linear model described in Appendix
A.1). This pattern was especially evident in junctions involving donor 1 spliced to each of
these acceptors (Figure 3.4A). Most dramatically, transcripts with splicing junctions between
D1 and A3 (tat messages) increased with time (p < 10−10), while D1ˆA4b junctions (used
in env/vpu or rev messages) were used reciprocally less (p < 10−10). Such kinetic changes
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affecting specific transcripts both with and without the Rev-response element cannot be
explained by the accumulation of Rev, and they may reflect differential transcript stability or
HIV-induced alterations to the host splicing machinery. Temporal changes in HOS cells were
confirmed using end point RT-PCR and analysis after electrophoresis on ethidium-stained
gels (Figure 3.4B).
3.4.6 Cell-type-specific splicing patterns
We also compared splicing between T cells and HOS cells and found significant cell type
differences (p < 10−10). For example, while transcripts with D1ˆA5 junctions were dominant
in both cell types, messages using the D1ˆA4c splice junction (encoding Env/Vpu or Rev)
made up the bulk of the remaining transcripts in T cells but were a minor species in
HOS-CD4-CCR5 cells. Likewise, Tat messages (using A3), which were quite abundant in
HOS cells at all time points, contributed relatively little to populations of transcripts in
primary T cells harvested at 48 hpi (Figure 3.4A). We also used end point PCR and analysis
on ethidium-bromide-stained gels to confirm that the relative ratios of transcripts containing
junctions to A3, A4a, A4b and A4c were different in HOS and T cells (Figure 3.4B).
3.4.7 Human variation in HIV-1 splicing
Quantitative comparisons also revealed modest differences in splicing between primary CD4+
T cells isolated from different human donors that were statistically significant (p < 10−10)
under a generalized linear model (Figure 3.4A). The magnitudes of predicted differences
were small, all < 33% and most < 10%.
3.5 Discussion
Use of single-molecule enrichment and long-read single-molecule sequencing has made possible
the most complete study to date of the composition of HIV-1 message populations, revealing
several new layers of regulation. Studies of the low-passage HIV89.6 isolate in a relevant cell
type showed numerous differences from studies of lab-adapted HIV strains in transformed
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Figure 3.4: Temporal, cell type and donor variability in accumulation of HIV-1 messages.
(A) In order to highlight changes in ratios of HIV-1 transcripts accumulating over time
during infection and between HOS-CD4-CCR5 cells and primary T cells, we used PacBio
read counts to calculate proportions of transcripts with splicing from the first major splice
donor, D1, to each of the mutually exclusive acceptors: A3, A4c, A4a, A4c, A5 and the novel
putative acceptor A5a. The heat map shows average data for T cell and HOS cell samples in
columns with the color tiles indicating the proportion of D1 splicing to each of the mutually
exclusive acceptors (rows), according to the color scale shown. (B) Reverse transcription and
bulk PCR amplification of HIV89.6 transcripts from HOS cells and primary T cells from one
human subject (subject 3) resolved by agarose gel electrophoresis and stained with ethidium
bromide verified temporal and cell type changes shown in (A).
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cell lines, highlighting the importance of studying the most relevant models. These data
also illustrate the limitations of gel-based assays for studying HIV-1 message population.
Multiple different combinations of HIV-1 exons yield mRNAs of similar sizes that are easily
confused in typical assays using gel electrophoresis. Thus, in many settings the more detailed
information provided by single-molecule amplification and single-molecule DNA sequencing
is more useful.
Using these methods, we have detected significant variations between HIV message pop-
ulations generated in T cells from different human donors. The differences were modest
compared to those observed between cell types or time points, perhaps not surprisingly
since any human polymorphisms strongly affecting mRNA processing might interfere with
normal gene expression. However, because tight calibration of message levels is important to
HIV-1, the observed differences in message ratios might affect HIV-1 acquisition or disease
progression. The variation in observed transcripts could also be affected by different kinetics
of infection in T cells from the different donors. In either case, these data suggest that human
polymorphisms may exist that affect HIV-1 message populations in infected individuals,
providing a new candidate mechanism connecting human genetic variation with measures of
HIV disease.
Sequences from the 89.6 viral strain revealed a class of small (∼1 kb) completely spliced
transcripts, most contributed by splicing to a new poorly conserved acceptor A8c. These
encoded two new proteins, one of which had Tat activity, and we showed that another, a Rev-
Nef fusion termed Ref, could be detected in cells. HIV89.6 is a particularly cytotoxic virus
isolated from the CSF of a patient, and it forms unusually large syncitia in macrophages449.
The abundance of 1-kb transcripts produced by this virus provides a possible explanation
for its unique properties. In addition to the novel acceptor A8c, we have also identified 3
putative novel splice donors and 11 putative novel acceptors, which require further studied
to clarify possible functions.
The wealth of new messages found here in HIV89.6 and in other HIV-1 isolates suggests
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there may be ongoing evolution of novel splice sites and new ORFs. Because splice acceptors
in HIV-1 are weak284, mutations creating sequences that even slightly resemble the 3′ splice
site consensus may be occasionally recruited as novel acceptors, creating new mRNAs. In
fact, new splice signals may evolve with relative ease—it has been estimated that reasonable
matches to the consensus for splice donors, acceptors and branch-point sites occur within
random sequence every 290, 490 and 24 bp, respectively464, though sequence substitutions
in HIV are usually also constrained by overlapping viral coding regions. We and others have
observed appearance of novel exons within the major HIV-1 introns426,428,429. Such long
stretches of RNA relatively devoid of competing splice sites may be particularly poised to
evolve new signals. On the other hand, most of the putative novel splice acceptors we observed
clustered near previously identified acceptors in HIV-1, suggesting that conserved cis-acting
splicing signals may recruit factors that act promiscuously on new nearby sequences. Clusters
of splice sites might also provide redundancies that protect vital messages, as suggested
previously465,466. Frequent evolution of new splice sites may allow viruses to test out new
combinations of exons, potentially yielding new RNAs and proteins, like those reported here.
However, such novelty must compete with immune constraints—unstable novel polypeptides
like Ref can be targeted to the proteasome and presented on MHC molecules as new epitopes
for immune recognition.
HIV has likely evolved to produce calibrated message populations in T cells which seem
to be altered with relative ease, as in infection in HOS cells, suggesting that therapeutic
disruption of correct splicing may be feasible. A few studies have begun to explore small
molecule therapy to disrupt HIV-1 splicing432,436. Several factors could be responsible for
the differences we observed between HOS and T cells, including hnRNP A/B and H, SC35,
SF2/ASF and SRp40288,467. Inhibition of SF2/ASF has already been shown to abrogate
HIV-1 replication in vitro432. Thus the lability seen here for function of these factors suggests
they may be attractive antiretroviral targets.
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CHAPTER 4: Gene activity in primary T cells infected with HIV89.6:
intron retention and induction of distinctive genomic
repeats
This chapter is under review as:
S Sherrill-Mix, K Ocwieja and F Bushman. Under Review.
Gene activity in primary T cells infected with HIV89.6: in-
tron retention and induction of distinctive genomic repeats.
Retrovirology
KE Ocwieja performed the infections and sequencing. I analyzed the data.
KE Ocwieja, FD Bushman and I planned the overall study. I produced
the figures. FD Bushman and I wrote the paper.
4.1 Abstract
Background: HIV infection has been reported to alter cellular gene activity, but published
studies have commonly assayed transformed cell lines and lab-adapted HIV strains, yielding
inconsistent results. Here we carried out a deep RNA-Seq analysis of primary human T cells
infected with the low passage HIV isolate HIV89.6.
Results: Seventeen percent of cellular genes showed altered activity 48 hours after infection.
In a meta-analysis including four other studies, our data differed from studies of HIV infection
in cell lines but showed more parallels with infections of primary cells. We found a global
trend toward retention of introns after infection, suggestive of a novel cellular response to
infection. HIV89.6 infection was also associated with activation of several human endogenous
retroviruses (HERVs) and retrotransposons, of interest as possible novel antigens that could
serve as vaccine targets. The most highly activated group of HERVs was a subset of the
ERV-9. Analysis showed that activation was associated with a particular variant of ERV-9
long terminal repeats that contains an indel near the U3-R border. These data also allowed
quantification of >70 splice forms of the HIV89.6 RNA and specified the main types of
chimeric HIV89.6-host RNAs. Comparison to over 100,000 integration site sequences from
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the same infected cell populations allowed quantification of authentic versus artifactual
chimeric reads, showing that 5′ read-in, splicing out of HIV89.6 from the D4 donor and 3′
read-through were the most common HIV89.6-host cell chimeric RNA forms.
Conclusions: Analysis of RNA abundance after infection of primary T cells with the
low passage HIV89.6 isolate disclosed multiple novel features of HIV-host interactions,
notably intron retention and induction of transcription of retrotransposons and endogenous
retroviruses.
4.2 Background
HIV replication requires integration of a cDNA copy of the viral RNA genome into cellular
chromosomes, followed by transcription and splicing to yield viral mRNA. Alternative
splicing allows the small 9.1 kb HIV genome to generate at least 108 mRNA transcripts
encoding at least 9 proteins and polyproteins284,419,425,430,469,470. During replication, HIV
also reprograms cellular transcription and splicing. For example, the virus-encoded Vpr
protein arrests the cell cycle249,251,252,254 and the viral Tat protein binds to P-TEFb and
alters transcription at the HIV promoter and some cellular promoters as well471–476.
Changes in host cell gene expression have been reported during HIV infection317–319,477–485
and differences in expression have been observed associated with the stage486 and progres-
sion487 of disease. Multiple studies suggest that cells detect HIV infection, in part through
the recognition of cytoplasmic DNA in abortive infections177,488,489, and respond by inducing
interferon-regulated, apoptotic and stress response pathways319,477–481,483–485. Several stud-
ies have also suggested that HIV infection disrupts normal cellular splicing pathways446,485.
However, results have varied with many experimental parameters, including target cell type,
HIV isolate and the duration of infection. Many previously published studies have focused
on infections with lab-adapted HIV strains in transformed cell lines317,319,477,482,485,490, and
so results may not be fully reflective of infections in patients.
HIV infection also appears to induce the expression of human endogenous retroviruses
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(HERVs)333, particularly HERV-K328–332, and retrotransposons334. Immune responses to
HERV proteins appear stronger in HIV-infected individuals suggesting candidate markers of
infection and possible vaccine targets337–340. In contrast, two recent RNA-Seq studies of
expression during HIV infection did not report increases in HERV RNA319,482. The origin
of this discrepancy is unclear.
The suggestion that HIV integration may disrupt cellular cancer-associated genes and
thereby promote cell proliferation491–494 has focused attention on the range of novel message
types formed when HIV integrates within transcription units366,423,495–497. Chimeric reads
containing HIV and cellular sequence are also of interest due to the potential of lentiviral
vectors to trigger oncogenesis in gene therapy patients through insertional mutagenesis498–501.
A better understanding of chimera formation would help clarify this phenomenon in both
infected patients and gene therapy using lentiviral vectors.
In this study, we sought to generate data more representative of HIV replication in patients
by using Illumina sequencing to analyze transcriptional responses after infection of primary
T cells with HIV89.6, a low passage patient isolate
449. This represents a continuation of a
long term effort to understand HIV-host cell interactions at the transcriptional level that
began with analysis of transcription by HIV89.6 in primary T cells using Pacific Biosciences
long read single molecule sequencing419. Our strategy here was to analyze a single time after
infection in depth with over 1 billion sequence reads from HIV89.6-infected and uninfected
host cells. These data were then combined with 147,281 unique integration site sequences
from the same infections and the Pacific Biosciences data on HIV89.6 transcription to 1)
elucidate effects of HIV infection on host cell mRNA abundances and splicing, 2) characterize
viral message structure in detail and 3) probe the nature of the chimeras formed between
host cell and viral RNAs.
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4.3 Methods
4.3.1 Cell culture and viral infections
HIV89.6 stocks were generated by the University of Pennsylvania Center for AIDS Research.
293T cells were transfected with a plasmid encoding an HIV89.6 provirus, and harvested virus
was passaged in SupT1 cells once. Viral stocks were quantified by measuring p24 antigen
content. Primary CD4+ T cells were isolated by the University of Pennsylvania Center
for AIDS Research Immunology Core from apheresis product from a single healthy male
donor (ND365) using the RosetteSep Human CD4+ T Cell Enrichment Cocktail (StemCell
Technologies). The Immunology Core maintains the IRB-approved protocol (IRB #705906)
and receipt of these cells is considered secondary use of de-indentified human specimens.
T cells were stimulated for 3 days at 0.5 × 106 cells per milliliter in R10 media (RPMI 1640
with GlutaMAX (Invitrogen) supplemented with 10% FBS (Sigma-Aldrich) with 100 units
U/mL recombinant IL2 (Novartis) + 5 µg/mL PHA-L (Sigma-Aldrich)). Cells were infected
in triplicate and mock infections were performed in duplicate. For each infection, 6.6 × 106
cells were mixed with 1.32 µg HIV89.6 in a total volume of 2.25 mL. Infection mixtures was
split into three wells of a 6 well plate for spinoculation at 1200 g for 2 hr at 37◦C. Cells were
incubated an additional 2 hr at 37◦C. Cells were then pooled into flasks and volume was
increased to a total of 12 mL. Spreading infection was allowed to proceed 48 hr at 37◦C,
after which cells were harvested. 1 × 106 cells were harvested for flow cytometry, and 6 × 106
cells were pelleted following two washes in PBS for nucleic acid extraction. Genomic DNA
and total RNA were isolated from 6× 106 T cells per infection using the AllPrep DNA/RNA
Mini Kit (Qiagen) with Qiashredder columns (Qiagen) for homogenization according to the
manufacturer’s instructions. DNA was eluted in 140 µL elution buffer. RNA samples were
treated with DNase prior to elution in 40 µL water.
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4.3.2 Analysis of HIV89.6 integration sites in primary T cells
Integration site sequences were determined for DNA fractions from the above infections
after ligation mediated PCR396. A total of 147,281 unique integration site sequences were
determined. An analysis of integration site distributions for these samples was reported in
Berry et al. 396 .
4.3.3 mRNA sequencing
Messenger RNA was isolated and amplified from purified total cellular RNA (3 µL or
approximately 9 µg from each uninfected sample, 25 µL or approximately 3 µg from each
infected sample) using the Illumina TruSeq RNA sample preparation kit according to
manufacturer’s protocol. SuperScript III (Invitrogen) was used for reverse transcription.
Each sample was tagged with a separate barcode and sequenced on an Illumina HiSeq 2000
using 100-bp paired-end chemistry.
4.3.4 Flow cytometry
To assess percent infected cells, 1 × 106 cells per infection were stained for flow cytometry.
All staining incubations were at room temperature. Cells were first washed in PBS and
then twice in FACS wash buffer (PBS, 2.5% FBS, 2 mM EDTA). Cells were fixed and
permeabilized with CytoFix/CytoPerm (BD) for 20 minutes and washed with Perm-Wash
Buffer (BD) before staining with anti-HIV-Gag-PE (Beckman Coulter) for 60 min. Finally
cells were washed in FACS wash buffer and resuspended in 3% PFA. Samples were run
on a LSRII (BD) and analyzed with FlowJo 8.8.6 (Treestar). Cells were gated as follows:
lymphocytes (SSC-A by FSC-A), then singlets (FSC-A by FSC-H), then by Gag expression
(FSC-A by Gag).
4.3.5 Analysis
Reads were aligned to the human genome using a combination of BLAT395 and Bowtie502
through the Rum pipeline503. Estimates of fragments per kilobase of transcript per million
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mapped reads and changes in expression for cellular genes were calculated by Cuﬄinks397.
Reads found to contain sequence similar to the HIV genome using a suffix tree algorithm were
aligned against the HIV89.6 genome using BLAT
395. All statistical analyses were performed
in R 3.1.2388. RNA-Seq reads from Chang et al. 319 were downloaded from the Sequence
Read Archive (SRP013224) and aligned using the Rum pipeline.
Gene lists were obtained from the supplementary materials of four other studies of differential
gene expression during HIV infection319,482,483,486. We called genes differentially expressed
in Li et al. 486 if they had a reported p < 0.01 or in Lefebvre et al. 482 , Chang et al. 319
and Imbeault et al. 483 if they had an adjusted p < 0.05. We called genes as differentially
expressed in our own study if the adjusted p < 0.01. For the comparison of differentially
expressed genes regardless of direction in figure 4.1 (below the diagonal), it was unclear
exactly how many genes were studied in each study so we assumed a background of the
14,192 genes (the number of genes which could be tested for significance in our data).
We obtained transcriptional profiles comparing immune cell subsets from the Molecular
Signatures Database504. MSigDB set names from the MSigDB used in Figure 4.2A were
GSE10325 LUPUS CD4 TCELL VS LUPUS BCELL, GSE10325 CD4 TCELL VS MYELOID,
GSE10325 CD4 TCELL VS BCELL, GSE10325 LUPUS CD4 TCELL VS LUPUS MYELOID,
GSE3982 MEMORY CD4 TCELL VS TH1, GSE22886 CD4 TCELL VS BCELL NAIVE,
GSE11057 CD4 CENT MEM VS PBMC, GSE11057 CD4 EFF MEM VS PBMC, GSE3982
MEMORY CD4 TCELL VS TH2 and GSE11057 PBMC VS MEM CD4 TCELL and in
Figure 4.2B were GSE36476 CTRL VS TSST ACT 72H MEMORY CD4 TCELL OLD,
GSE10325 CD4 TCELL VS LUPUS CD4 TCELL, GSE22886 NAIVE CD4 TCELL VS 12H
ACT TH1, GSE3982 CENT MEMORY CD4 TCELL VS TH1, GSE17974 CTRL VS ACT
IL4 AND ANTI IL12 48H CD4 TCELL, GSE24634 IL4 VS CTRL TREATED NAIVE CD4
TCELL DAY5, GSE24634 NAIVE CD4 TCELL VS DAY10 IL4 CONV TREG, GSE1460
CD4 THYMOCYTE VS THYMIC STROMAL CELL and GSE1460 INTRATHYMIC T
PROGENITOR VS NAIVE CD4 TCELL ADULT BLOOD.
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We downloaded the RepeatMasker412 track from the UCSC genome browser505 and used
the SAMtools library506 to assign reads to the repeat regions. HERV-K age estimates were
obtained from the supplementary materials of Subramanian et al. 507 .
We used a Bayesian estimate of the ratio of expression in uninfected and HIV-infected
samples to account for sampling effort and differing expression in genomic regions. We
modeled the observed counts as a binomial distribution with a flat beta prior (α = 1,β = 1)
separately for uninfected and infected samples. We then Monte Carlo sampled the two
posterior distribution to estimate the posterior distribution of the ratio. For introns, the
number of binomial successes was set to the number of reads mapped to the intron and the
number of trials was the total number of reads observed in the genes overlapping that intron.
For repeat regions, the number of binomial successes was set to the number of reads mapped
to that region and the number of trials was the total number of reads mapped to the human
genome.
To estimate determinants of LTR12C expression, we fit a logistic regression for which
LTR12C increased in expression with HIV89.6 infection (95% Bayesian credible interval
>1) on to characteristics of the LTR12C regions. We extracted all the LTR12C regions
from the human genome and determined the U3-R boundary using a ends free alignment of
the previously reported U3-R border508–512 against the sequences. Regions less than 1,000
bases long were discarded. Previous studies disagreed about the location of the LTR12C
transcription start site and it appears that transcription may start in several places509,510.
We took the 5′ most site that had agreement between studies (transcription starting with
TGGCAACCC). We split the sequences into short, medium and long length classes based
on an indel about 70 bases upstream from the transcription start site. For each length class,
we generated a consensus sequence and counted the Levenshtein edit distance between the
consensuses and each corresponding sequence. We also counted the number of NFY motifs
(CCAAT or ATTGG), MZF1 motifs (GTGGGGA) and GATA2 motifs (GATA or TATC)
in the entire U3 region or checked in any of the three motifs was present in the 150 bases
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Sample Infection
rate (%)
Reads Human reads HIV reads % HIV % HIV in
infected
Uninfected-1 — 232,450,106 212,391,460 — — —
Uninfected-2 — 235,048,212 203,760,783 — — —
Infected-1 37.5 234,378,088 199,871,662 10,219,315 4.86 13.0
Infected-2 26 226,078,422 198,436,507 7,322,556 3.56 13.7
Infected-3 21 233,750,850 205,747,441 7,241,973 3.40 16.2
Table 4.1: Samples used in this study, their infection rates and sequencing depth. “% HIV in
infected” is an estimate based on the assumption that infected and uninfected cells contain
equal amounts of mRNA.
upstream of the TSS. A final regression model was selected using stepwise regression with
an AIC cutoff of 5. For display, the LTR12C sequences were aligned with MUSCLE513.
The abundance of the HIV RNA size classes was estimated as described in Figure 4.6. These
estimates were then multiplied by the within size class proportions estimated by Ocwieja
et al. 419 using PacBio sequencing of HIV89.6 to yield proportions over 78 measured HIV89.6
RNAs.
4.4 Results
4.4.1 Infections studied
Primary CD4+ T cells from a single human donor were infected with HIV89.6, a clade B
primary clinical isolate449, in three replicates. For comparison, two additional replicates
from the same donor were mock infected. Samples were harvested 48 hours after viral
inoculation, which allowed for widespread infection in the primary T cell cultures, though
some cells may have been infected secondarily by viruses produced in the first round. Thus
cultures probably were not tightly synchronized but did have extensive representation of
infected primary T cells. From these samples, we obtained 1,161,705,678 101-bp reads from
primary CD4+ T cells from a single donor; 1,021,207,853 were mapped to the human genome
and 24,783,844 to the HIV89.6 provirus (Table 4.1). Below we first discuss the influence of
infection on cellular gene activity and RNA splicing, then analyze HIV RNAs and lastly
identify chimeras formed between HIV and cellular RNAs.
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4.4.2 Changes in gene activity in primary T cells upon infection with HIV89.6
We observed significant expression changes in 3,142 genes (false discovery rate of q < 0.01),
which is 17.1% of expressed cellular genes. The genes with most extreme increases, all >6×
fold higher, during HIV infection included IFI44L, RSAD2, HMOX1, MX1, USP18, IGJ,
OAS1, CMPK2, DDX60, IFI44, IFI6, IFNG and CCL3. All of these have been reported
to be involved in innate immunity514 or are interferon-inducible515, highlighting a strong
innate immune response in the cells studied. Genes with the largest decreases, all >3× fold
lower, were GNG4, GPA33, IL6R, CCR8, RORC, AFF2 and CCR2.
Many gene ontology categories were significantly enriched for differentially expressed genes.
Notably upregulated with infection were genes involved in apoptosis, immune responses
and cytokine production (all q < 10−4) and down-regulated were genes involved in viral
gene expression and translation elongation and termination (all q < 10−19). These changes
suggest that the cells responded to HIV infection with the induction of inflammatory,
interferon-regulated and apoptotic responses, patterns posited from several previous stud-
ies319,477–484,490,516. Expression significantly increased for several genes that are characteristic
of other hematopoietic lineages, e.g. hemoglobin β , CD8, CD20 and CD117, while several
CD4+ T cell specific genes, e.g. CD4 and CD3, were downregulated, potentially consistent
with de-differentiation of infected or bystander cells. We return to this point in the discussion.
4.4.3 Comparison of transcriptional profiles from HIV89.6 infection of primary
T cells to data on HIV infection in other cell types
We sought to identify the transcriptional responses that were most conserved upon HIV
infection and so collected and analyzed data from four other studies of transcription in
HIV-infected cells (Table 4.2). These included two studies of infection of the SupT1 cell
line319,482, a study of ex vivo infection of primary CD4+ T cells483 and a study of lymphatic
tissue biopsies from acutely viremic patients486. Genes were scored as increased or decreased
in activity in infected cell populations, and the amount of agreement was compared among
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Cell type HIV type Differentially expressed
genes (Up/Down)
Study
Primary CD4+ T HIV89.6 3393 (1756/1637) This study
Primary CD4+ T NL4-3 BAL-IRES-HSA 228 (182/46) Imbeault et al. 483
Lymph node biopsies Acute infection 448 (383/65) Li et al. 486
SupT1 HIVLAI 4997 (2666/2331) Chang et al.
319
SupT1 NL4-3∆env-eGFP/VSV-G 579 (212/367) Lefebvre et al. 482
Table 4.2: Data from this study and four others used for meta-analysis of human gene
expression changes during HIV infection
the different studies.
No gene was called as differentially expressed in all five studies. Eight genes were differentially
expressed in the same direction in 4 out of 5 studies; AQP3 and EPHX2 were down-regulated
with HIV infection and CD70, EGR1, FOS, ISG20, RGS16 and SAMD9L were up-regulated.
Several of the up-regulated genes are known to be interferon-inducible, again emphasizing
the role of innate immune pathways.
For each pair of studies, we compared whether they agreed on the identities of differentially
expressed genes and whether they agreed on the direction of change (Figure 4.1). The
responses to infection in primary cells showed notable differences to responses in the SupT1
cell line. The two SupT1 studies were significantly similar to each other (p < 10−15) but were
not significantly associated or were negatively associated with data from ex vivo primary
cells and from lymphatic tissue from acutely infected HIV patients. In contrast, our data
was significantly associated with the primary cell (p < 10−15) and lymphatic tissue data
(p = 0.003). This documents significant differences in responses to HIV infection between
infected primary cells and SupT1 cells and suggests that results of infections in primary
cells more closely align with actual acute HIV infections in patients. SupT1 cells might
be expected to respond to infection differently that primary cells since they have several
nonsynonymous mutations in innate immunity genes517, have blocks in immune signaling
pathways518 and fail to activate many interferon-stimulated genes during HIV infection484.
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Figure 4.1: Comparisons among stud-
ies quantifying cellular gene expression
after HIV infection. For each pair of
studies, the association between up- and
down-regulation calls was measured for
genes identified by both studies as differ-
entially expressed (above the diagonal).
As another comparison, we also mea-
sured the agreement between studies for
which genes were called differentially ex-
pressed regardless of direction (below
the diagonal). The color scale shows the
conservative (i.e. closest to 1) boundary
of the confidence interval of the odds
ratio with blue indicating a positive as-
sociation and red a negative association
between studies. For confidence inter-
vals overlapping 1, the value was set to
1. Therefore all colored squares indicate
significant associations.
4.4.4 Comparison of the HIV infected cell transcriptional profiles to additional
experimental T cell profiles
To investigate the transcriptional changes in more depth, we compared the results of the five
studies of HIV infection to transcriptional profiles comparing immune cell subsets available
at the Molecular Signatures Database (MSigDB)504. The MSigDB reports genes that are
increased or decreased in relative expression for 185 pairs of transcriptional profiles involving
CD4+ T cells. We compared the lists of affected genes in each pair to genes altered in
activity by HIV infection. Those pairs of studies with the most significant associations with
HIV89.6 data are show in Figure 4.2A. For comparison, the associations with the four other
HIV transcriptional profiling studies mentioned above are shown as well.
The most significant associations for our data showed gene expression in HIV89.6-infected
cells moving away from typical T cell expression patterns and towards patterns more similar
to B cells, myeloid cells and bulk peripheral blood mononuclear cells (all Fisher’s exact test
p < 10−15) (Figure 4.2A). These changes were also seen, although to a lesser extent, in the
Imbeault et al. 519 study which also used primary CD4+ T cells.
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For comparison, we also extracted those profiles most strongly associated with the transcrip-
tional data on lymphatic tissue of HIV patients486. The profiles showed patterns similar to
strongly stimulated T cells, autoimmune disease and to the Th1 T cell subset (all p < 0.01)
(Figure 4.2B). Our data in primary CD4+ T cells paralleled the changes seen in lymphatic
tissue. These transcriptional changes again highlights the strong immune response generated
by HIV infection in primary cells.
4.4.5 Intron retention
Cells respond to infection by shutting down macromolecular synthesis at multiple levels520–524,
so we investigated whether cells also showed perturbations in splicing efficiency after infection.
As a probe, we created a database of cellular genomic regions annotated exclusively as exons
or introns in all splice forms in the UCSC gene database407 and quantified expression in
these regions in infected and uninfected cells. We found a significant increase in intronic
sequences relative to exonic sequence (Wilcoxon p < 10−15) (Figure 4.3A). This increase
in intronic sequence was reproducible between replicates in our study (Kendall’s τ = 0.42,
p < 10−15) (Figure 4.3B). We reanalyzed RNA-Seq data from Chang et al. 319 and also
documented intron retention which correlated with the changes seen in our data (Kendall’s
τ = 0.12, p < 10−15) (Figure 4.3C).
A possible artifactual explanation for enrichment of intronic sequences could involve greater
DNA contamination in the infected cells samples. That is, if the relative amount of DNA
differed between treatments, the amount of apparent intronic sequences could also differ
due to sequencing of contaminating DNA. To examine whether DNA contamination was
abundant in our samples, we compiled a collection of 27 large gene desert regions, defined
here as 1) regions outside the centrosome and first and last cytoband, 2) containing less than
1% unknown sequence, 3) containing no genes annotated in UCSC genes407, 4) containing
no repeats annotated in the repeatMasker database412 and 5) spanning more than 100
kb. No reads were mapped to these 41 Mb of gene deserts in any sample, arguing against
explanations based on DNA contamination. Thus these data indicate that intron retention
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Figure 4.2: Comparisons of the effect of
HIV infection on cellular gene expression
to additional studies comparing tran-
scription in subsets of immune cells. The
MSigDB database was used to extract
185 sets of differentially expressed genes
from pairs of transcriptional profiling
studies of immune cell subsets involving
CD4+ T cells. For each pair of studies,
we used Fisher’s exact test to measure
the association between up- and down-
regulation calls for genes identified as
differentially expressed in both our HIV
study and the comparator immune sub-
sets. A) The transcriptional profiles with
strongest associations with changes ob-
served in our study of HIV89.6 infection
of primary T cells. Blue indicates a pos-
itive association between changes seen
in HIV-infected cells and the first im-
mune subset (text colored blue) while
red indicates a positive association with
the second immune subset (text colored
red). The color scale shows the con-
servative (i.e. closest to 1) boundary of
the confidence interval of the odds ratio.
For confidence intervals overlapping 1,
the value was set to 1. Therefore all
colored squares indicate significant asso-
ciations. B) As in A, but showing the
transcriptional profiles most strongly as-
sociated with changes observed in lymph
node biopsies from acutely infected pa-
tients486.
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Figure 4.3: Changes in the abundance of intronic regions with HIV infection. Expression
of intronic and exonic regions was quantified as the proportion of reads mapping within
the intron/exon out of the total reads mapping to the transcription units overlapping that
intron/exon. A) Comparison of the ratios of expression between infected and uninfected
replicates in exclusively intronic or exonic regions of transcription units. B) Reproducibility
of intron retention between replicates. Each point quantifies the change in expression with
HIV infection for a specific intronic region. The x-axis shows changes in gene activity
accompanying infection for one set of replicates (Infected-1 and Infected-2 vs. Uninfected-1)
and the y-axis shows the same data for different replicates (Infected-3 vs. Uninfected-2).
C) Reproducibility of intron retention between studies. The plot is arranged as in B but
with all data from our study combined on the x-axis and corresponding data from Chang
et al. 319 on the y-axis.
was increased in these cell populations upon HIV infection, revealing a previously undisclosed
aspect of the host cell transcriptional response to infection.
4.4.6 Induction of transcription from HERVs and LINEs by HIV89.6 infection
In our data, several of the intronic regions with the greatest increases in expression contained
HERVs. Thus we investigated the expression of HERVs, transposons and other repeated
sequences. Figure 4.4A shows a comparison of the association between changes in expression
with HIV89.6 infection and genomic repeat types annotated in the RepeatMasker database
412
over varying levels of differential expression. At high levels of expression change, ERV-9 (odds
ratio at 4× expression: 152, 95% CI:82.5–259) and its long terminal repeat LTR12C (odds
ratio at 4× expression: 144, 95% CI: 98.2–207) are the only repeats highly associated with
HIV infection. Looking at genomic repeats with any significant increase during HIV infection,
the expression of many recently acquired genomic repeats, including L1HS, LTR5 Hs (a
human specific LTR of HERV-K), AluYa5, AluYg6 and SVA D and SVA F, were associated
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with HIV89.6 infection (Figure 4.4B).
We saw a relationship between the age of genomic repeats and its likelihood of being induced
by HIV89.6 infection. The most highly enriched repeats were associated with relatively recent
hominid-specific repeat classes as annotated by the RepeatMasker database (repeat classes
with p < 10−50 odds ratio: 31.6, 95% CI: 8.88–112). In HERV-K (HML-2), the most recently
active endogenous retrovirus in the human genome507,525,526, we saw that integrations unique
to the human genome507 were more likely to be differentially expressed than older HERV-Ks
(odds ratio: 5.38, 95% CI: 1.93–16.0).
Previous RNA-Seq studies of cellular expression during HIV infection in transformed cell
lines did not report increases in HERV mRNA319,482. To investigate this difference, we
downloaded and analyzed the RNA-Seq data from Chang et al. 319 , which quantified gene
activity in transformed SupT1 cells infected with a lab-adapted strain of HIV. We found a
much higher level of HERV expression in their data in both HIV-infected cells and uninfected
controls than in primary cells (Figure 4.4C). We suspect that in SupT1 cells, as with many
cancerous cells336,527–530, the baseline expression of transposons and endogenous retroviruses
is higher than in primary cells, masking further induction by HIV infection.
We observed heterogeneous expression among ERV-9/LTR12C sequences and so investigated
the primary sequence determinants. We observed that ERV-9/LTR12C has three variants of
differing length in the U3 region just upstream of the transcription start site (Figure 4.5A),
an important region for transcription initiation509. The U3 region of LTR12C also contains
multiple motifs for transcription factors NFY, GATA2 and MZF1512. To clarify factors
affecting expression levels, we counted the number of motifs matching these transcription
factors’ binding motifs, assigned each LTR12C to one of the length classes, counted the
number of mutations away from the consensus for that length class and checked for integration
in a transcription unit. We then carried out a regression analysis to test the effects of these
variables on LTR12C differential expression. We found that HIV89.6-induced transcription
was more likely with the fewer mutations away from consensus, the number of locations
68
A
ss
oc
ia
tio
n
w
ith
H
IV
8
9
.6
in
fe
ct
io
n
Fold-change cutoff
1
10-20
10-40
10-60
10-80
<10-100
1 5 10 15
HERV9-int
LTR12C
A
A
ss
oc
ia
tio
n
w
ith
H
IV
8
9
.6
in
fe
ct
io
n
1
10-20
10-40
10-60
10-80
<10-100
L1HS
L1P1
L1PA2
L1PA3
L1PA4
L1PA5
AluYb8
MIRb
AluYa5
AluYg6
THE1B
LTR12C
LTR5_Hs
SVA_C
SVA_D
SVA_F
D
N
A
LI
N
E
LT
R
R
C
R
N
A
rR
N
A
S
at
el
lit
e
sc
R
N
A
S
IN
E
sn
R
N
A
sr
pR
N
A
tR
N
A
O
th
er
B
P
er
ce
nt
of
hu
m
an
al
ig
ne
d
re
ad
s
0
2
4
6
8
10
Alu CR
1
ER
V1
ER
VK
ER
VL
ER
VL
Ma
LR h
AT
Ch
arli
e L
1 L2 MIR TcM
ar
Tig
ger
CD4+ T Control
CD4+ T HIV infected
SupT1 Control
SupT1 HIV infected
C
Figure 4.4: Repeat categories enriched
upon infection with HIV. A) The asso-
ciation of repeat regions differentially
expressed after HIV89.6 infection of pri-
mary T cells observed for varying thresh-
olds of differential expression. The
threshold used to call a gene differen-
tially expressed based on the Bayesian
posterior median was varied and Fisher’s
exact test was used to assess whether
any genomic repeats had a significant
association with this differential expres-
sion. Note that only ERV-9 (annotated
as HERV9-int in the RepeatMasker
database) and it’s corresponding long
terminal repeat LTR12C were signifi-
cantly associated with large changes in
expression. B) Enrichment of repeat cat-
egories in regions differentially expressed
(Bayesian 95% credible interval >1) be-
tween HIV-infected and control CD4+ T
cells. The repeated sequences are or-
dered on the x-axis by the extent of
induction within each class, the y-axis
shows the p-value for upregulation after
infection. The dashed line indicates a
Bonferroni corrected p value of 0.05. (C)
The proportion of human mapped reads
that align within classes of genomic re-
peats for data from primary CD4+ T
cells from this study and SupT1 cells
from Chang et al. 319 . A single read map-
ping multiple times to a given category
was only counted once.
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matching the NFY transcription factor binding motif (CCAAT) and LTRs containing the
short length variant of the 3′ U3 region. The presence of a MZF1 motif near the transcription
start site decreased transcription (Figure 4.5B).
4.4.7 HIV mRNA synthesis and splicing
Over 24 million Illumina reads mapped to HIV89.6, yielding an average coverage of over
240,000-fold. Reads mapping to HIV89.6 comprised between 3.4–4.8% of mapped reads in
the infected samples (Table 4.1). It is unclear whether HIV infection increases or decreases
the amount of mRNA in infected cells but if we assume HIV-infected cells contain the
same amount of mRNA as uninfected cells and adjust for rates of infection ranging between
21–37.5% (Table 4.1), we estimate that HIV transcripts comprise between 13.0–16.2% of
the total polyadenylated mRNA nucleotides in infected cells 48 hours after initial infection.
This parallels previous estimates of around 10%531 at 48 hours postinfection, 38% at 24
hours319 or 30% after 72 hours477.
Over 47,257 single reads spanned previously reported HIV splice junctions, allowing a
quantitative assessment of donor and acceptor utilization (Figure 4.7A). As expected from
previous studies419,425, the most abundant junctions were D1-A5 and D4-A7. We confirmed
the use of unusual splice acceptors A8c and A5a, previously reported in HIV89.6
419. In the
Illumina sequencing, we saw a higher abundance of D1-A1 and D1-A2 splice junctions than
in PacBio sequencing419, possibly indicative of recovery bias in PacBio sequencing.
A 3′ bias is apparent in our sequencing data (Figure 4.6). This could be due to the poly-A
capture step of the protocol where any break in the RNA would result in distal 5′ sequences
being lost532. We used sequence reads from the large unspliced HIV intron 1 to measure this
bias using a regression of the log of the number of fragments with a 5′-most end starting at
a given position against the distance of that position from the viral polyadenylation site,
yielding an estimated probability of breakage of 0.021% per base (Figure 4.6). Given this
rate of truncation, there is only a 14% chance of reaching the 5′ end of the 9171 nt unspliced
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Figure 4.5: Characteristics of LTR12C sequences associated with induction upon infection
of primary T cells with HIV89.6. A) An alignment of the 3
′ end of the U3 region of repeats
annotated as ERV-9 LTR12C. Each row is a LTR sequence and each column a base in that
sequence colored by nucleotide identity (A: green, T: red, C: blue, G: yellow). Three distinct
classes are visible with a short, medium and long form. Mutations away from the consensus
can also be seen. B) The coefficients (points) and ±1.96 standard errors (horizontal lines) of
a logistic regression comparing differential expression of LTR12C to the presence of MZF1
and NFY motifs, short/medium/long length alternate forms of the U3-R region, mutations
away from the consensus for each length form and integration inside a transcription unit.
The coefficient shown for mutations away from consensus is for a 10 mutation difference
and the coefficient shown for NFY motifs is for a change of 5 additional motifs. All other
coefficients are for binary values.
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HIV genome ((1 − 0.00021)9171).
Ocwieja et al. 419 determined the relative abundance of HIV89.6 of similarly sized transcripts
using PacBio single molecule sequencing, but were not able to estimate the relative abundance
of all transcripts due to a sequencing bias favoring shorter transcripts. For this reason,
relative abundances could only be specified within message size classes (i.e. the 4 kb, 2 kb
and unexpectedly a 1 kb size class as well) and the overall quantitative abundances were
unknown. Our RNA-Seq data are unable to reconstruct the multiply spliced messages due
to short read lengths but do permit estimation of size class abundances after correcting for
3′ bias (Figure 4.6). Thus the PacBio data reported by Ocwieja et al. 419 and the Illumina
data reported here can be combined together to determine complete relative abundance of
78 HIV89.6 transcripts (Figure 4.7B).
The most abundant HIV mRNAs were the unspliced HIV genome (37.6%), a transcript
encoding Nef (D1-A5-D4-A7: 15.5%), two 1 kb size class transcripts (D1-A5-D4-A8c: 10.6%,
D1-A8c: 4.9%) and two Rev-encoding transcripts (D1-A4c-D4-A7: 4.2%,D1-A4b-D4-A7:
3.1%).
Using these abundances, we can estimate the number of HIV89.6 genomes in these primary T
cells 48 hours after infection. To determine the proportion of the mRNA nucleotides from viral
transcripts, we multiplied the estimated abundances by their transcript lengths. Unspliced
genome transcripts appear to form 79% of the mRNA nucleotides from HIV89.6 transcripts.
Assuming T cells contain at least 0.1 pg of mRNA then an infected cell should contain at
least 0.011 pg of unspliced HIV transcript (0.1pg × 0.14HIV mRNA ntcell mRNA nt × 0.79unspliced mRNA ntHIV mRNA nt )
or, assuming 9171 bases of RNA weigh about 5 × 10−6 pg, at least 2200 HIV genomes at 48
hour post infection. This estimate roughly agrees with previous estimates of HIV production
per cell531,533,534.
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Figure 4.6: Estimating relative
abundance of HIV89.6 message
size classes using RNA-Seq data.
A) RNA-Seq coverage of the
HIV89.6 genome for the replicates
in this study. Each replicate is in-
dicated by a different color. The
HIV genome is shown on the x-
axis and the number of reads
that aligned to each position is
shown on the y-axis. Black line
indicates the 0.021% coverage de-
crease per base distance from the
3′ end of the mRNA estimated
from a least squares fit on the
read counts in the first intron.
B) Diagram of the segments of
the HIV89.6 RNA present in each
of 9 kb, 4 kb, 2 kb and 1 kb size
class.
C) The proportion of reads
mapped to each of the segments
of the HIV89.6 genome shown in
B adjusted by the length of the
segment. Each replicate is shown
by a different color.
D) Corrected representation of
RNA segments from the differ-
ent size classes. Because cDNA
synthesis was primed from the
polyA tail, more 3′ sequences are
recovered preferentially. Using
the bias estimate from A, we ad-
justed each genome segment by
the inverse of the bias predicted
based on its distance from the 3′
end of the mRNA. Corrected pro-
portions for the indicated RNA
segments are shown colored by
replicate.
E) The proportion of each size
class was inferred using the esti-
mates in D by calculating the dif-
ference between segments. Repli-
cates are indicated by color.
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Figure 4.7: Transcription and splicing
of the HIV89.6 RNA. A) Junctions be-
tween HIV splice donors and acceptors
observed in the RNA-Seq data. Ac-
ceptors are shown as the columns and
donors as the rows with the coloring in-
dicating the frequency of each pairing.
B) The relative abundance of 78 HIV89.6
transcripts as determined by a combi-
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association of multiple splice junctions
in single sequence reads. The Illumina
short read sequencing allowed normal-
ization of message abundances between
size classes. The inferred HIV message
population is shown colored by relative
abundance.
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4.4.8 Human-HIV chimeric reads
In our data, 80,045 reads contained sequences matching to both HIV and human genomic
DNA, but a considerable complication arises because chimeras can be formed artifactually
during the preparation of libraries for sequence analysis535–542. Many of the chimeric
sequences in our data contained junctions between the HIV and human sequence where the
ends of the human and HIV sequence were similar and potentially complementary (Figure
4.8A). This raises the concern that some of these chimeras could be products of in vitro
recombinations during the reverse transcription, amplification and sequencing processes.
Template switching between sequences with shared similarity is a well established property
of retroviral reverse transcriptase enzymes used in RNA-Seq library preparation543–545.
Priming off incomplete transcripts during DNA synthesis is another potential source of
chimeric transcripts535,536,546,547. Failing to account for chimeras can hinder interpretation
of deep sequencing data537–542.
Also consistent with artifactual chimera formation, 7,354 reads (9.2% of chimeric messages)
contained HIV sequences joined to human mitochondrial sequences, yet HIV proviruses have
not previously been found integrated in mitochondrial DNA423. To probe this further, we
used ligation-mediated PCR to recover integration site junctions from the same infected cell
populations analyzed by RNA seq, yielding 147,281 unique integration sites (Figure 4.8B)396.
No integrations in mitochondrial DNA were detected. We conclude that chimeric HIV-
mitochondrial sequence reads in the RNA-seq data represent artifacts of library construction
and so used these chimeras as an assay to evaluate subsequent data filtering steps. We
reasoned that reads without sequence similarity at junctions between human and HIV
mapping were less likely to be artifacts caused by template switching. Filtering to only reads
where no overlap and no unknown intervening sequence was present between human and HIV
portions left 2181 junctions and reduced the proportion of reads containing mitochondrial
DNA to 2.4%. Of the remaining HIV-human chimeric reads, the HIV portion of 605 sequences
bordered the 3′ or 5′ end of HIV or an HIV splice donor or acceptor. Filtering to these
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more likely authentic junctions left only 2 (0.3%) chimeric reads containing mitochondrial
sequence. This decrease in likely mitochondrial artifacts suggests that the filtering was
effective. The high rate of mitochondrial chimeras in the unfiltered sequences raises the
concern that artifacts may easily distort results in studies using similar amplification and
sequencing techniques.
Chimeric messages composed of HIV and cellular RNA sequences can be formed by cellular
gene transcription reading into the integrated provirus, by HIV transcription reading out
through the viral polyadenylation site or by splicing between human and viral splice sites.
In our filtered data, the predominant forms appear to be derived from reading through the
HIV polyadenylation signal into the surrounding DNA (78%), splicing out of the viral D4
splice donor to join to human slice acceptors (17%) and reading into the HIV 5′ LTR from
human sequence (4.0%) (Figure 4.8C). No splice site other than D4 had more than two
chimeric reads observed.
The filtered chimeric reads had many traits consistent with biological chimera formation.
The reads containing HIV D4 joined to human sequences had the characteristics expected of
splicing—72.1% of the chimeric junctions mapped to known human acceptors and 96.1%
mapped to a location immediately preceded by the AG consensus of human mRNA acceptors.
The reads containing the 5′ or 3′ LTR border were almost exclusively (93%) found in
transcription units, with odds of being in a gene 2.3-fold (95% CI: 1.6–3.2×) higher than
integration sites from the same sample. The readthrough chimeras were also more likely
to be located in an exon than integration sites (odds ratio: 2.1×, 95% CI: 1.6–2.6× only
considering integration sites and chimeras in transcription units).
Chimeric sequences have the potential to alter the expression of proto-oncogenes leading
to proliferation of the host cell498–501. In our data, we saw no significant enrichment of
integrations in transcription units annotated as proto-oncogenes by the Uniprot Knowledge-
base548,549 (Fisher’s exact test p = 0.15). Chimeras were enriched relative to integration sites
in genes annotated in a broader collection of cancer-related genes550 (odds ratio: 1.3, 95%
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CI: 1.1–1.7). However, the expression of overlapping genes, as estimated by Cuﬄinks, was
even more highly associated with chimeric reads (generalized linear model of chimera versus
integration site on log(FPKM): p = 2 × 10−9) and adding the cancer-related gene annotation
was not significantly associated after accounting for expression (ANOVA: p = 0.06). This
lack of enrichment might be expected since cells were infected for only 48 hours and it is
unlikely that there would be time for any selection to occur.
We next compared whether the human and viral segments of chimeric reads agreed or
disagreed in orientation (i.e. strand transcribed) for reads with the human portion mapped
within annotated transcription units. The sequencing technique used here does not preserve
strand information, but we can check whether the strand of a sequence read agrees or
disagrees with the annotated gene strand and compare this to the observed strand of the
HIV portion of the read. Chimeras involving HIV splice donor D4 were more highly enriched
for matching orientations (odds ratio: 52.5×, 95% CI: 12.1–307×) suggesting that pairing
with human splice acceptors constrains the orientation of D4 chimeric reads. We also found a
strong association between the orientation of the human and HIV portions of chimeric reads
within 3′ and 5′ chimeras (odds ratio: 6.2×, 95% CI: 3.9–10.2×). This highly significant
enrichment of HIV and human genes in the same orientation (Fisher’s exact test p < 10−15)
might indicate that antisense HIV RNA is rapidly degraded by a response to double-stranded
RNA or that polymerases oriented in opposing directions interfere with one another during
elongation.
Based on these data, we can propose a lower bound on the relative abundance of chimeras. If
we assume that our filtering removed nearly all artifacts so that we have few false positives,
then our estimate should be lower than the true proportion of chimeras. In our data, only
604
12,689,879 = 0.0048% of reads containing sequence mapping to HIV also contained identifiable
chimeric junctions. However, this is an underestimate because in an HIV-derived mRNA, any
fragment of the sequence will be mappable to HIV, while for a chimeric sequence only a read
spanning the HIV-human junction will allow identification of a chimera. If we assume that
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Figure 4.8: Analysis of chimeric RNA se-
quences containing both human and HIV
sequences. A) The length of overlap-
ping sequence (regions of complementar-
ity potentially favoring chimera forma-
tion) matching both human and HIV at
inferred chimeric junctions. The x-axis
shows the length of the overlap and the
y-axis shows the frequency of chimeric
junctions with the indicated extent of
overlap. B) Chromosomal distribution of
uniquely mapping HIV integration sites
from the same infections of primary T
cells and comparison to uniquely map-
ping human sequences in chimeric reads
observed in RNA-Seq. Note that the
mitochondrial genome, denoted as M,
has no authentic integration sites but
does have extensive matches to chimeric
junctions found in the RNA-Seq data.
C) Counts of the location in the HIV
genome of the HIV-human junctions in
filtered chimeric reads.
25 bases of sequence are necessary to map to human or HIV sequence, then, with the 100-bp
reads used here, only read fragments starting between 75- and 25-bp downstream of the
chimeric junction will be identifiable. If we assume the average chimeric mRNA sequences is
at least 2 kb long, then a read from a chimeric sequence has at most a 502000 = 2.5% chance
of containing a mappable junction. Thus, a lower bound for the proportion of HIV mRNA
that also contain human-derived sequences is 0.2% (0.0048%
2.5%
). Looking only at splicing from
HIV donor D4, we saw 16,843 reads containing a junction from D4 to an HIV acceptor and
104 reads from D4 to human sequence. Thus, in our data, 0.6% of D4 splice products form
junctions with human acceptors instead of HIV acceptors.
4.5 Discussion
Here we used RNA-Seq to analyze mRNA accumulation and splicing in primary T cells
infected with the low passage isolate HIV89.6. We did not carry out dense time series analysis,
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compare different human cell donors or compare different perturbations of the infections—
instead, we focused on generating a dense data set at a single time point. We analyzed
replicate infected cell and control samples to allow discrimination of within-condition versus
between-condition variation and assessed differences using a series of bioinformatic approaches.
Many previous studies have used microarray technology or RNA-Seq to study gene activity
in HIV-infected cells317,319,477–485,490, usually analyzing infections of transformed cell lines or
laboratory adapted strains of HIV-1. Here we present what is to our knowledge the deepest
RNA-Seq data set reported for infection in primary T cells using a low passage HIV isolate
(HIV89.6).
This RNA-Seq data set was paired with a set of 147,281 unique integration site sequences
extracted from the same infections, which were critical to our ability to quality control
chimeric reads. An advantage of studies using cell lines and laboratory adapted strains
is that a high proportion of cells can be infected, whereas in this study we achieved only
∼30% infection. In this study, T cells were activated using IL-2 and PHA-L. Further studies
investigating the effects of cells activated in a more physiological way might provide further
benefits. However, we report distinctive features of the transcriptional response not seen
in studies of HIV infections in cell lines. Novel in this study are 1) identification of intron
retention as a consequence of HIV infection, 2) the finding of activation of ERV-9/LTR12C
after HIV infection, 3) generation of a quantitative account of the structures and abundances
of over 70 HIV89.6 messages and 4) clarification of the predominant types of HIV-host
transcriptional chimeras. These findings are discussed below.
Broad changes in host cell mRNA abundances were evident after infection, with over 17%
of expressed genes changing significantly in activity. Changes included response to viral
infection, apoptosis and T cell activation. Although it is not possible here to separate
the response of infected and bystander cells, this study highlights the drastic changes in
cellular expression caused by HIV-1 infection. In a meta-analysis including four previously
published studies, no gene was detected as differentially expressed in all five studies and
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only a handful of genes appeared in four out of five studies. Further analyses showed that
expression changes appear to be cell type specific, raising concerns that studies using cell
lines may not fully reflect host cell responses in in vivo infections.
Unexpectedly, intronic sequences were more common in the RNA-Seq data from cells after
HIV89.6 infection than in mock infected cells. The mechanism is unclear. It is possible that
the splicing machinery is reduced in activity after 48 hours of infection, perhaps as a part of
the antiviral response of infected and bystander cells. HIV infection does appear to alter
expression and localization of some splicing factors446,551,552 and genes involved in RNA
splicing were more likely to be differentially expressed in our study (Benjamini-Hochberg
corrected Fisher’s exact test: q = 2×10−5). Alternatively, fully spliced mRNAs might be more
rapidly degraded after infection, possibly by interferon-mediated induction of RNaseL553
or off-target binding of viral protein Rev might mediate export of incompletely spliced
cellular transcripts226,227. A speculative possibility is that HIV89.6 encodes a factor that
alters cellular splicing or promotes mRNA degradation to optimize splicing and translation
of viral messages.
Infection resulted in increased expression of specific cellular repeated sequences. HERVs, in
particular HERV-K, have previously been observed to show increased RNA accumulation with
HIV infection328–333,340 and possibly represent vaccine targets because of their production
of distinctive proteins335–340. Here, though we saw modest increases in HERV-K expression,
ERV-9 had the greatest change in expression (33 LTR12C and 14 ERV-9 annotated regions
with greater than 4× change in expression). Previous RNA-Seq studies of HIV infection in
cell lines did not report increases in HERV expression319,482 but this difference is likely due
to a much higher baseline expression of HERVs in transformed cell lines. We also observed
increases in LINE and Alu element transcription, as has been reported previously334, and
expression changes in ERV-9/LTR12C expression associated with transcription factor motifs
and U3 variants.
Many of the repeated sequence elements that were induced by HIV89.6 infection are relatively
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recently integrated in the human genome. The reason for this pattern is unclear. It may
be that older elements have accumulated more mutations, resulting in an inactivation of
transcriptional signals. Alternatively, perhaps the elements that are induced have been
recruited for transcriptional control of cellular functions, so that their transcriptional activity
is preserved evolutionarily511,554–557.
Comparison of the results of sequencing HIV89.6 messages using long-read single molecule
sequencing (Pacific Biosciences) and dense short read sequencing (Illumina data reported
here) allowed a full quantitative accounting of more than 70 HIV89.6 splice forms. The full
length unspliced HIV RNA comprised 37.6% of all messages, corresponding to more than
2000 genomes per cell. Notably abundant messages included the full length genome and
spliced transcripts encoding Nef and Rev transcripts. The full set of messages is summarized
in Figure 4.7B.
Our previous analysis using PacBio sequencing419 revealed an unusually prominent 1 kb
size class. HIV89.6 encodes a splice acceptor (A8c) within Nef responsible for formation of
the short messages. Our data indicated that two members of the 1-kb size class, D1-A5-
D4-A8c and D1-A8c, accounted for 10.6% and 4.9% of all viral messages. The 1 kb size
class as a whole accounted for fully 20% of messages. The function of this large amount
of 1 kb transcript is unknown. The most abundant 1 kb transcripts do not appear to
encode significant open reading frames although other 1 kb transcripts can encode a Rev-
Nef fusion419. Most HIV/SIV variants do appear to encode an acceptor near this position,
suggesting a potential unknown function for these short spliced forms419,427,431. This analysis
also suggests a lower proportion of 4kb than has been seen for another isolate322 suggesting
that these ratios may vary with strain, time of infection or other conditions.
After filtering, we detected a sizeable number of apparently authentic chimeras containing
both HIV and cellular sequences. Mechanisms of insertional activation have been studied
intensively in animal models of transformation and in adverse events in human gene therapy.
One of the most common mechanisms involves insertion of a retroviral enhancer near a
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cellular promoter, so that transcription of a nearby gene is increased499,558–560. However,
another common mechanism involves formation of chimeric messages involving both cellular
and viral/vector sequences498,499. A targeted in vitro study of chimeric message formation
by lentiviral vectors showed examples of multiple types of read-in and -out and splice-in and
-out500, which may have been more frequent and more varied than for HIV89.6 proviruses
studied here. The low level of splicing and reading into HIV in this study may be a reflection
of the high rate HIV transcription in these infected cells–because HIV was so highly expressed,
there would be more opportunities for polymerase to splice out of or read through the HIV
genome than to read or splice in. The vast majority of HIV proviruses in expanded clones
in well-suppressed patients appear to be defective494—going forward, it will be of interest to
investigate whether these HIV proviruses are damaged in ways that promote formation of
chimeric transcripts.
Lastly, we note that several features of the transcriptional response to HIV89.6 infection were
suggestive of de-differentiation away from T cell specific expression patterns. The increase
in expression of cellular HERVs and LINEs is characteristic of cells in early development.
Specific HERVs and transposons, including ERV-9/LTR12C and HERV-K, have been
implicated in regulating gene activity early in development511,554,557,561–564. Several genes
related to other hematopoietic cell types showed elevated RNA abundance after HIV89.6
infection. These data are of interest given the finding that patients undergoing long term
ART can contain long lived T cell clones that may contribute to the latent reservoir494,565–568.
Possibly the transcriptional responses seen in infected primary T cells here are reflective
of processes leading to formation of the long-lived latently-infected cells with stem-like
properties.
4.6 Conclusions
Infections of primary T cells with a low passage HIV isolate showed several distinctive
features compared to previously published data using T cell lines and/or lab-adapted HIV
strains. We found strong changes in expression in genes related to immune response and
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apoptosis similar to studies of HIV infection in patient samples and primary cells but different
from studies performed in SupT1 cell lines. Notable changes after infection included intron
retention and activation of recently integrated retrotransposons and endogenous retroviruses,
in particular LTR12C/ERV-9. We also present complete absolute estimation of over 70
messages from HIV89.6 and specify the major virus-host chimeras as splicing from viral
splice donor 4 to cellular acceptors and readthrough from the 5′ and 3′ ends of the provirus.
4.7 Availability of supporting data
RNA-Seq reads from this study are available at the Sequence Read Archive under accession
number SRP055981. The integration site data is available at the Sequence Read Archive
under accession number SRP057555.
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5.1 Abstract
Diagnostic methods for detecting and quantifying HIV RNA have been improving, but
efficient methods for point-of-care analysis are still needed, particularly for applications in
resource-limited settings. Detection based on reverse-transcription loop-mediated isothermal
amplification (RT-LAMP) is particularly useful for this, because when combined with
fluorescence-based DNA detection, RT-LAMP can be implemented with minimal equipment
and expense. Assays have been developed to detect HIV RNA with RT-LAMP, but existing
methods detect only a limited subset of HIV subtypes. Here we report a bioinformatic study
to develop optimized primers, followed by empirical testing of 44 new primer designs. One
primer set (ACeIN-26), targeting the HIV integrase coding region, consistently detected
subtypes A, B, C, D, and G. The assay was sensitive to at least 5000 copies per reaction for
84
subtypes A, B, C, D, and G, with Z-factors of above 0.69 (detection of the minor subtype F
was found to be unreliable). There are already rapid and efficient assays available for detecting
HIV infection in a binary yes/no format, but the rapid RT-LAMP assay described here has
additional uses, including 1) tracking response to medication by comparing longitudinal
values for a subject, 2) detecting of infection in neonates unimpeded by the presence of
maternal antibody, and 3) detecting infection prior to seroconversion.
5.2 Introduction
Despite the introduction of efficient antiretroviral therapy, HIV infection and AIDS continue
to cause a worldwide health crisis570. Methods for detecting HIV infection have improved
greatly with time571–today rapid assays are available that can detect HIV infection in a
yes-no format using a home test kit that detects antibodies in saliva. Viral load assays that
quantify viral RNA with quick turn-around time are widely available in the developed world.
However, quantitative viral load assays are not commonly available with actionable time
scales in much of the developing world. This motivates the development of new rapid and
quantitative assays that can be used at the point of care with minimal infrastructure572,573.
One simple and quantitative detection method involves reverse transcription-based loop
mediated isothermal amplification (RT-LAMP)574. In this method, a DNA copy of the viral
RNA is generated by reverse transcriptase, and then isothermal amplification is carried out to
increase the amount of total DNA. Primer binding sites are chosen so that a series of strand
displacement steps allow continuous synthesis of DNA without requiring thermocycling.
Reaction products can be detected by adding an intercalating dye to reaction mixtures
that fluoresces only when bound to DNA, allowing quantification of product formation by
measurement of fluorescence intensity. Such assays can potentially be packaged in simple
self-contained devises and read out with no technology beyond a cell phone.
RT-LAMP assays for HIV-1 have been developed previously and reported to show high
sensitivity and specificity for subtype B, the most common HIV strain in the developed
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world573,575,576. Another recent study reported RT-LAMP primer set optimized for the
detection of HIV variants circulating in China577, and another on confirmatory RT-LAMP
for group M viruses578. Assays have also been developed for HIV-2579. A complication
arises in using available RT-LAMP assays due to the variation of HIV genomic sequences
among the HIV subtypes580,581, so that an RT-LAMP assay optimized for one viral subtype
may not detect viral RNA of another subtype582. Tests presented below show that many
RT-LAMP assays are efficient for detecting subtype B, for which they were designed, but
often performed poorly on other subtypes. Subtype C infects the greatest number of people
worldwide, including in Sub-Saharan Africa, where such RT-LAMP assays would be most
valuable, motivating optimization for subtype C. Several additional non-B subtypes are also
responsible for significant burdens of disease world-wide583.
Here we present the development of an RT-LAMP assay capable of detecting HIV-1 subtypes
A, B, C, D, and G. We first carried out a bioinformatic analysis to identify regions conserved
in all the HIV subtypes. We then tested 44 different combinations of RT-LAMP primers
targeting this region in over 700 individual assays, allowing identification of a primer set
(ACeIN-26) that was suitable for detecting these subtypes. We propose that the optimized
RT-LAMP assay may be useful for quantifying HIV RNA copy numbers in point-of-care
applications in the developing world, where multiple different subtypes may be encountered.
5.3 Methods
5.3.1 Viral strains used in this study
Viral strains tested included HIV-1 92/UG/029 (Uganda) (subtype A, NIH AIDS Reagent
program reagent number 1650), HIV-1 THRO (subtype B, plasmid derived, University of
Pennsylvania CFAR)584, CH269 (subtype C, plasmid derived, University of Pennsylvania
CFAR)584, UG0242 (subtype D, University of Pennsylvania CFAR), 93BRO20 (subtype F,
University of Pennsylvania CFAR), HIV-1 G3 (subtype G, NIH AIDS Reagent program
reagent number 3187)585.
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Viral stocks were prepared by transfection and infection. Culture supernatants were cleared
of cellular debris by centrifugation at 1500g for 10 min. The supernatant containing virus
was then treated with 100 U DNase (Roche) per 450 uL virus for 15 min at 30◦C. RNA was
isolated using the QiaAmp Viral RNA mini kit (Qiagen GmbH, Hilden, Germany). RNA
was eluted in 80 uL of the provided elution buffer and stored at -80◦C.
Concentration of viral RNA copies was calculated from p24 capsid antigen capture assay
results provided by the University of Pennsylvania CFAR or the NIH AIDS-reagent program.
In calculating viral RNA copy numbers, we assumed that all p24 was incorporated in virions,
all RNA was recovered completely from stocks, 2 genomes were present per virion, 2000 p24
molecules per viral particle, and the molecular weight of HIV-1 p24 was 25.6 kDa.
5.3.2 Assays
RT-LAMP reaction mixtures (15 µL) contained 0.2 µM each of primers F3 and B3 (if a
primer set used multiple B3 primers, mixture contained 0.2 µM of each); 1.6 µM each of FIP
and BIP primers (if a primer set had multiple FIP primes, reaction mixture contained 0.8
µM of each FIP primer); and 0.8 µM each of LoopF and LoopB primers; 7.5 µL OptiGene
Isothermal Mastermix ISO-100nd (Optigene, UK), ROX reference dye (0.15 µL from a 50X
stock), EvaGreen dye (0.4 µL from a 20X stock; Biotium, Hayward, CA); HIV RNA in 4.7
µL; AMV reverse transcriptase (10U/µL) 0.1 µL and water to 15 µL. In most cases where
two primer sets were combined, the total primer concentration within the reaction was
doubled such that the above individual primer molarities were maintained. For the mixture
ACeIN-26+F-IN (S2 Table, line 46), the total primer concentration was not doubled–the
F-IN primer set comprised 25% of the total primer concentration, and the ACeIN-26 primer
set comprised 75% of the total primer concentration with the ratios of primers listed above
preserved. This mixture was combined 1:1 with the ACe-PR primer set (S2 Table, line 47)
such that total primer concentration in the final mixture was doubled.
Amplification was measured using the 7500-Fast Real Time PCR system from Applied
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Biosystems with the following settings: 1 minute at 62◦C; 60 cycles of 30 seconds at
62◦C and 30 seconds at 63◦C. Data was collected every minute. Product structure was
assessed using dissociation curves which showed denaturation at 83◦C. Products from selected
amplification reactions were analyzed by agarose gel electrophoresis and showed a ladder of
low molecular weight products (data not shown).
Product synthesis was quantified as the cycle of threshold for 10% amplification. Z-factors586
were calculated from tests of 24 replicates using the ACeIN-26 primer set in assays with
viral RNA of each subtype. No detection after 60 min was given a value of 61 min in the
Z-factor calculation.
5.4 Results
5.4.1 Testing published RT-LAMP primer sets against multiple HIV subtypes
We first assessed the performance of existing RT-LAMP assays on RNA samples from
multiple HIV subtypes. We obtained viral stocks from HIV subtypes A, B, C, D, F, and
G, estimated the numbers of virions per ml, and extracted RNA. RNAs were mixed with
RT-LAMP reagents which included the six RT-LAMP primers, designated F3, B3, FIP, BIP,
LF and LB574. Reactions also contained reverse transcriptase, DNA polymerase, nucleotides
and the intercalating fluorescent EvaGreen dye, which yields a fluorescent signal upon DNA
binding. DNA synthesis was quantified as the increase in fluorescence intensity over time,
which yielded a typical curve describing exponential growth with saturation (examples are
shown below). Results are expressed as threshold times (Tt ) for achieving 10% of maximum
fluorescence intensity at the HIV RNA template copy number tested.
In initial tests, published primer sets targeting the HIV-1 subtype B coding regions for
capsid (CA), protease (PR), and reverse transcriptase (RT) (named B-CA, B-PR and B-RT)
were assayed in reactions with RNAs from four of the subtypes. Results with each primer set
tested are shown in Figure 5.1 in heat map format, where each tile summarizes the results of
tests of 5000 RNA copies. Primers and their groupings into sets are summarized in S1 and
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S2 Tables, average assay results are in S3 Table, and raw assay data is in S4 Table. Assays
(Figure 5.1, top) with the B-CA, B-PR and B-RT primer sets detected subtypes B and D
at 5000 RNA copies with threshold times less than 20 min. However, assays with B-CA
and B-RT detected subtypes C and F with threshold times > 50 min, indicating inefficient
amplification and the potential for poor separation between signal and noise. B-PR did
not detect subtype C at all. In an effort to improve the breadth of detection, we first tried
mixing the B-PR primers, which detected clade F (albeit with limited efficiency) with the
B-CA and B-RT primers (Figure 5.1 and S3 and S4 Tables). In neither case did this provide
coverage of all four clades tested. We thus did not test these primer sets on RNAs from the
remaining subtypes and instead sought to develop primer sets targeting different regions of
the HIV genome.
5.4.2 Primer design strategy
To design primers that detected multiple HIV subtypes efficiently, we analyzed alignments
of HIV genomes (downloaded from the Los Alamos National Laboratory site580) for regions
with similarity across most viruses, revealing that a segment of the pol gene encoding
IN was particularly conserved (Figure 5.2A). A total of six primers are required for each
RT-LAMP assay574. We used the EIKEN primer design tool to identify an initial primer set
targeting this region. In further analysis, positions in the alignments were identified within
primer landing sites that commonly contained multiple different bases. Primer positions
were manually adjusted to avoid these bases when possible, and when necessary mixtures
were formulated containing each of these commonly occurring bases (S1 and S2 Tables).
An extensive series of variants targeting the IN coding region was tested empirically in
assays containing RNAs from multiple subtypes (5000 RNA copies per reaction, over 700
total assays; S3 and S4 Tables). Based on initial results, primers were further modified by
adjusting the primer position or addition of locked nucleic acids as described below.
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Figure 5.1: Summary of amplification results for all the RT-LAMP primer sets tested in
this study. The data is shown as a heat map, with more intense yellow coloring indicating
shorter amplification times (key at bottom). Primer sets tested are named along the left of
the figure. Primer sequences, and their organization into LAMP primer sets, are cataloged
in S1 and S2 Tables. The raw data and averaged data are collected in S3 and S4 Tables.
ACeIN-26 primer set (highlighted) had one of the best performances across the subtypes
and a relatively simple primer design.
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Figure 5.2: Bioinformatic analysis to design subtype-agnostic RT-LAMP primers. A)
Conservation of sequence in HIV. HIV genomes (n = 1340) from the Los Alamos National
Laboratory collection were aligned and conservation calculated. The x-axis shows the
coordinate on the HIV genome, the y-axis shows the proportion of sequences matching the
consensus for each 21 base segment of the genome (red points). The black line shows a
101 base sliding average over these proportions. The vertical red shading shows the region
targeted for LAMP primer design that was used as input into the EIKEN primer design tool.
Numbering is relative to the HIV89.6 sequence. B) Aligned genomes, showing the locations
of the ACeIN-26 primers. Sequences are shown with DNA bases color-coded as shown at the
lower right. Each row indicates an HIV sequence and each column a base in that sequence.
Horizontal lines separate the HIV subtypes (labeled at left). Arrows indicate the strand
targeted by each primer. Primers targeting the negative strand of the virus are shown as
reverse compliments for ease of viewing.
91
5.5 Testing different primer designs
Our first design, ACeIN-1 (“ACe” for “All Clade” and “IN” for “integrase”), targeted the
HIV IN coding region and contained multiple bases at selected sites to broaden detection
(Figure 5.1). ACeIN-2 and-3 have primers (B3) with slightly different landing sites. Tests
showed that the mixture of primers allowed amplification with a shorter threshold time than
did either alone (Figure 5.1).
We also tried to design a new primer set to the CA coding region (Figure 5.1, ACeCA)
but found that the set only amplified clade B, and not efficiently. Thus this design was
abandoned.
ACeIN-3 through-6 were altered by inserting a polyT sequence between the two different
sections of FIP and BIP in various combinations, a modification introduced with the goal of
improving primer folding, but these designs performed quite poorly (Figure 5.1).
Because the FIP primer appeared to bind the region with most variability among clades, we
tried variations that bound to several nearby regions. These were tried with and without
the polyT containing BIP and FIP primers in various combinations (Figure 5.1, ACeIN-7
through-22). We also tried mixing all of the variations of FIP together (ACeIN-23; S2 Table).
The ACeIN-23 primer set was tried as a mixture with the B-PR set to try to capture clade
F, yielding a relatively effective primer set (Figure 5.1, ACeIN-23+B-PR).
In an effort to increase affinity, an additional G/C pair was added to F3 and tested with
various other IN primers (Figure 5.1, ACeIN-24 through-31). Testing showed improvement,
with ACeIN-26 showing particularly robust amplification.
In a second effort to increase primer affinities, we substituted locked nucleic acids (LNAs) for
selected bases that were particularly highly conserved among subtypes (Figure 5.1, ACeIN-30,
-31, -32, -33, and-34). Some improvement was shown over the non-LNA containing bases.
However, the ACeIN-26 primer set was as effective as or better than any LNA containing
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Primer name Sequence
ACeIN-F3 c CCTATTTGGAAAGGACCAGC
ACeIN-B3a TCTTTGAAAYATACATATGRTG
ACeIN-B3b AACATACATATGRTGYTTTACTA
ACeIN-FIPe CTTGGTACTACYTTTATGTCACTAAARCTACTCTGGAAAGGTG
ACeIN-FIPf CTTGGCACTACYTTTATGTCACTAAARCTYCTCTGGAAAGGTG
ACeIN-BIP GGAYTATGGAAAACAGATGGCAGCCATGTTCTAATCYTCATCCTG
ACeIN-LF TCTTGTATTACTACTGCCCCTT
ACeIN-LB GTGATGATTGTGTGGCARGTAG
Table 5.1: The primers from the ACeIN-26 primer set selected for further study
primer sets.
In further tests, the ACeIN-26, -28 and-30 primers were tested combined with the ACePR
primer set (a slightly modified version of the B-PR primer set, S2 Table, row 2, designed
to accommodate a wider selection of HIV-1 subtypes) but no improvement was seen and
efficiency may even have fallen for some subtypes. We also designed a primer set that
matched exactly to the targeted sequences found in the problematic subtype F, and mixed
this set with the ACeIN-26 primers. However, no improvement was seen (Figure 5.1, mixtures
with F-IN set). Mixing the ACeIN-26 primers with both the ACePR and F-specific primers
did yield effective primer sets (Figure 5.1, ACeIN-26+F-IN and ACeIN-26+F-IN+ACePR).
However, amplification efficiency was not greatly improved over the ACeIN-26 primer set, so
we proceeded with the simpler ACeIN-26 primer set (Figure 5.2B and Table 5.1) in further
studies.
5.5.1 Performance of the optimized RT-LAMP assay
The ACeIN-26 RT-LAMP primer set was next tested to determine the minimum concentration
of RNA detectable under the reaction conditions studied (Figure 5.3). RNA template amounts
were titrated and time to detection quantified. Tests showed detection after less than 20
min of incubation for 50 copies of subtypes A or B, detection after less than 30 min for 5000
copies for C, D, and G, and detection after less than 20 min for 50,000 copies for F.
For clinical implementation the reliability of an assay is critical. This is commonly sum-
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Figure 5.3: Performance of the AceIN-26 primer set with different starting RNA concentra-
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shows the threshold time (y-axis) as a function of log RNA copy number (x-axis) added to
the reaction. In the right hand panels, values were dithered where two points overlapped to
allow visualization of both.
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Figure 5.4: Examples of time
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marized as a Z-factor586, which takes into account both the separation in means between
positive and negative samples and the variance in measurement of each. An assay with
a Z-factor above 0.5 is judged to be an excellent assay. Z-factors for detection of each of
the subtypes at 5000 RNA copies per reaction were > 0.50 for subtypes A, B, C, D, and
G, respectively (Figure 5.4, n = 24 replicates per test). Detection of subtype F at 5000
copies per reaction was sporadic, showing a much lower Z-factor. Therefore our ACeIN-26
RT-LAMP primer set appears well suited to detect 5000 copies of subtypes A, B, C, D and
G.
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5.6 Discussion
Here we present an RT-LAMP assay optimized to identify multiple HIV subtypes. Infections
with subtype B predominate in most parts of the developed world, but elsewhere other
subtypes are more common583. Thus nucleic acid-based assays for use in the developing
world need to query HIV subtypes more broadly. Previously reported RT-LAMP assays,
while effective at detecting subtype B, commonly showed poor ability to detect at least some
of the HIV subtypes, including C, which is common in the developing world (Figure 5.1).
Here we first carried out an initial bioinformatic survey to identify regions conserved across
all HIV subtypes that could serve as binding sites for RT-LAMP primers. We then tested
primer sets targeting these regions empirically for efficiency. Testing 44 different primer
sets revealed that assays containing ACeIN-26 were effective in detecting 5000 copies of
RNA from subtypes A, B, C, D, and G within 30 minutes of incubation. For these five
subtypes, the times of incubation to reach the threshold times were not too different, which
simplifies interpretation when the subtype in the sample is unknown. Regardless of the
efficiency, these assays can be applied to longitudinal studies of changes in viral load within
an individual. We propose that RT-LAMP assays based on the ACeIN-26 primer set can be
useful world-wide for assaying HIV-1 viral loads in infected patients.
There are several limitations to our study. Subtypes A, B, C, D, and G were detected
efficiently and showed Z-factors above 0.5, but subtype F was detected reliably only with
higher template amounts, probably due to more extensive mismatches with the ACeIN-26
primer set. Subtype F is estimated, however, to comprise only 0.59% of all infections
globally583, though it is common in some regions. For many of the common circulating
recombinant forms, such as AE and BC, the target site for ACeIN-26 is from a subtype
known to be efficiently detected, though in some cases the efficiency of detection is not easy
to predict and will need to be tested. We did not test subtypes beyond A, B, C, D, F and
G, and we did not attempt to assess multiple different variants within each subtype. Thus,
while we do know that our RT-LAMP assays are more widely applicable than many of those
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reported previously, we do not know whether they are able to detect all strains efficiently. In
addition, although we carried out more than 700 assays in this study, there remain multiple
parameters that could be optimized further, such as primer concentrations, salt type and
concentration, temperature, and divalent metal concentrations, so there are likely further
opportunities for improvement. Also, possible effects of RNA quality on assay performance
were not tested rigorously.
A particularly important parameter for further optimization is primer sequence. Several
groups have recently published primer sets optimized for broad detection of different HIV
lineages577,578, offering opportunities for creating sophisticated primer blends with increased
breadth of detection. However, in developing such mixtures, it will be important to monitor
for possible complicating interactions of primers with each other. As an example of ongoing
development of mixtures, we found that addition of another primer to the ACeIN-26 set
that was matched to a common subtype C lineage allowed improved detection of subtype C
variants (S1 Report). In order to improve detection of subtype F, which was suboptimal with
ACeIN-26, additional primer sets could be mixed to specifically target subtype F, though
the ones we tried so far did not work well. It will be useful to explore the performance of
broader primer mixtures in future work.
Today rapid assays are available that can report infection efficiently, for example by detecting
anti-HIV antibodies in oral samples–however, the nucleic acid-based method presented here
has additional potential uses. We envision combining the RT-LAMP assay with simple
point-of-care devices for purifying blood plasma572 and quantitative analysis of accumulation
of fluorescent signals587. In one implementation of the technology, cell phones could be used
to capture and analyze results, thereby minimizing equipment costs. Point-of-care devices are
available facilitating the concentration of viral RNA from blood plasma or saliva587 to allow
the detection of the 1000 RNA copy threshold that the WHO defines as virological treatment
failure (World Health Organization, Consolidated ARV guidelines, June 2013). Together,
these methods will allow assessment of parameters beyond just the presence/absence of
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infection. Quantitative RT-LAMP assays should allow tracking of responses to medication,
detection in neonates (where immunological tests are confounded by presence of maternal
antibody), and early detection before seroconversion.
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CHAPTER 6: Conclusions and future directions
In this dissertation, we described studies characterizing HIV-1 latency, expression and
alternative splicing and host cell response to infection. We then developed point-of-care
methods for the detection of infection and quantification of viral load. These projects suggest
many avenues for continuing research.
6.1 Latency and integration location
In Chapter 2, we showed that the chromosomal location of integration affects proviral latency
but the mechanisms appear to differ between cell culture models. Similarly a recent study
of nine cell culture models found that no single model reliably predicted the performance of
activating compounds in ex vivo tests of latently infected cells from HIV patients588. This
suggests that either some cell culture models do not accurately reflect latency in patients or
that there are diverse subsets of cells with differing mechanisms of latency within patients.
Cell culture models are currently used to screen potentially therapeutic compounds148,588. If
some cell culture models are not representative of in vivo conditions then potential treatments
may be discarded or marked for development erroneously. Further comparisons between
additional cell culture models and additional replicates of existing models might allow
discrimination between batch/lab effects and reveal patterns between models. Comparison
with cells extracted from patients or infected lab animals might offer a gold standard
comparison although it is difficult to obtain large amounts of cells and difficult to distinguish
defective provirus from latent provirus in such populations.
Various treatments are now being considered for the reactivation of latent provirus588. To
further understand the mechanisms of these treatments, it would be informative to compare
the features of latent provirus induced by a given treatment to latent viable provirus
remaining uninduced. Repeated cell sorting and integration site sequencing might provide
insight on mechanism. For example, one could first sort out cells with active provirus, then
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treat with the potential latency modulator and sort out cells with newly active provirus and
then treat with a strong inducer or alternative stimuli and sort out cell with newly activated
provirus. This would give subsets of cells where latent proviruses had been activated by
treatment and cells with provirus which were not activated by treatment but still inducible.
Synergies between treatments could be assessed and the location of integration sites could
be determined and used to locate patterns of genomic features correlated with induction for
each treatment.
Current efforts at “shock and kill” therapy, inducing latent virus to activate and then
eliminating infected cells, focus on histone deacetylase inhibitors. If there are diverse
mechanisms of latency within patients then much of the latent reservoir may remain
unactivated by single-target therapies. Clinical trials with histone deacetylase inhibitors
have shown some small increases in viral RNA but little decrease in the latent reservoir of
HIV383,589–591. It appears that the majority of viable latent provirus from patient cells are
not reactivated by current therapies592. These results are particularly worrisome because a
functional cure for HIV will likely require a greater than 10,000-fold reduction of the latent
reservoir593.
In Chapter 2, we used publicly available genomic data. Perhaps there is some chromosomal
feature with a strong association with latency but the data is not currently available or
varies greatly between cell populations. More varieties of annotations are rapidly becoming
available594–598. Decreasing sequencing costs599–601 may also make it feasible to measure
more epigenetic features in the exact cell population of interest. Repeating analyses similar
to Chapter 2, perhaps by simply rerunning the reproducible report in Appendix A.2 with
new data, would allow any new features to be monitored for correlations with latency.
6.2 HIV-1 alternative splicing
In Chapters 3 and 4, we showed that HIV RNA spliceforms are more diverse than previously
appreciated and estimated the abundances of viral spliceforms. We also showed that splicing
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at some splice sites vary between host subjects, between cell types and over the course of
infection. Further characterization of viral splicing would be beneficial to the study and
treatment of HIV-1 especially as there were some technical limitations to our research that
might be improved upon using current techniques.
We studied HIV splicing using droplet PCR455 and a set of customized primer in Chapter
3 and bulk sequencing of cellular mRNA in Chapter 4. Sequencing biases and difficulties
determining full length transcripts from short reads hindered characterization of HIV
messages. One alternative to these techniques is the targeted capture and enrichment602,603
of HIV-specific sequences. Using probes targeted to conserved regions of HIV, similar to
finding conserved regions for primers as in Chapter 5, would allow for enrichment of viral
reads without the biases induced by primer-based PCR while still allowing for efficient use
of sequencing effort.
The research in Chapter 3 was also limited by a short read bias in the PacBio sequencing.
PacBio sequencing has improved604 and additional long read sequencers have been devel-
oped605–607. In addition, Illumina MiSeq sequencers can now produce 25 million paired 300
bp reads in a single run608,609 and better spliceform estimation methods are being devel-
oped610,611. These improved sequencing techniques might allow for more straightforward
analysis of new samples and verification of our previous results.
RNA transcribed antisense to the canonically expressed strand of HIV have been ob-
served482,612–617. These transcripts may be translated to proteins618,619 that trigger immune
response in infected individuals617,618,620. Our sequencing techniques were designed only for
the HIV positive strand (Chapter 3) or did not preserve strand information (Chapter 4).
Strand-specific sequencing621,622 of multiple HIV strains under varying cellular conditions
would clarify the identity of these transcripts.
Cryptic polypeptides encoding epitopes recognized through major histocompatibility complex
type I also appear to be generated from alternative reading frames in the sense strand of
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the virus623,624. Ribosome profiling625–627 of infected cells might reveal whether transcripts
generated through alternative splicing or antisense expression are likely to be translated.
These cryptic transcripts could offer new opportunities in vaccine design617,620,628,629 but
first their abundance, identity and conservation across strains of HIV must be ascertained.
We observed that splicing varies over the course of infection, between human subjects and
between cell types. Further sampling could reveal additional patterns in these splicing
changes.
Long-lived reservoir of HIV infected cells exist in both macrophages630,631 and resting
central memory CD4 T cells139,140,143,632,633. It may be difficult to obtain enough viral
RNA from resting CD4 cells632 but macrophages provide an interesting target. Splicing
changes due to differing abundances of splice factors have been reported in macrophages446.
Characterization of splicing in these important reservoirs might aid in the understanding of
latency.
We quantified the splicing of a single clinical isolate and showed unexpected diversity. Most
previous studies of HIV splicing have been performed with lab-adapted strains425. Additional
studies could determine if the high number of transcripts seen here is an anomaly and whether
additional cryptic splice sites and novel proteins or epitopes exist. In addition, an important
subset of HIV are the founder viruses transmitted between hosts634,635. These viruses are
not well studied and perhaps their splicing and gene expression differ from the rest of the
viral swarm of infected patients. Comparisons to splicing in other retroviral taxa might
highlight evolution and adaptation in this viral lineage.
Disruption of RNA processing can drastically reduce HIV replication288,636–639. Inhibition
of cellular splicing factors reduces the reproduction of HIV in many genome-wide siRNA
screens433,435,640 and several members of the spliceosome interact with viral proteins in
affinity pulldowns310. Small molecules that inhibit cellular SR splicing proteins and disrupt
viral splicing show promise as antiretroviral therapies432,641–643. Characterization of splicing
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in cells treated with splicing inhibitors could reveal potential escape pathways and optimal
combinations of drug therapies.
6.3 Host expression during HIV infection
In Chapter 4, we saw many changes in host expression and splicing in HIV infected cells
including intron retention and strong changes in apoptotic and innate immunity genes.
We focused on generating a dense data set at a single time point and subject to allow
discrimination of within-condition versus between-condition variation. Further sampling
using more human subjects and time points, improved sequencing techniques, alternative
culturing and extraction and more viral strains would clarify and extend these patterns.
In our primary cell infections, only about 25% of cells were infected with HIV. This makes
it difficult to distinguish between the responses of bystander and infected cells. In addition,
changes in expression due to cellular response to infection are confounded with changes
due to hijacking of cellular controls by the virus. For example, bystander cell death has
been suggested as a major driver of HIV pathogenesis644,645 but our data do not make it
clear whether bystander or infected cells are undergoing apoptosis. Cell pull-down with a
labelled HIV strain519 or an anti-Env antibody646 or flow cytometry with a labelled antibody
targeting HIV antigen152,647 might allow the separation of bystander and infected cells.
Additionally, abortive infections can drive cell death489,645 so our populations might be a
mix of three responses; cells responding to a progressive infection, cells responding to an
aborted infection and cells responding to neighbor cell infections. A useful control might be
to infect cells with integrase-deficient virions to guarantee that all infections are aborted.
This would provide a good measure of innate immune response and the effect of abortive
infections undiluted by productive HIV infection and help to deconvolute the patterns seen
in mixed populations.
HIV infection appeared to increase the abundance of intronic sequences. Perhaps these
transcripts escape degradation due to decreased cellular RNA surveillance or mistargeted
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export of incompletely spliced cellular transcripts by viral protein Rev. Alternatively, HIV
Vpr protein has been reported to disrupt nuclear integrity and allow mixing of nuclear and
cytoplasmic components253. These sequences might represent incompletely spliced mRNA
that escaped into the cytoplasm before processing. Infection with a Vpr-deficient HIV virus
and separate isolation of RNA from nuclear and cytoplasmic compartments648–650 would
test these hypotheses.
We saw that chimeric sequences were almost entirely derived from read-in or -out from
viral long terminal repeats or splicing from the viral splice donor D4 to human acceptors.
With this knowledge, we could use targeted amplification of these three sites, analogous to
integration site sequencing396,423,495, on cellular cDNA to get a much deeper and cleaner
sampling of chimera formation. Comparison of these data to deeply sequenced integration
site data from the same samples might reveal associations between integration location and
chimera formation.
MicroRNA are small RNAs that block translation through base pairing with comple-
mentary mRNA651–653. Viral derived microRNA, perhaps in part from Dicer processing
of the structured trans-activation response element of HIV614,654–656, may suppress HIV
expression217,657,658 and inhibit apoptosis656 but the presence of such microRNA is controver-
sial219,659. HIV may suppress silencing by microRNA216–218 but this is also controversial219.
Cellular microRNA may have antiviral effects660,661 or be exploited by HIV to enhance
replication662–666 or promote latency667,668 but there seems to be disagreement on which
microRNA are involved among different studies669. High-throughput genome-wide assays of
small RNA482,516 from primary cells infected with patient isolates would help clarify these
debates.
6.4 LAMP PCR and lab-on-a-chip
In Chapter 5, we report a loop-mediated isothermal amplification system using primers
optimized to to detect most subtypes of HIV-1. An alternative to a single broadly targeted
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primer set would be to design separate primer sets targeted specifically to each subtype so
that a positive amplification would then be able to discriminate viral subtype. Different viral
subtypes can have different rates of disease progression670–673, transmission dynamics674–676
and response to treatment677–679. Simple low-cost devices with multiple reactions chambers
could be used to both identify viral subtype, estimate viral load680,681 and allow more
informed treatment decisions.
A LAMP chip with subtype-specific primers would also allow the detection of intersubtype
superinfections. Superinfection of a single individual with multiple distinct strains of HIV is
common in high risk individuals567,682–685 and the general population686. Superinfection with
a phenotypically different strain of HIV can lead to disease progression687–692 or drug resis-
tance693. Superinfection also allows recombination between divergent strains682,688,689,691,694
and this rapid exchange of genetic information can lead to more fit recombinant strains and
worsen the global epidemic58,62,689,695,696. LAMP detection of superinfection could allow
early intervention and suppression in superinfected individuals.
The techniques described in Chapter 5 also allow for rapid development of detection assays
for novel pathogens. For example, in a recent outbreak in West Africa, Zaire ebolavirus
has infected over 26,000 confirmed, probable and suspected cases and caused over 11,000
reported deaths697–699. Early detection and quarantine are essential to the control of this
epidemic700. Amplification of Ebola virus nucleic acid through polymerase chain reaction is
the best diagnostic test currently available but the necessary resources are often not available
in these resource-poor regions701,702. Antigen-based tests are quicker and available at the
point-of-care but are not as accurate or sensitive as polymerase chain reaction tests and are
still in limited supply702. Loop-mediated isothermal amplification offers the potential for
rapid, sensitive and efficient detection of Ebola virus RNA but available LAMP primers703 do
not match the current outbreak strain. Using sequences from the recent outbreak697,704 and
the methods described in Chapter 5, we designed primers to match all known Zaire ebolavirus
(Figure 6.1). These primer combined with simple lab-on-a-chip devices for purifying blood
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plasma572 and imaging fluorescent signals587,680 could allow rapid point-of-care detection of
Ebola virus.
6.4.1 Conclusions
These studies contribute to the study and treatment of HIV-1 by revealing aspects of latency,
expression and host response. They highlight the importance of primary cell models and
the effects that host cell can have on viral processes. With rapidly increasing sequencing
throughput, further studies like those presented here offer the opportunity for a deeper
and broader understanding of HIV-1 biology and host response and further development of
diagnostics and therapeutics.
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Figure 6.1: Bioinformatic analysis to design Ebola virus RT-LAMP primers. A) Conservation
of sequence in Ebola virus. Ebola virus genomes (n = 131) from Genbank and sequences
from the recent Zaire ebolavirus outbreak697 were aligned and conservation calculated.
The x-axis shows the coordinate on the Ebola genome, the y-axis shows the proportion
of sequences matching the consensus for each 21 base segment of the genome (red points).
The black line shows a 101 base sliding average over these proportions. The vertical red
shading shows the region targeted for LAMP primer design that was used as input into the
EIKEN primer design tool and grey shading indicates the area covered by the optimized
primer set. Numbering is relative to the Ebola Mayinga sequence. B) Aligned genomes,
showing the locations of the LAMP primers. Sequences in the grey-shaded region in A are
shown, with DNA bases color-coded as shown at the lower right. Each row indicates an
Ebola virus sequence and each column a base in that sequence. Horizontal lines separate
Ebola virus outbreaks (SLE: Seirra Leone, GIN: Guinea, COD: DR Congo, GAB: Gabon).
Arrows indicate the strand targeted by each primer. Primers targeting the negative strand
of the virus are shown as reverse compliments for ease of viewing.
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APPENDIX A.1 : Generalized linear models of changes in
use of mutually exclusive HIV-1 splice
acceptors
Reads splicing from D1 to one of five mutually exclusive acceptors, D3, D4c, D4a, D4b,
D5, and D5a, in three primers, 1.2, 1.3 and 1.4, were collected. Since these data are based
on counts, we modeled them as Poisson distributed with an extra variance term allowing
for additional variance using a quasi-Poisson generalized linear model with log link. We
accounted for differences in sequencing effort by including the total number of D1 to mutually
exclusive acceptors reads in each primer-sample as an offset. Differences in the read counts
a) over time,b) between human donor and c) cell type were analyzed separately. A term
was included for each acceptor and its interaction with the variable of interest. The models
included primer and replicate terms and their individual interactions with acceptor to
account for any confounding factors.
A.1.1 HOS vs T Cells
R command:
glm(count˜offset(log(total)) + acceptor:primer + acceptor:isHos
+ acceptor , data = mutEx[mutEx$time == 48,],
family = 'quasipoisson ')
Difference between HOS and T cells may be confounded by run differences between early
sequencing and later sequencing. Verification by agarose gel (Figure 3.4B) suggest that these
differences are likely biological.
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Variable Df Deviance Resid. Df Resid. Dev F Pr(>F )
NULL 395 138 330
acceptor 5 133 985 390 4345 9004 <2.2 × 10−16
acceptor:primer 12 751 378 3594 21.03 <2.2 × 10−16
acceptor:isHos 6 2466 372 1127 138.1 <2.2 × 10−16
So after accounting for primer-acceptor bias, the difference between HOS and T cells is
significant.
The interesting terms in the model are:
Variable Estimate Std. Error t value Pr(>|t |)
acceptorA3:isHosTRUE 1.4717 0.065 86 22.35 <2.2 × 10−16
acceptorA4a:isHosTRUE −0.9449 0.1246 −7.583 2.73 × 10−13
acceptorA4b:isHosTRUE −0.9285 0.1059 −8.767 <2.2 × 10−16
acceptorA4c:isHosTRUE −1.228 0.1066 −11.51 <2.2 × 10−16
acceptorA5:isHosTRUE 0.090 82 0.026 08 3.483 0.000 555
acceptorA5a:isHosTRUE 0.6308 0.079 40 7.945 2.33 × 10−14
So it appears A3 is up; A4c, A4a and A4b are down; A5 is up a little and A5a up in HOS.
A.1.2 HOS Over Time
R command:
glm(value˜offset(log(total)) + acceptor + acceptor:primer
+ acceptor:time , data=mutEx[mutEx$isHos ,],
family ='quasipoisson ')
Looking only within HOS, we see a significant linear effect of time:
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Variable Df Deviance Resid. Df Resid. Dev F Pr(>F )
NULL 53 17 962
acceptor 5 17 710 48 252.2 6698 <2.2 × 10−16
acceptor:primer 12 18.0 36 234.2 2.834 0.010 18
acceptor:time 6 217.8 30 16.4 68.65 3.57 × 10−16
We are assuming that a particular acceptor will have the same change in all three primers
here.
The interesting terms are:
Variable Estimate Std. Error t value Pr(>|t |)
acceptorA3:time 0.024 77 0.001 778 13.93 1.22 × 10−14
acceptorA4a:time −0.016 21 0.002 812 −5.765 2.69 × 10−6
acceptorA4b:time −0.025 26 0.002 271 −11.12 3.62 × 10−12
acceptorA4c:time 0.015 867 0.003 050 5.202 1.32 × 10−5
acceptorA5:time −0.001 918 0.000 631 3 −3.038 0.004 90
acceptorA5a:time 0.004 919 9 0.001 969 2.499 0.0182
So A3, A4c and A5a increase over time and A4a, A4b and A5 decrease over time. All of
these coefficients are with a log link and linear and so multiplicative. That means that for
example A3 will increase 2.5%/hour (exp(.0247)) or equivalently 81% (1.02524) over 24hours.
A.1.3 Between Human Comparison
R command:
glm(value˜offset(log(total)) + acceptor + acceptor:run
+ acceptor:primer + acceptor:subject ,
data=mutEx[! mutEx$isHos ,], family = 'quasipoisson ')
In humans, we added a term to account for any potential run bias between the three
replicates. Subject refers to the seven human blood donors from which T cells were collected:
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Variable Df Deviance Resid. Df Resid. Dev F Pr(>F )
NULL 377 128 430
acceptor 5 126 446 372 1985 19 598 <2.2 × 10−16
acceptor:run 12 136 360 1849 8.792 1.77 × 10−14
acceptor:primer 12 850 348 998 54.91 <2.2 × 10−16
acceptor:subject 36 597 312 401 12.86 <2.2 × 10−16
So after accounting for any run and primer bias, subject ID has a statistically significant
effect on our observed counts. If we compare everything to subject 7, the interesting terms
are:
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Variable Estimate Std. Error t value Pr(>|t |)
acceptorA3:subject6 −0.001 399 0.072 86 −0.019 0.9847
acceptorA4a:subject6 −0.112 90 0.049 44 −2.284 0.023 07
acceptorA4b:subject6 −0.054 33 0.040 38 −1.345 0.1795
acceptorA4c:subject6 0.028 29 0.033 60 0.842 0.4005
acceptorA5:subject6 0.016 83 0.016 00 1.051 0.2939
acceptorA5a:subject6 −0.030 85 0.060 92 −0.506 0.6129
acceptorA3:subject5 −0.077 67 0.074 23 −1.046 0.2962
acceptorA4a:subject5 −0.1144 0.049 82 −2.296 0.0223
acceptorA4b:subject5 −0.0684 0.040 90 −1.672 0.0956
acceptorA4c:subject5 −0.085 85 0.034 75 −2.471 0.0140
acceptorA5:subject5 0.038 88 0.016 16 2.406 0.0167
acceptorA5a:subject5 0.078 77 0.060 38 1.304 0.1930
acceptorA3:subject4 −0.1849 0.095 78 −1.931 0.0544
acceptorA4a:subject4 0.071 86 0.057 91 1.241 0.2156
acceptorA4b:subject4 0.126 20 0.047 14 2.677 0.0078
acceptorA4c:subject4 −0.100 21 0.043 03 −2.329 0.0205
acceptorA5:subject4 −0.001 16 0.019 69 −0.059 0.9531
acceptorA5a:subject4 0.023 46 0.073 53 0.319 0.7499
acceptorA3:subject3 −0.003 51 0.086 65 −0.041 0.9677
acceptorA4a:subject3 0.071 07 0.055 64 1.277 0.2024
acceptorA4b:subject3 0.006 46 0.046 99 0.138 0.8907
acceptorA4c:subject3 −0.063 34 0.040 76 −1.554 0.1212
acceptorA5:subject3 0.010 52 0.018 87 0.557 0.5776
acceptorA5a:subject3 −0.070 95 0.072 85 −0.974 0.3309
acceptorA3:subject2 −0.2329 0.091 76 −2.539 0.0116
acceptorA4a:subject2 0.024 05 0.056 43 0.426 0.6702
acceptorA4b:subject2 0.1107 0.045 35 2.441 0.0152
acceptorA4c:subject2 0.021 76 0.039 52 0.551 0.5823
acceptorA5:subject2 −0.003 760 0.018 69 −0.201 0.8407
acceptorA5a:subject2 −0.1608 0.073 51 −2.187 0.0295
acceptorA3:subject1 0.095 36 0.065 56 1.454 0.1468
acceptorA4a:subject1 0.029 32 0.044 31 0.662 0.5087
acceptorA4b:subject1 −0.2144 0.038 43 −5.578 5.28 × 10−8
acceptorA4c:subject1 −0.3974 0.033 85 −11.74 <2.2 × 10−16
acceptorA5:subject1 0.091 44 0.014 70 6.221 1.58 × 10−9
acceptorA5a:subject1 0.027 47 0.055 94 0.491 0.6238
So there were small but significant effects between subjects especially between subject 1 and
subjects 2–7. A potential confounder is that T cells were collected from apheresis product in
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subject 1 and from whole blood in subjects 2–7 although why this would affect later assays
is unknown.
113
APPENDIX A.2 : Reproducible report of HIV integration
sites and latency analysis
A.2.1 Supplementary data
Additional File 2 is a gzipped csv file that includes a row for each uniquely mapped provirus
and its surrounding genomic annotations. The csv file should have 12436 rows (excluding
header) with 6252 expressed and 6184 latent proviruses.
integrationData <- read.csv(" AdditionalFile2.csv.gz",
stringsAsFactors = FALSE)
nrow(integrationData)
## [1] 12436
table(integrationData$isLatent)
##
## FALSE TRUE
## 6252 6184
A.2.2 Lasso regression
The lasso regressions take a while to run so I’ve turned down the number of cross validations
here (set eval=FALSE below to completely skip this step). Leave one out and 480-fold cross
validation were used in the paper but processing may take a few days without parallel
processing. Lasso regression requires the R glmnet package.
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notFitColumns <- c("id", "chr", "pos", "strand", "sample", "isLatent
")
samples <- unique(as.character(integrationData$sample))
sampleMatrix <- do.call(cbind , lapply(samples , function(x)
integrationData$sample == x))
colnames(sampleMatrix) <- gsub(" ", "_", samples)
interact <- function(predMatrix , columns , addNames = NULL) {
out <- do.call(cbind , lapply (1: ncol(columns), function(x)
predMatrix * columns[, x]))
if (!is.null(addNames)) {
if (length(addNames) != ncol(columns)) {
stop(simpleError ("Names not same length as columns "))
}
colnames(out) <- sprintf ("%s_%s", rep(addNames , each = ncol(
predMatrix)),
rep(colnames(predMatrix), length(addNames)))
}
return(out)
}
fitData <- as.matrix(integrationData[, !colnames(integrationData) %in
% notFitColumns ])
fitData2 <- as.matrix(cbind(interact(fitData , sampleMatrix , colnames(
sampleMatrix)),
fitData , sampleMatrix))
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library(glmnet)
penalties <- rep(1, ncol(fitData2))
penalties[ncol(fitData2) - (ncol(sampleMatrix):1) + 1] <- 0
lassoFit <- cv.glmnet(fitData2 , integrationData$isLatent , family = "
binomial", type.measure = "class", nfolds = 3, penalty.factor =
penalties)
seperateFits <- lapply(samples , function(x) cv.glmnet(fitData[
integrationData$sample == x, ], integrationData$isLatent[
integrationData$sample == x], family = "binomial", type.measure =
"class", nfolds = 3))
names(seperateFits) <- samples
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A.2.3 Correlation
We looked for correlation between the genomic variables and expression status of the
proviruses.
corMat <- apply(fitData , 2, function(x) sapply(samples , function(y) {
selector <- integrationData$sample == y
if (sd(x[selector ]) == 0)
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return (0)
isLatent <- integrationData[selector , "isLatent "]
cor(as.numeric(isLatent), x[selector], method = "spearman ")
}))
quantile(corMat , seq(0, 1, 0.1))
## 0% 10% 20% 30%
## -0.185223020 -0.081555830 -0.048938130 -0.030895834
## 40% 50% 60% 70%
## -0.018053321 -0.005613895 0.003580982 0.017822483
## 80% 90% 100%
## 0.036694554 0.062003356 0.170642314
If we looked for genomic variables consistently correlated or anti-correlated with proviral
expression status with an FDR q-value less than 0.01, no variable was significantly correlated
in more than 3 samples.
pMat <- apply(fitData , 2, function(x) sapply(samples , function(y) {
selector <- integrationData$sample == y
if (sd(x[selector ]) == 0)
return(NA)
isLatent <- integrationData[selector , "isLatent "]
cor.test(as.numeric(isLatent), x[selector], method = "spearman",
exact = FALSE)$p.value
}))
adjustPMat <- pMat
adjustPMat[, ] <- p.adjust(pMat , "fdr")
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downPMat <- upPMat <- adjustPMat
downPMat[corMat > 0] <- 1
upPMat[corMat < 0] <- 1
table(apply(upPMat < 0.01 & !is.na(upPMat), 2, sum))
##
## 0 1 2 3
## 298 27 38 10
table(apply(downPMat < 0.01 & !is.na(downPMat), 2, sum))
##
## 0 1 2 3
## 216 36 63 58
A.2.4 RNA expression
We fit a logistic regression to a polynomial of log RNA-Seq reads within 5000 bases from
Jurkat cells for the Jurkat sample and T cells for the rest.
rna <- ifelse(integrationData$sample == "Jurkat",
integrationData$log_jurkatRNA ,
integrationData$rna_5000)
rna2 <- rnaˆ2
rna3 <- rnaˆ3 #
rna4 <- rnaˆ4
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glmData <- data.frame(isLatent = integrationData$isLatent , sample =
integrationData$sample ,
rna , rna2 , rna3 , rna4)
glmMod <- glm(isLatent ˜ sample * rna + sample * rna2 + sample *
rna3 + sample * rna4 , data = glmData , family = "binomial ")
summary(glmMod)
##
## Call:
## glm(formula = isLatent ˜ sample * rna + sample * rna2 + sample *
## rna3 + sample * rna4 , family = "binomial", data = glmData)
##
## Deviance Residuals:
## Min 1Q Median 3Q Max
## -2.2899 -0.9864 -0.8676 1.0960 1.6007
##
## Coefficients:
## Estimate Std. Error z value
## (Intercept) 1.7623655 0.2138859 8.240
## sampleBcl -2 transduced -2.1625912 0.7061524 -3.062
## sampleCentral Memory -2.5010063 0.2437685 -10.260
## sampleJurkat -2.0800202 0.2836871 -7.332
## sampleResting 0.7840481 0.3312247 2.367
## rna -0.6567268 0.2344422 -2.801
## rna2 0.1387703 0.0770589 1.801
## rna3 -0.0167219 0.0094076 -1.777
## rna4 0.0007572 0.0003845 1.969
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## sampleBcl -2 transduced:rna 0.5750186 0.6366537 0.903
## sampleCentral Memory:rna 0.9067758 0.2750955 3.296
## sampleJurkat:rna 0.5294036 0.3867163 1.369
## sampleResting:rna 0.0366276 0.3436248 0.107
## sampleBcl -2 transduced:rna2 -0.0369353 0.1878816 -0.197
## sampleCentral Memory:rna2 -0.2106715 0.0915492 -2.301
## sampleJurkat:rna2 -0.0766215 0.1641153 -0.467
## sampleResting:rna2 -0.0760450 0.1086998 -0.700
## sampleBcl -2 transduced:rna3 0.0032503 0.0213743 0.152
## sampleCentral Memory:rna3 0.0237064 0.0112661 2.104
## sampleJurkat:rna3 0.0042183 0.0263910 0.160
## sampleResting:rna3 0.0153132 0.0128711 1.190
## sampleBcl -2 transduced:rna4 -0.0002532 0.0008267 -0.306
## sampleCentral Memory:rna4 -0.0009877 0.0004627 -2.135
## sampleJurkat:rna4 0.0001725 0.0014215 0.121
## sampleResting:rna4 -0.0008049 0.0005119 -1.572
## Pr(>|z|)
## (Intercept) < 2e-16 ***
## sampleBcl -2 transduced 0.00219 **
## sampleCentral Memory < 2e-16 ***
## sampleJurkat 2.27e-13 ***
## sampleResting 0.01793 *
## rna 0.00509 **
## rna2 0.07173 .
## rna3 0.07549 .
## rna4 0.04891 *
## sampleBcl -2 transduced:rna 0.36643
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## sampleCentral Memory:rna 0.00098 ***
## sampleJurkat:rna 0.17101
## sampleResting:rna 0.91511
## sampleBcl -2 transduced:rna2 0.84415
## sampleCentral Memory:rna2 0.02138 *
## sampleJurkat:rna2 0.64059
## sampleResting:rna2 0.48419
## sampleBcl -2 transduced:rna3 0.87913
## sampleCentral Memory:rna3 0.03536 *
## sampleJurkat:rna3 0.87301
## sampleResting:rna3 0.23415
## sampleBcl -2 transduced:rna4 0.75939
## sampleCentral Memory:rna4 0.03280 *
## sampleJurkat:rna4 0.90339
## sampleResting:rna4 0.11585
## ---
## Signif. codes:
## 0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1
##
## (Dispersion parameter for binomial family taken to be 1)
##
## Null deviance: 17240 on 12435 degrees of freedom
## Residual deviance: 15874 on 12411 degrees of freedom
## AIC: 15924
##
## Number of Fisher Scoring iterations: 4
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A.2.5 Strand orientation
We used a Fisher’s exact test to check if silent/inducible proviruses were enriched when
integrated in the same strand orientation as cellular genes.
selector <- integrationData$inGene == 1
strandTable <- with(integrationData[selector , ], table(ifelse(
isLatent , "Silent/Inducible", "Active "), ifelse(inGeneSameStrand
== 1, "Same", "Diff"), sample))
apply(strandTable , 3, fisher.test)
## $Active
##
## Fisher 's Exact Test for Count Data
##
## data: array(newX[, i], d.call , dn.call)
## p-value = 0.06061
## alternative hypothesis: true odds ratio is not equal to 1
## 95 percent confidence interval:
## 0.7219466 1.0081995
## sample estimates:
## odds ratio
## 0.8532127
##
##
## $`Bcl -2 transduced `
##
## Fisher 's Exact Test for Count Data
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##
## data: array(newX[, i], d.call , dn.call)
## p-value = 2.177e-05
## alternative hypothesis: true odds ratio is not equal to 1
## 95 percent confidence interval:
## 1.446896 2.872562
## sample estimates:
## odds ratio
## 2.036148
##
##
## $`Central Memory `
##
## Fisher 's Exact Test for Count Data
##
## data: array(newX[, i], d.call , dn.call)
## p-value = 0.2907
## alternative hypothesis: true odds ratio is not equal to 1
## 95 percent confidence interval:
## 0.9386167 1.2320238
## sample estimates:
## odds ratio
## 1.07529
##
##
## $Jurkat
##
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## Fisher 's Exact Test for Count Data
##
## data: array(newX[, i], d.call , dn.call)
## p-value = 0.1674
## alternative hypothesis: true odds ratio is not equal to 1
## 95 percent confidence interval:
## 0.9207548 1.5699893
## sample estimates:
## odds ratio
## 1.202007
##
##
## $Resting
##
## Fisher 's Exact Test for Count Data
##
## data: array(newX[, i], d.call , dn.call)
## p-value = 0.5732
## alternative hypothesis: true odds ratio is not equal to 1
## 95 percent confidence interval:
## 0.7825231 1.1405158
## sample estimates:
## odds ratio
## 0.9447415
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A.2.6 Acetylation
To reduce correlation between acetylation marks, we generated the first ten principal
components of the acetylation data and ran a logistic regression against them. We compared
the cross validated performance of this regression with a base model only including which
dataset the integration site came from. The cross-validation here has been reduced for
efficiency but 480-fold cross-validation was used in the paper.
acetyl <- integrationData[, !grepl(" logDist", colnames(
integrationData)) & grepl("ac", colnames(integrationData))]
acetylPCA <- princomp(acetyl)
cumsum(acetylPCA$sdev [1:10]ˆ2/ sum(acetylPCA$sdev ˆ2))
## Comp.1 Comp.2 Comp.3 Comp.4 Comp.5 Comp.6
## 0.5947268 0.6786611 0.7267433 0.7610502 0.7833616 0.7964470
## Comp.7 Comp.8 Comp.9 Comp .10
## 0.8093295 0.8215027 0.8299358 0.8372584
cv.glm <- function(model , K = nrow(thisData), subsets = NULL) {
modelCall <- model$call
thisData <- eval(modelCall$data)
n <- nrow(thisData)
if (is.null(subsets))
subsets <- split (1:n, sample(rep(1:K, length.out = n)))
preds <- lapply(subsets , function(outGroup) {
subsetData <- thisData[-outGroup , , drop = FALSE]
predData <- thisData[outGroup , , drop = FALSE]
thisModel <- modelCall
thisModel$data <- subsetData
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return(predict(eval(thisModel), predData))
})
pred <- unlist(preds)[order(unlist(subsets))]
subsetId <- rep(1:K, sapply(subsets , length))[order(unlist(
subsets))]
return(data.frame(pred , subsetId))
}
inData <- data.frame(isLatent = integrationData$isLatent , sample = as
.factor(integrationData$sample),
acetylPCA$score[, 1:10])
modelPreds <- cv.glm(glm(isLatent ˜ sample + Comp.1 + Comp.2 +
Comp.3 + Comp.4 + Comp.5 + Comp.6 + Comp.7 + Comp.8 + Comp.9 +
Comp.10, family = "binomial", data = inData), K = 5)
basePreds <- cv.glm(glm(isLatent ˜ sample , family = "binomial",
data = inData), subsets = split (1: nrow(inData),
modelPreds$subsetId),
K = 5)
modelCorrect <- sum(( modelPreds$pred > 0) == integrationData$isLatent
)
baseCorrect <- sum(( basePreds$pred > 0) == integrationData$isLatent)
prop.test(c(baseCorrect , modelCorrect), rep(nrow(integrationData),
2))
##
## 2-sample test for equality of proportions with
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## continuity correction
##
## data: c(baseCorrect , modelCorrect) out of rep(nrow(
integrationData), 2)
## X-squared = 0.00017372 , df = 1, p-value = 0.9895
## alternative hypothesis: two.sided
## 95 percent confidence interval:
## -0.01187726 0.01219890
## sample estimates:
## prop 1 prop 2
## 0.6362978 0.6361370
A.2.7 Gene deserts
We used Fisher’s exact test to look for an association between integration outside a gene
and proviral expression status.
geneTable <- table(integrationData$isLatent , integrationData$inGene ,
integrationData$sample)
apply(geneTable , 3, fisher.test)
## $Active
##
## Fisher 's Exact Test for Count Data
##
## data: array(newX[, i], d.call , dn.call)
## p-value < 2.2e-16
## alternative hypothesis: true odds ratio is not equal to 1
## 95 percent confidence interval:
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## 0.3629548 0.5446204
## sample estimates:
## odds ratio
## 0.4452621
##
##
## $`Bcl -2 transduced `
##
## Fisher 's Exact Test for Count Data
##
## data: array(newX[, i], d.call , dn.call)
## p-value = 0.1052
## alternative hypothesis: true odds ratio is not equal to 1
## 95 percent confidence interval:
## 0.9203418 2.3478599
## sample estimates:
## odds ratio
## 1.472224
##
##
## $`Central Memory `
##
## Fisher 's Exact Test for Count Data
##
## data: array(newX[, i], d.call , dn.call)
## p-value = 0.7803
## alternative hypothesis: true odds ratio is not equal to 1
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## 95 percent confidence interval:
## 0.8525329 1.1253952
## sample estimates:
## odds ratio
## 0.9791165
##
##
## $Jurkat
##
## Fisher 's Exact Test for Count Data
##
## data: array(newX[, i], d.call , dn.call)
## p-value = 0.5443
## alternative hypothesis: true odds ratio is not equal to 1
## 95 percent confidence interval:
## 0.7909269 1.6167285
## sample estimates:
## odds ratio
## 1.127836
##
##
## $Resting
##
## Fisher 's Exact Test for Count Data
##
## data: array(newX[, i], d.call , dn.call)
## p-value = 3.071e-08
130
## alternative hypothesis: true odds ratio is not equal to 1
## 95 percent confidence interval:
## 0.4384828 0.6864112
## sample estimates:
## odds ratio
## 0.5500205
We used a two-sample t-test to investigate whether there was a significant difference in
distance to the nearest gene between expressed and silent/inducible proviruses integrated
outside genes.
geneDistData <- integrationData [! integrationData$inGene , c(" isLatent
", "logDist_nearest", "sample ")]
by(geneDistData , geneDistData$sample , function(x) t.test(
logDist_nearest ˜ isLatent , data = x))
## geneDistData$sample: Active
##
## Welch Two Sample t-test
##
## data: logDist_nearest by isLatent
## t = -2.4539, df = 287.73 , p-value = 0.01472
## alternative hypothesis: true difference in means is not equal to 0
## 95 percent confidence interval:
## -0.80738340 -0.08867607
## sample estimates:
## mean in group FALSE mean in group TRUE
## 9.608737 10.056767
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##
## ---------------------------------------------
## geneDistData$sample: Bcl -2 transduced
##
## Welch Two Sample t-test
##
## data: logDist_nearest by isLatent
## t = 0.40978 , df = 86.2, p-value = 0.683
## alternative hypothesis: true difference in means is not equal to 0
## 95 percent confidence interval:
## -0.6309351 0.9586004
## sample estimates:
## mean in group FALSE mean in group TRUE
## 9.036872 8.873039
##
## ---------------------------------------------
## geneDistData$sample: Central Memory
##
## Welch Two Sample t-test
##
## data: logDist_nearest by isLatent
## t = -0.07188, df = 861.61 , p-value = 0.9427
## alternative hypothesis: true difference in means is not equal to 0
## 95 percent confidence interval:
## -0.2371374 0.2203819
## sample estimates:
## mean in group FALSE mean in group TRUE
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## 10.19225 10.20063
##
## ---------------------------------------------
## geneDistData$sample: Jurkat
##
## Welch Two Sample t-test
##
## data: logDist_nearest by isLatent
## t = -1.8217, df = 139.56 , p-value = 0.07064
## alternative hypothesis: true difference in means is not equal to 0
## 95 percent confidence interval:
## -1.26342086 0.05167979
## sample estimates:
## mean in group FALSE mean in group TRUE
## 9.925782 10.531652
##
## ---------------------------------------------
## geneDistData$sample: Resting
##
## Welch Two Sample t-test
##
## data: logDist_nearest by isLatent
## t = -5.1275, df = 193.49 , p-value = 7.096e-07
## alternative hypothesis: true difference in means is not equal to 0
## 95 percent confidence interval:
## -1.2687917 -0.5638568
## sample estimates:
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## mean in group FALSE mean in group TRUE
## 9.489931 10.406255
To check for a relationship between silent/inducible status and distance to CpG islands, we
used a two sample t-test on the logged distance and saw a significant difference between
silent/inducible and expressed proviruses (before accounting for a correlation between being
near CpG islands and in genes)
t.test(integrationData$logDist_cpg ˜ integrationData$isLatent)
##
## Welch Two Sample t-test
##
## data: integrationData$logDist_cpg by integrationData$isLatent
## t = -2.0233, df = 12381, p-value = 0.04306
## alternative hypothesis: true difference in means is not equal to 0
## 95 percent confidence interval:
## -0.105657514 -0.001675563
## sample estimates:
## mean in group FALSE mean in group TRUE
## 10.16362 10.21728
sapply(unique(integrationData$sample), function(x) with(
integrationData[integrationData$sample ==
x, ], p.adjust(t.test(logDist_cpg ˜ isLatent)$p.value , method = "
bonferroni",
n = 5)))
## Active Central Memory Jurkat
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## 0.512040457 1.000000000 1.000000000
## Bcl -2 transduced Resting
## 1.000000000 0.005866539
Many CpG islands are found near genes. To account for this relationship, we used an ANOVA
test including whether the integration site was inside a gene prior to including CpG islands.
After including integration inside genes, CpG islands were not significantly associated with
silent/inducible status of the proviruses with all samples grouped or individually after
Bonferonni correction for multiple comparisons.
anova(with(integrationData , glm(isLatent ˜ I(logDist_nearest == 0) +
logDist_cpg , family = "binomial ")), test = "Chisq")
## Analysis of Deviance Table
##
## Model: binomial , link: logit
##
## Response: isLatent
##
## Terms added sequentially (first to last)
##
##
## Df Deviance Resid. Df Resid. Dev
## NULL 12435 17240
## I(logDist_nearest == 0) 1 26.2682 12434 17213
## logDist_cpg 1 1.1328 12433 17212
## Pr(>Chi)
## NULL
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## I(logDist_nearest == 0) 2.971e-07 ***
## logDist_cpg 0.2872
## ---
## Signif. codes:
## 0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1
sapply(unique(integrationData$sample), function(x) {
p.adjust(anova(with(integrationData[integrationData$sample == x,
], glm(isLatent ˜ I(logDist_nearest == 0) + logDist_cpg ,
family = "binomial ")), test = "Chisq")[" logDist_cpg", "Pr(>Chi
)"], method = "bonferroni", n = 5)
})
## Active Central Memory Jurkat
## 1.0000000 1.0000000 1.0000000
## Bcl -2 transduced Resting
## 1.0000000 0.2007788
A.2.8 Alphoid repeats
When analyzing repetitive elements, we treated each read as an independent observation and
included reads with multiple alignments to the genome. Additional File 3 is a gzipped csv file
containing a row for each read with multiple alignments and one row for each dereplicated
integration site with a single alignment with the count variable indicating the number of
reads dereplicated to that integration site. There should be 26,190 rows (excluding header)
with 14,494 rows of expressed provirus and 11,696 rows of silent/inducible provirus.
repeats <- read.csv(" AdditionalFile3.csv.gz", check.names = FALSE ,
stringsAsFactors = FALSE)
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nrow(repeats)
## [1] 26190
summary(repeats$isLatent)
## Mode FALSE TRUE NA's
## logical 14494 11696 0
notRepeatColumns <- c("id", "isLatent", "sample", "count")
To analyze whether there was an association between proviral expression status and integra-
tion within alphoid repeats, we used Fisher’s exact test with a Bonferroni correction for five
samples. For comparison, we looked at the association between proviral expression and the
other repeats in the RepeatMasker database. We did not Bonferroni correct for the multiple
repeat types so that the repeats could be compared with the analysis of alphoid repeats (for
which we had an a priori hypothesis for an association with latency).
dummyX <- rep(c(TRUE , FALSE), 2)
dummyY <- rep(c(TRUE , FALSE), each = 2)
repeatData <- repeats[, !colnames(repeats) %in% notRepeatColumns]
repeatData <- repeatData[, apply(repeatData , 2, sum) > 0]
testRepeats <- function(x, repeats) {
sapply(samples , function(thisSample , repeats) {
selector <- repeats$sample == thisSample
repLatent <- rep(repeats$isLatent[selector], repeats$count[
selector ])
repRepeat <- rep(x[selector], repeats$count[selector ])
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fisher.test(table(c(dummyX , repLatent), c(dummyY , repRepeat))
- 1)$p.value
}, repeats)
}
repeatPs <- apply(repeatData , 2, testRepeats , repeats[,
notRepeatColumns ])
table(apply(repeatPs * 5 < 0.05, 2, sum))
##
## 0 1 2 3
## 611 76 15 1
which(apply(repeatPs * 5 < 0.05, 2, sum) >= 3)
## ALR/Alpha
## 178
p.adjust(repeatPs[, "ALR/Alpha"], "bonferroni ")
## Active Central Memory Jurkat
## 5.026890e-02 3.940207e-03 1.027189e-08
## Bcl -2 transduced Resting
## 1.000000e+00 2.424896e-02
A.2.9 Neighbors
We looked at all pairs of viruses on the same chromosome separated by no more than a
given distance, e.g. 100 bases, either with all samples pooled or split between within sample
pairs or between sample pairs.
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allNeighbors <- data.frame(id1 = 0, id2 = 0)[0, ]
ids <- 1:nrow(integrationData)
for (chr in unique(integrationData$chr)) {
chrSelector <- integrationData$chr == chr
neighborPairs <- data.frame(id1 = rep(ids[chrSelector], sum(
chrSelector)),
id2 = rep(ids[chrSelector], each = sum(chrSelector)))
neighborPairs <- neighborPairs[neighborPairs$id1 <
neighborPairs$id2 , ]
allNeighbors <- rbind(allNeighbors , neighborPairs)
}
allNeighbors$dist <- abs(integrationData$pos[allNeighbors$id1] -
integrationData$pos[allNeighbors$id2 ])
allNeighbors$latent1 <- integrationData$isLatent[allNeighbors$id1]
allNeighbors$latent2 <- integrationData$isLatent[allNeighbors$id2]
allNeighbors$sample1 <- integrationData$sample[allNeighbors$id1]
allNeighbors$sample2 <- integrationData$sample[allNeighbors$id2]
allNeighbors <- allNeighbors[allNeighbors$dist <= 1e+06, ]
The expected number of matching pairs was calculated as
∑
j ∈samples nj,d (θ j,dθ¬j,d + (1 −
θ j,d ) (1 − θ¬j,d )) for between sample, ∑j ∈samples nj,d (θ2j,d + (1 − θ j,d )2) for within sample and
nd (θ
2
d + (1 − θd )2) for all pairs, where nj,d is the number of pairs of proviruses separated by
no more than d base pairs where the first provirus is from sample j, θ j,d is the proportion of
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silent/inducible proviruses in sample j appearing in at least one pair of proviruses separated
by less than d base pairs and ¬j means all samples except sample j.
dists <- unique(round (10ˆ seq(1, 6, 1)))
pairings <- do.call(rbind , lapply(dists , function(x, allNeighbors) {
inSelector <- allNeighbors$dist <= x & allNeighbors$sample1 ==
allNeighbors$sample2
outSelector <- allNeighbors$dist <= x & allNeighbors$sample1 !=
allNeighbors$sample2
allSelector <- allNeighbors$dist <= x
out <- data.frame(dist = x, observedIn = sum(allNeighbors[
inSelector , "latent1 "] == allNeighbors[inSelector , "latent2 "])
, observedOut = sum(allNeighbors[outSelector ,
"latent1 "] == allNeighbors[outSelector , "latent2 "]),
observedAll = sum(allNeighbors[allSelector , "latent1 "] ==
allNeighbors[allSelector , "latent2 "]), totalIn = sum(
inSelector),
totalOut = sum(outSelector), totalAll = sum(allSelector))
out$expectedIn <- sum(with(allNeighbors[inSelector , ], sapply(
samples ,
function(x) {
inLatent <- c(latent1[sample1 == x], latent2[sample2 ==
x])[! duplicated(c(id1[sample1 == x], id2[sample2 ==
x]))]
if (length(inLatent) == 0) return (0)
return(sum(sample1 == x) * (mean(inLatent)ˆ2 + mean(!
inLatent)ˆ2))
})))
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out$expectedOut <- sum(with(allNeighbors[outSelector , ],
sapply(samples , function(x) {
inLatent <- c(latent1[sample1 == x], latent2[sample2 ==
x])[! duplicated(c(id1[sample1 == x], id2[sample2 ==
x]))]
outLatent <- c(latent1[sample1 != x], latent2[sample2 !=
x])[! duplicated(c(id1[sample1 != x], id2[sample2 !=
x]))]
if (length(inLatent) == 0) return (0)
return(sum(sample1 == x) * (mean(inLatent) * mean(
outLatent) +
mean(! inLatent) * mean(! outLatent)))
})))
out$expectedAll <- sum(with(allNeighbors[allSelector , ],
{
allLatent <- c(latent1 , latent2)[! duplicated(c(id1 ,
id2))]
return(length(latent1) * (mean(allLatent)ˆ2 + mean(!
allLatent)ˆ2))
}))
return(out)
}, allNeighbors))
rownames(pairings) <- pairings$dist
To look for more matches than expected by random pairing between neighboring proviruses,
we used a one sample Z-test of proportion to compare the observed number of matching
pairs with the expected proportion of pairs.
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combinations <- c(All = "All", `Between sample ` = "Out", `Within
sample ` = "In")
lapply(combinations , function(x, pairing) {
vars <- sprintf(c(" observed%s", "expected%s", "total%s"), x)
expectedProb <- pairing[, vars [2]]/ pairing[, vars [3]]
prop.test(pairing[, vars [1]], pairing[, vars [3]], p =
expectedProb)
}, pairings ["100" , ])
## $All
##
## 1-sample proportions test with continuity correction
##
## data: pairing[, vars [1]] out of pairing[, vars [3]], null
probability expectedProb
## X-squared = 13.002 , df = 1, p-value = 0.0003111
## alternative hypothesis: true p is not equal to 0.5000141
## 95 percent confidence interval:
## 0.5586837 0.6962353
## sample estimates:
## p
## 0.63
##
##
## $`Between sample `
##
## 1-sample proportions test with continuity correction
##
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## data: pairing[, vars [1]] out of pairing[, vars [3]], null
probability expectedProb
## X-squared = 0.21919 , df = 1, p-value = 0.6397
## alternative hypothesis: true p is not equal to 0.4836763
## 95 percent confidence interval:
## 0.3570532 0.5572662
## sample estimates:
## p
## 0.4554455
##
##
## $`Within sample `
##
## 1-sample proportions test with continuity correction
##
## data: pairing[, vars [1]] out of pairing[, vars [3]], null
probability expectedProb
## X-squared = 24.446 , df = 1, p-value = 7.644e-07
## alternative hypothesis: true p is not equal to 0.5561437
## 95 percent confidence interval:
## 0.7140170 0.8776751
## sample estimates:
## p
## 0.8080808
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A.2.10 Compiling this document
This document was generated using R’s Sweave function (http://en.wikipedia.org/wiki/
Sweave). If you would like to regenerate this document, download Additional Files 2, 3 and
4 from Sherrill-Mix et al. 366 and make sure the files are all in the same directory and named
AdditionalFile2.csv.gz, AdditionalFile3.csv.gz and AdditionalFile4.Rnw. Then compile by
going to that directory and using the commands:
R CMD Sweave AdditionalFile4.Rnw
pdflatex AdditionalFile4.tex
Note that you will need R and LATEX (and the R package glmnet if you would like to rerun
the lasso regressions) installed.
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